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Abstract 
Investigations into the mechanism of action of oligosaccharyl 
transferase (OT), the enzyme that catalyzes the first committed step in the 
biosynthesis of all asparagine-linked glycoproteins, were conducted. Research 
focused on kinetic studies with small reactive molecules and tripeptide 
substrates and inhibitors; these experiments were designed to specifically 
probe the OT active site. • Commercially available chemical modification 
agents were used to identify a reactive cysteine residue in or near the 
oligosaccharide binding site. Based on this observation, a novel biotinylated 
sufhydryl modification reagent, methyl N-biotinoyl( aminoethane)-
thiolsulfonate (BMTS), was developed. BMTS selectively modified the 
Wbplp subunit of OT, thereby identifying this subunit as the site of the 
reactive cysteine and all or part of the oligosaccharide binding site. 
The role of the required divalent metal cofactor was examined through 
a series of parallel kinetic experiments on two substrates for OT: the 
asparagine-containing tripeptide Bz-Asn-Leu-Thr-NHMe and the 
corresponding thioasparagine tripeptide Bz-Asn(yS)-Leu-Thr-NHMe. These 
substrates were evaluated with OT which had been treated to remove metal 
and independently reconstituted with four different metal cations. The sizes 
and thiophilicities of the metal cations had a different, but direct impact on 
the kinetic behavior of each of the two peptides. These results place the metal 
cofactor in proximity to the peptide substrate during catalysis and suggest that 
it may play a direct mechanistic role. In addition, a detailed analysis of the 
glycopeptide product of the thioasparagine tripeptide suggests that OT plays a 
specific role in directing the regiochemistry of asparagine glycosylation. 
Through an iterative process, a new class of competitive inhibitors for 
OT was designed which exhibit nanomolar binding constants and are the first 
vii 
reported potent inhibitors for OT. The slow, tight binding inhibition 
observed with these peptides suggests that they may mimic the transition 
state of the glycosylation reaction. Nine irreversible peptidyl inactivators for 
OT were also evaluated; these affinity labels were designed to probe the 
peptide binding site of the enzyme. Based on the results with these 
inactivators, a proposal for the design of more potent affinity labels for OT is 
presented. 
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Chapter 1. Asparagine-Linked Glycosylation 
2 
1.1 Introduction 
Glycosylation is potentially the most complex category of protein 
modification reactions within eukaryotic systems.1 An incredible degree of 
diversity is introduced into glycoproteins by the wide array of monosaccharides 
available as well as by the potential for different chemical linkages between each 
pair of carbohydrates.2 The size of each oligosaccharide chain in glycoproteins 
can vary greatly, ranging from a single monosaccharide to complex, branched 
structures comprising of as many as 15 to 40 sugars. In addition, many proteins 
are glycosylated at multiple sites with different carbohydrate groups; more than 
twenty terminal oligosaccharide sequences are available and can be used in 
combination to generate further diversity.3 In many cases, this structural 
diversity defines the biological role of each of the modified proteins. 
Glycoproteins have been implicated in such varied processes as the immune 
response,4 proper intracellular targeting,5 intercellular recognition,6 and protein 
folding, stability and solubility.7-10 These functions are often modulated by the 
structure of both the oligosaccharide and the protein. An understanding of the 
biosynthesis of glycoproteins is of intense interest because of the diversity 
displayed by these critical biomolecules. 
The most common forms of protein-carbohydrate modifications fall into 
three general categories: N-linked modification of asparagine, 0-linked 
modification of serine or threonine, and glycosylphosphatidyl inositol 
derivatization of the C-terminus carboxyl group (Figure 1-1).11 Each of these 
transformations is catalyzed by one or more enzymes which demonstrate 
different peptide sequence requirements and reaction specificities. N-linked 
glycosylation is catalyzed by a single enzyme, oligosaccharyl transferase (OT), 
and involves the co-translational transfer of a lipid-linked tetradecasaccharide 
(GlcNAc2-Man9-Glc3) to an asparagine side chain within a nascent polypeptide. 
3 
The subsequent diversification of these conjugates arises from enzyme catalyzed 
processing steps that occur in the endoplasmic reticulum (ER) and Golgi 
apparatus after the addition of the first triantennary oligosaccharide complex. 
I N-Terminus I 
• • • 
> -♦_.er, 
~Xaa-Thr-
♦ N-Acetylglucosamine 
• N-Acetylgalactosamine 
■ Mannose 
• Glucose 
6- Glucosamine 
D Inositol 
® Phosphate 
,/'\JV' Protein 
~ Lipid 
IC-Terminus I 
Figure 1-1. A Schematic Representation of the Major Types of Carbohydrate-
Protein Linkages. The core oligosaccharide structures (shown here) can be 
further modified through the addition of new monosaccharides or the cleavage 
of terminal saccharides. 
In contrast, O-linked glycosylation proceeds through the direct, post-
translational transfer of single monosaccharides to threonine and/ or serine 
residues within folded polypeptides. In general, the peptide sequence 
specificities of the O-linked glycosylation enzymes are not well understood12 and 
activity is attributed to several different enzymes. For example, the principal 
mode of O-linked glycosylation in yeast involves the transfer of a single mannose 
from the lipid-linked donor dolichol phosphate mannose (Dol-P-Man) to a 
4 
hydroxy amino acid,13 while one example of O-linked glycosylation in 
mammalian systems involves the transfer of an N-acetylgalactosamine residue 
from uridine diphosphate-N -acetylgalactosamine (UDP-GalNAc) to 
threonine.1 4,15 O-linked glycoprotein modifications with xylose and fucose 
residues have also been observed in mammalian systems (not shown in Figure 1-
1).16,17 
Proteins can also be modified with a complex glycosylphosphatidyl 
inositol (GPI) construct at the polypeptide carboxyl terminus; this derivatization 
confers new properties by anchoring the protein to membrane bilayers.18 
Substrates for GPI modification must terminate with one of six amino acids: Cys, 
Asp, Asn, Gly, Ala, or Ser.19 The a-carboxylic acid of these polypeptides is 
modified by an ethanolamine phosphate which is attached to a glycan with the 
sequence Man-al,2-Man-al,6-Man-al,4-GlcNH2. The terminal glucosamine of 
this tetrasaccharide is attached to the C-6 of a myo-inositol ring which is linked to 
a diglyceride through a phosphate. The core structure, ethanolamine phosphate-
Man-al,2-Man-al,6-Man-al,4-GlcNH2-myo-inosi tol phosphate-diglyceride is 
conserved, however the length of the glyceride chains is variable. Further 
alterations of this sequence follow the initial modification and can include the 
addition of a second ethanolamine phosphate, additional monosaccharides, or 
the palmitoylation of the myo-inositol.19 
Following protein glycosylation, the core oligosaccharide structures are 
subject to a sophisticated array of glycosyl transferase and hydrolase enzymes. 
For example, in the case of N-linked glycosylation, following transfer to an 
asparagine residue within the protein, the core tetradecasaccharide GlcNAc2-
Man9-Glc3 is immediately processed in a series of reactions which cleave the 
three terminal glucose and four mannose residues. This processed glycoprotein 
is subsequently translocated to the Golgi where glycosyl transferases catalyze the 
5 
elaboration of the glycoprotein through the transfer of additional 
monosaccharides such as fucose, galactose and sialic acid from the corresponding 
nucleotide diphosphates. These reactions act in concert to produce the diverse 
N-linked glycoconjugate structures characteristic of mature proteins.20 The final 
oligosaccharide sequence often determines the cellular destination of the 
assembled glycoprotein. It is estimated that 100-200 glycosyl transferases are 
required to generate the diversity observed within glycoproteins.5,21,22 Several of 
the enzymes involved in the assembly and cleavage of extended oligosaccharides 
have been isolated and characterized and significant progress has been made in 
developing a mechanistic understanding of these processes.23,24 In contrast to 
carbohydrate trimming and elongation, details pertaining to the mechanism of 
the transfer of carbohydrate groups to the side chains of amino acids within 
proteins is less well understood. In particular, how do the enzymes involved in 
these processes mediate transfer to the target amino acid side chain in the 
presence of much more reactive moieties within the protein? Also, what factors 
govern the specificities of these transfers, as not all seemingly acceptable 
sequences undergo glycosylation? The mechanism of transfer to asparagine side 
chains is one of the most intriguing glycosylation reactions in this regard because 
of the seemingly inherent lack of reactivity of the carboxamide side chain. 
This introductory chapter presents a summary of the current literature on 
oligosaccharyl transferase, the enzyme that catalyzes asparagine-linked 
glycosylation. Specifically, recent advances in the purification and 
characterization of the enzymatic complex, mechanistic and conformational 
elucidation of the reaction process and the conformational consequences of 
asparagine glycosylation will be discussed. Finally, a summary of the thesis 
research presented in this dissertation and how it contributes to the current 
understanding of this complex enzymatic system will be outlined. 
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1.2 Asparagine-Linked Glycosylation 
Oligosaccharyl transferase is a membrane associated, multimeric enzyme 
localized in the lumen of the endoplasmic reticulum. In the reaction catalyzed by 
OT, illustrated in Figure 1-2, a complex oligosaccharide is transferred from a 
lipid-linked pyrophosphate donor (1) to a nascent polypeptide chain as the 
peptide is translocated into the lumen of the endoplasmic reticulum. The peptide 
primary sequence requirements for glycosylation are minimal; the asparagine 
must reside within the consensus sequence Asn-Xaa-Thr/Ser (NXT /S) where 
Xaa can be any of the 20 natural amino acids except proline.25-27 In vivo, 
threonine-containing sequences are almost 3 times more likely to be glycosylated 
than the corresponding serine-containing analogs.28 However, the efficiency of 
NXT glycosylation in vitro exceeds that of NXS sequences by as much as 40 
fold. 29 This first step in the N-linked glycosylation process appears to be 
conserved throughout eukaryotic evolution.30 
1.3 Biochemical Characterization of Oligosaccharyl Transferase 
Future research on the mechanism of action of OT will be greatly 
facilitated by the availability of a significant g_uantity of pure enzyme; however, 
purification efforts towards this end have been hindered by the inherent lability 
of enzyme activity during solubilization. Recently, significant advances have 
been made in achieving stable enzyme extracts, through the addition of 
phosphatidylcholine (PC),31 sucrose or glycerol. In the presence of these 
additives, several research groups have succeeded in purifying OT to 
homogeneity; sequencing and analysis of several of the subunits have also been 
accomplished. OT has been purified from three mammalian sources (canine 
pancreas,32 porcine liver microsomes33 and human liver microsomes34), one 
avian source (hen oviduct microsomes),35 and the yeast S. cerevisiae.30,36,37 
Lipid-linked oligosaccharide 
1: R=Glc3Man9 
2: R=H 
Oligosaccharyl 
transferase 
7 
Dolichol, n=13-15 
Dol-P-P 
Figure 1-2. The Glycosylation Reaction Catalyzed by Oligosaccharyl Transferase. 
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Comparison of the protein subunits from each of these purifications 
evidences a high degree of conservation throughout evolution (see Table 1-1). In 
fact, a subunit of OT, from the insect Drosophila melananogaster, has recently been 
identified and sequenced using a PCR-mediated cloning strategy guided by the 
conserved regions of the canine and yeast enzymes. 38 
Table 1-1 - Comparison of Genetically Characterized Subunits of OT Isolated 
from Different Sources. 
Mammalian 
(Canine32,39 /Porcine33 / 
Human34) 
Ribophorin I (66/66/65 kDa) 
Ribophorin II (63/63/65 kDa) 
OST48 (48/48/50 kDa) 
Avian Ovid uct35 
Ribophorin I (65 kDa) 
Ribophorin II (65 kDa) 
OST48 (50 kDa) 
Yeast (S. cerevisiae)40A1 
Nltlp/Ostlp (64 kDa) 
Swplp (30 kDa) 
Wbplp (45 kDa) 
The first purification reported was that of the canine pancreas enzyme 
which was isolated as a trimeric complex of polypeptides with molecular weights 
of 66, 63 and 48 kDa.32 The 48 kDa polypep,tide has been designated as OST48 
and is not homologous with any known proteins. Sequence comparisons and 
protein immunoblotting of the 66 and 63 kDa subunits demonstrated that they 
are identical to Ribophorin I and Ribophorin II respectively (two previously 
identified integral membrane proteins found only in the rough endoplasmic 
reticulum). The porcine liver OT has been purified as a tetrameric complex of 
polypeptides and is similar to the canine pancreatic enzyme.33 Ribophorin I, 
Ribophorin II and OST48 have all been identified, as well as an additional 40 kDa 
polypeptide not observed in the canine enzyme complex. Further purification to 
a dimeric complex of OST48 and Ribophorin I yielded an unstable enzyme with 
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partial activity. Treatment of this dimer with trypsin demonstrated that 
Ribophorin I was more susceptible to proteolysis than OST48; partial activity was 
retained during proteolysis suggesting that OST48 is the catalytically competent 
subunit. However, this experiment does not rule out the participation of a 
proteolytic fragment of Ribophorin I. The remaining two subunits, Ribophorin II 
and the 40 kDa polypeptide, are suggested to be involved in stabilizing the 
enzymatic complex.33 
Similar to the canine enzyme, the avian OT enzyme was purified as a 
trimeric complex of polypeptides with molecular weights of 65, 65 and 50 kDa.35 
The 50 kDa polypeptide was completely sequenced by overlaying peptide 
fragments obtained from cleavage by various different enzymatic and chemical 
methods. This sequence was found to be 92% identical to OST48. The two 65 
kDa fragments were resistant to N-terminal sequencing, but cyanogen bromide 
cleavage followed by separation and sequencing of several fragments suggests 
that these two polypeptides correspond to Ribophorin I and Ribophorin II. The 
human OT enzyme was purified from liver microsomes and found to contain 
three subunits, identified as Ribophorin I (66kDa), Ribophorin II (63 kDa) and a 
third subunit with a molecular weight of 50 kDa which was found to be 98% 
identical to the canine OST48.34 
The multimeric enzyme complex in yeast has been isolated as both a 
tetrameric and a hexameric complex of polypeptides.30,36,37 Two of the subunits 
have been identified as Wbplp and Swplp, with molecular weights of 45 and 30 
kDa, respectively. The remaining polypeptides have molecular weights of 64 
and 34 kDa in the tetrameric complex30,36 and 64, 34, 16, and 9 kDa in the 
hexameric complex.37 Independent depletion studies have indicated that both 
Wbplp and Swplp are absolutely required for in vivo and in vitro OT activity.42A3 
Additionally, these two subunits can be chemically crosslinked suggesting that 
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the polypeptides are members of the same multisubunit complex.43 The 34 kDa 
subunit, Ost3p, is not essential for glycosylation; however, deletion of this 
subunit produces an impaired oligosaccharyl transferase complex which 
selectively underglycosylates membrane bound proteins.44 Ost2p, the 16 kDa 
subunit, is essential for yeast viability and mutations in this subunit have been 
shown to produce an enzyme complex with decreased in vitro activity.45 
Comparison of the yeast and mammalian enzyme complexes reveals a 
remarkable degree of similarity: Wbp 1 p exhibits 25% sequence homology to 
OST48;39 the 64 kDa polypeptide, designated Nltlp or Ostlp, is homologous to 
Ribophorin 1;30,36,40 Swplp is similar to the carboxyl-terminal half of Ribophorin 
II;37 a peptide which would be analogous to the amino-terminal half of 
Ribophorin II has not yet been identified in yeast. 
Five of the subunits of the yeast enzyme complex, Wbplp,46 Swplp,43 
Ostlp40 /Nltlp36 Ost2p,45 and Ost3p44 have been sequenced and characterized. 
The results of these studies are summarized in Figure 1-3. Each of the subunits 
contains at least one C-terminal hydrophobic domain. Additionally, four of the 
polypeptides include an amino terminus signal sequence (17-20 amino acids) 
which is cleaved prior to complete maturation of the protein; Ost2p does not 
contain a signal sequence, suggesting that the N-terminus of this subunit is 
located in the cytosol.45 Wbplp and Nltlp are both multiply glycosylated with 
N-linked high mannose oligosaccharides, indicating that mature OT is a self-
processing enzyme.37 In fact, concanavalin A (a high mannose binding lectin) 
was successfully used to partially purify OT in two of the procedures described 
above.36,37 Ost3p contains one potential N-linked glycosylation site, but this site 
does not appear to be glycosylated.44 
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N-linked CHO site LJ C Ost2p L-J 
I 2 50 130 
Hydrophobic domain .JVVVV" 
Swp1 C 
21 193 288 
N C Ost3p 
23 186 350 
L.J L.J 
L..J L..J 
N 
I I 
./VVVV' C Wbp1 
21 60 332 388 420 
L.J L.J L.J L.J 
L..J L..J L..J L..J 
I I I I Ost1/ N .fVVVVV'C 
18 99 217 336 399 453 476 Nlt1 
Ost2p 
130aa, 
Terminal Met removed 
Three short C-terminal 
hydrophobic domains 
Ost3p 
350aa, 
22aa signal peptide removed 
Four C-terminal 
hydrophobic domains 
Not essential for viability 
Ost1/Nlt1 
476aa 
Swp1 
288aa, 
20aa signal peptide removed 
Three short C-terminal 
hydrophobic domains 
Wbp1 
420aa 
20aa signal peptide removed 
One C-terminal hydrophobic domain 
KKTN ER retention sequence 
17aa signal peptide removed 
One C-terminal hydrophobic 
domain 
Figure 1-3. A Schematic Representation of the Oligosaccharyl Transferase 
Subunits Characterized to Date.40-45 
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1.4 Substrates for N-linked Glycosylation 
1.4.1 Lipid-Linked Oligosaccharide Donor 
The normal physiological glycosylation process results in the transfer of a 
triantennary branched oligosaccharide made up from two N-acetyl glucosamine, 
nine mannose and three glucose residues (1, Dol-P-P-GlcNAc2-Man9-Glc3, Figure 
1-2).47A8 This tetradecasaccharide derivative is biosynthesized through a series 
of stepwise transfers to dolichol phosphate before being transferred en bloc to the 
peptide acceptor.49,50 The first step in the biosynthesis of the lipid-linked donor 
involves transfer of a single N-acetyl glucosamine from UDP-GlcNAc to dolichol 
phosphate and the formation of a pyrophosphate bond with concomitant release 
of UMP. The second GlcNAc is subsequently transferred to the newly formed 
Dolichol-P-P-GlcNAc in a reaction that results in the formation of a ~-1,4-
glycosidic linkage. The remaining 12 sugars are subsequently added to this 
lipid-linked disaccharide. The first five mannose residues are directly transferred 
from GDP-Man, while the last four mannose residues, as well as the terminal 
glucose residues (from UDP-Gk) are added via the intermediacy of a dolichol 
phosphate derivative before being added to the assembling glycolipid. The 
oligosaccharide of the final glycolipid is located on the lumenal side of the 
ER.s1,s2 
Although the substrate recognized by OT in vivo 1s a complex 
tetradecasaccharide, the enzyme catalyzed reaction in vitro proceeds with similar 
efficiencies utilizing simpler truncated substrates such as the di-N -
acetylglucosamine derivative 2, (Dol-P-P-GlcNAc2, Figure 1-2) and Dol-P-P-
GlcNAc2-Man1. However, the lipid-linked monosaccharide Dol-P-P-GlcNAc is 
not a substrate for the solubilized enzyme.50 The ability of OT to readily utilize a 
simple lipid-linked disaccharide as the carbohydrate donor in the glycosylation 
of asparagine residues has greatly facilitated the study of this enzyme. These 
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truncated substrates are accessible through synthetic and enzymatic methods 
and radiolabeled monosaccharides can be incorporated into the desired 
compounds for enzymatic assays . The chitobiosyl analog 2 has been chemically 
synthesized by two different methods. 53,54 These synthetic methods are hindered 
by availability of reactants and difficulty in purification. Compound 2 has also 
been prepared enzymatically by incubating liver microsomes with radiolabeled 
UDP-GlcNAc in the presence of divalent magnesium. The reactions catalyzed by 
the microsomal enzymes are as follows: 
Enzyme I 
Dol-P + UDP-GlcNAc .. Dol-P-P-GlcNAc + UMP 
Enzyme II 
Dol-P-P-GlcNAc + UDP-GlcNAc --- Dol-P-P-(GlcNAc)i + UDP 
(2) 
The biosynthesis of 2 from dolichol phosphate and UDP-GlcNAc appears to be 
limited due to low conversions to the desired lipid-linked mono- and 
disaccharides. This technical problem has recently been overcome by applying a 
combination of chemical and enzymatic methods. Efficient preparations of lipid-
linked substrates for assaying N-linked glycosylation are generated by treating 
synthetic Dol-P-P-GlcNAc with UDP-GlcNAc, in the presence of divalent 
magnesium and liver microsomes.55 This process results in conversions in excess 
of 60% and allows for the selective incorporation of radiolabeled GlcNAc (3H at 
C-6) at the terminal saccharide position; the specific activity of the substrate can 
therefore be varied as needed. 
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1.4.2 Peptide Acceptor 
The second substrate for N-linked glycosylation is a nascent polypeptide 
chain containing an asparagine residue within an NXT /S consensus sequence. 
As previously stated, OT does not accept peptides which contain proline as the 
middle residue in the NXT /S triad. The exclusion of NPT /S sequences suggests 
that local secondary structure plays an important role in determining the 
outcome of glycosylation. This theory is further underscored by the fact that 10-
30% of all NXT /S sequences remain unglycosylated in mature proteins, even 
though they meet the primary sequence requirements.28,56 Proteins that are 
destined for glycosylation are synthesized by membrane-associated ribosomes 
with an initial signal peptide (approximately 16 residues) which guides the 
newly synthesized protein through the intracellular membrane bilayer into the 
lumen of the endoplasmic reticulum (ER). The signal peptide is subsequently 
cleaved by a signal peptidase. The NXT /S sequence must clear the lumenal side 
of the membrane bilayer by 12-14 residues before glycosylation can occur; 
however, the nascent polypeptide remains bound to the membrane of the ER and 
is likely to be only locally folded during OT mediated catalysis.57 In fact, a direct 
correlation between lack of tertiary structure and glycosylation acceptor ability 
has been observed by subjecting unglycosylated NXT /S sequences in native 
proteins to varying levels of reducing and denaturing conditions and then 
reexamining these unfolded proteins for substrate behavior with OT. In many 
cases, the proteins did not exhibit any glycosyl acceptor properties prior to 
unfolding; however, three out of seven of the proteins examined were efficiently 
glycosylated following sulfitolysis.58 
In the cellular process, OT recognizes an extended peptide sequence as it 
crosses the membrane bilayer; however, the tripeptide recognition sequence is 
sufficient for in vitro glycosylation, provided the two termini are capped by 
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protecting groups which mimic the amide backbone of an extended peptide. 
With synthetic tripeptides, OT will glycosylate peptides capped with benzoyl 
(Bz), octanoyl, butanoyl, acetyl (Ac), carbobenzyloxy (Cbz) and tert-
butoxycarbonyl (Boe) groups at the amino terminus, although the carbamate 
modifications of the Cbz and Boe groups yield very poor substrates.59-62 The 
carboxy terminus is most effectively protected as a primary or secondary amide, 
although methyl esters are tolerated. The tripeptide Bz-Asn-Leu-Thr-NHMe (3, 
Bz-NLT-NHMe), where the amino terminus has been protected with a benzoyl 
group and the carboxy terminus as a methyl amide, is an effective synthetic 
tripeptide for in vitro investigations.62 
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The tripeptide consensus sequence has been thoroughly investigated by 
selective replacement of each amino acid with key natural and synthetic amino 
acids and reexamination of the substrate behavior of the new tripeptide analog. 
These studies have revealed that the first position in the sequence almost 
invariably requires an asparagine residue. Tripeptides containing glutarnine or 
N~Lmethylasparagine are not tolerated by the enzyme nor do they inhibit the 
glycosylation of natural sequences.62 Tripeptides containing ~-fluoroasparagine 
are very poorly glycosylated, at a rate of less than 2% that of Bz-Asn-Leu-Thr-
NHMe (3).63 However, the enzyme has been shown to tolerate a tripeptide 
which contains a thioasparagine [Asn(-yS)] residue in the first position. This 
compound exhibits a similar KMapp, but has a greatly reduced V max when 
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compared to Bz-Asn-Leu-Thr-NHMe.64 The second position in the consensus 
tripeptide may include most of the 20 natural amino acids except proline; in 
addition, incorporation of aspartic acid as the center residue depresses glycosyl 
acceptor efficiency. The unnatural amino acids a-aminoisobutryic acid and D-
alanine in the central position are not recognized.59 The third position, a 
hydroxy amino acid in the natural substrate sequences, is also invariant. 
Tripeptides containing Val,29 Thr(~-OMe),29,65 ~-hydroxynorvaline66 and allo-
Thr67 in the C-terminal position are not recognized by OT. Peptides which 
incorporate cysteine in this position show a low, but measurable, level of 
glycosyl acceptor activity. 
1.5 Conformational Requirements for N-Linked Glycosylation 
Oligosaccharyl transferase exhibits a simple requirement for peptidyl 
substrates containing the NXT /S consensus sequence, yet it catalyzes an unusual 
and specific reaction wherein the nucleophilicity of the asparagine side chain is 
greatly enhanced. In addition to the asparagine residue, the absolute 
requirement for an unmodified hydroxyl amino acid implies a direct role for the 
hydroxyl group in catalysis. Beyond these straightforward tripeptide 
requirements, additional features are important since many seemingly acceptable 
NXT /S sequences still remain unglycosylated following translation and 
translocation into the lumen of the ER.28,56 Understanding the potential role of 
substrate conformation in contributing to the specificity of the reaction is a 
prerequisite for developing a satisfactory mechanistic model. At the time of 
glycosylation, the peptide substrate is relatively free of tertiary structure, 
although local secondary structural motifs are still available as recognition 
elements. Since tripeptides are accepted as substrates, the length of the 
consensus triad limits the types of available hydrogen-bonded motifs to simple 
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turns, since other structural features such as a-helices or P-sheets tend to require 
longer peptides for complete formation. Tripeptide substrates are most readily 
compatible with two types of turns: The P-turn and the Asx-turn. These two 
turns are illustrated in Figure 1-4 for the peptide Ac-Asn-Xaa-Thr-NHMe. 
Asx-turn P-turn (type I) 
Figure 1-4. A Comparison Between an Asx-Turn and a P-Turn for the Tripeptide 
Ac-Asn-Xaa-Thr-NH2. 
The P-turn results in a complete chain reversal, and is characterized by a 
hydrogen bond between the threonine amide and the carbonyl of the residue 
immediately preceeding the asparagine. In the case of Ac-Asn-Xaa-Thr-NHMe 
(Figure 1-4), the hydrogen-bonding carbonyl is provided by the acetyl group. 
The Asx-turn involves a hydrogen-bonding array similar to that of a P-turn; 
however, in this case, the hydrogen bond acceptor is the carbonyl oxygen of the 
asparagine side chain. The polypeptide backbone has a more extended 
conformation and does not experience a complete chain reversal. Approximately 
18% of all asparagine and aspartic acid side chains appear to be involved in Asx-
turns in proteins.68 In fact, a statistical survey of globular proteins by Baker et 
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al. 69 indicates that 55% of all hydrogen bonds to the carbonyl side chain of 
asparagine residues are provided by the backbone NH of the (i+2) residue. It is 
noteworthy that the homologous residue glutamine is never glycosylated and 
this apparent contradiction in reactivity may be explained by the distinct 
conformational preferences of this residue. Specifically, the carboxamide side 
chain of glutamine is seldom involved in short range hydrogen-bonding 
interactions. The possibility that the Asx-turn or the ~-turn is the unique 
secondary motif preferentially recognized by OT has been considered as an 
explanation for both the specificity of the enzyme and the enhanced 
nucleophilicity of the peptidyl substrate, particularly in model mechanisms 
which rely on secondary structure to position the hydroxyl moiety within direct 
proximity to the asparagine side chain.25,26,64 
The ability of OT to recognize and glycosylate short peptidyl substrates 
has enabled researchers to investigate the structural requirements for 
glycosylation by designing molecules which contain all of the recognition 
elements of the consensus sequence, but which are constrained or restricted to 
specific conformations. Kinetic analyses of these compounds have provided a 
detailed understanding of the role of conformation in asparagine-linked 
glycosylation. 
Initial studies correlating substrate acceptor properties and solution state 
conformation suggested that the Asx-turn might be the key recognition motif.59 
To rigorously distinguish between the Asx-turn and the ~-turn, a study was 
carried out which placed the reactive tripeptide sequence with asparagine in 
either the (i) or (i + 1) position of a constrained type I ~-turn that had been built 
into the architecture of a cyclic hexapeptide (4a and 4b).60 The type I ~-turn was 
fixed by the incorporation of a prolyl-o-amino acid dipeptide at the non-reactive 
end of the cyclic compound. This dipeptide sequence imposes a constrained type 
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II ~-turn in the cyclic peptide and therefore limits the conformations accessible to 
the stucture.70 
0 H2N~~~H2N 0 
~---<'~'\( Type I 
H2N 
H~ 0 -~oH 
,,f ~N\ 
•. NH ~ 0 f==O Type I ~ 0 NH o ~-turn 
Type II i O H H N 
~-turn GN~N0 
HOA_ 0 
Type 11 06 o H H ~ ~-turn 
~-turn NJ(_,NY\ 
A O HO 
4a 4b 
One and two dimensional NMR studies were utilized to verify the turn 
conformations of compounds 4a and 4b. These two compounds were assayed for 
substrate activity with OT and compared to the activities of two standard 
peptides, Ac-Asn-Leu-Thr-OMe and Ac-Asn-Leu-Thr-NHMe. The results of 
these studies are summarized in Table 1-2. With the reactive asparagine 
conformationally constrained into a ~-turn (as in compounds 4a and 4b ), the 
resultant peptides did not exhibit any detectable substrate behavior with OT. 
Table 1-2 - Kinetic Analysis of Conformationally Constrained Peptides with 
Porcine Liver OT60 
Peptide 
Ac-Asn-Leu-Thr-OMe 
Ac-Asn-Leu-Thr-NHMe 
c(Pro-D-Ser-Asn-Gly-Thr-Val) (6a) 
c(Pro-D-Phe-Asn-Asn-Ala-Thr) (6b) 
aAc-Asn-Leu-Thr-OMe as standard 
Apparent 
KM(mM) 
6.7 
0.3 
>20 
>20 
Relative 
V (%)a 
100 
150 
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In complementary studies, a constrained Asx-turn was incorporated into a 
cyclic NXT sequence, c[Asn-Add]-Thr-NHMe (5), through a side chain to main 
chain lactam cyclization. An unnatural amino acid, (S)-2-aminodecanedioic acid 
(Add), was utilized in the central position to provide functionality for cyclization 
with the amino terminus.71 This cyclization was selected because modeling 
studies indicated that it would constrain the critical Asn \j/ and Xaa <j> dihedral 
angles to generate an Asx-turn. The presence of an Asx-turn was confirmed 
through NMR experiments on an aqueous solution of the peptide (43% 
methanol). The peptide was analyzed for substrate activity with OT and 
compared to the linear analog, NCLButanoyl-Asn-Leu-Thr-NHMe (6). 
Introduction of a cyclic constraint improved the KM tenfold, from 800 µM for 6 to 
78 µM for 5, indicating that the preorganization provided by the Asx-turn 
enhanced enzyme/substrate affinity. The relative maximal velocities of the two 
compounds remained similar. The enhancement of enzyme affinity for the 
constrained peptide, 5, with a well-defined Asx-turn conformation firmly 
demonstrates the importance of the Asx-turn over the ~-turn, as the recognition 
motif for OT. 
0 
HN✓N 0 
yo H HN 
H2N HO,, ... ~NHMe 
CH3 0 
5 
6: AfX-Butanoyl-Asn-Leu-Thr-NHMe 
7: AfX-Butanoyl-G In-Leu-Th r-N H Me 
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In addition, circular dichroism (CD) studies were carried out on 5, 6 and 
N<X-Butanoyl-Gln-Leu-Thr-NHMe (7). The spectrum obtained for 7, which is not 
a substrate for OT, resembled that of a random coil (Figure 1-5) with a strong 
negative ellipticity at 198 nM. However, the CD spectrum for 5 was quite 
distinct, with a greatly diminished negative ellipticity at 198 nm and a strong 
signal at 218 nm, providing complementary spectroscopic evidence of the 
ordered secondary structure promoted by the cyclic constraint. These results 
were independent of the solution composition which was varied from 2%-43% 
methanol in water. While the CD spectrum for 6 was primarily random coil, a 
small signal was present at 218 nm indicating the presence of some secondary 
structure.71 
Previous studies by Bause72 had examined the effects of disulfide 
constraints on glycosylation acceptor properties. In all cases where the presence 
of the disulfide enhanced a p-turn structure, glycosyl acceptor properties 
diminished. In light of the proposal that an Asx-turn is the recognition motif for 
N-linked glycosylation, reexamination of the Bause results support the 
hypothesis that acceptor ability of an NXT sequence is related to peptides which 
can access an Asx-turn motif. With a complete understanding of the necessary 
secondary structural features required for N-linked glycosylation, mechanistic 
investigations can be designed to consider the roles of the hydroxy amino acid 
and the amide backbone in enhancing the nucleophilicity of the asparagine side 
chain. 
1.6 Mechanistic Considerations 
To complete N-linked glycosylation, cooperation between OT and the 
hydrogen-bonding array provided by the peptidyl substrate results in the 
activation of a normally non-nucleophilic amino acid . Currently, the generation 
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Figure 1-5. CD Spectra of Constrained and Linear Tripeptide Substrates for 
Oligosaccharyl Transferase.71 Samples were prepared by dissolving each 
tripeptide in a 40% methanol/water solution at pH 4.5. In each case, the final 
peptide concentration was 500 µM. 
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of this unusual reactivity is the main focus of mechanistic investigations. 
Evidence in support of or against different mechanistic proposals is most readily 
obtained by examining the kinetic properties of substrate analogs. By selectively 
altering different features of a natural substrate to generate a nonnatural 
substrate or an inhibitor, information about specific features of the active site, or 
of the reaction intermediates, can be surmised. 
Initially, Marshall25 proposed that the acidity of one of the asparagine 
amide protons is increased by the presence of a hydrogen bond between the 
hydroxyl moiety of the threonine or serine and the carbonyl of the carboxamide 
side chain (Figure 1-6A). This interaction would increase the acidity of the 
carboxamide protons and thereby facilitate ionization to affording a nucleophilic 
anionic nitrogen species that could subsequently engage in the glycosylation 
event. Bause29 proposed a different hydrogen-bonding array wherein one of the 
carboxamide protons of the asparagine side chain serves as a proton donor to the 
hydroxyl group of the threonine or serine, thus increasing the nucleophilicity of 
the carboxamide nitrogen (Figure 1-6B). Both of these mechanisms rely on the 
ability of the tripeptide substrate to position the hydroxyl moiety within 
hydrogen-bonding distance of the asparagine side chain. 
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Figure 1-6. Schematic Representations of Two Different Peptide Activation 
Mechanisms for Oligosaccharyl Transferase. Figure 1-6A, proposed by 
Marshall.25 Figure 1-6B proposed by Bause.29 
Two different peptides have been examined which incorporate an aspartic 
acid in place of the required asparagine residue within the consensus triad. If, 
during the reaction course of glycosylation, a negative charge is developed on the 
asparagine nitrogen, then the aspartate replacement would potentially mimic the 
charge distribution of this intermediate and therefore afford a competitive 
inhibitor. The peptides Tyr-Asp-Leu-Thr-Ser-Val29 and Bz-Asp-Leu-Thr-
NHMe64 (8, Table 1-3) do not inhibit OT, even at high concentrations (>SmM), 
although each would be expected to maintain the hydrogen-bonding array of an 
Asx-turn; this result suggests that a negative charge is not developed at this 
center during the reaction process.64 
An additional mechanism for asparagine linked glycosylation has been 
proposed which incorporates aspects of the favored mechanism for some of the 
glutamine amidotransferase family of enzymes.73 This proposal61 involves the 
release of an active site bound "NH3" from the asparagine side chain in 
conjunction with the formation of a cyclic isoasparagine intermediate. The 
activated ammonia reacts with the lipid-linked oligosaccharide donor to form 
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chitobiosyl amine which reopens the isoasparagine to complete the glycosylation 
event. This mechanism is unlikely as the constrained peptide 5 is an optimized 
substrate for OT in spite of its inability to cyclize to isoasparagine (isoAsn). In 
addition, synthetic preparations of Bz-is0Asn-Leu-Thr-NH2 revealed that this 
tripeptide is neither a substrate for nor an inhibitor of OT. Finally, this 
mechanistic proposal does not consider the absolute requirement for a hydroxyl 
amino acid. 
The conformational studies identifying the Asx-turn as the likely 
recognition motif for asparagine linked glycosylation have prompted the 
development of a new mechanistic proposal for OT-mediated catalysis. In this 
proposal, the unique hydrogen-bonding array provided by the Asx-turn is 
suggested to facilitate protonation of the carbonyl of the asparagine side chain. 
Enzyme-mediated deprotonation at the nitrogen subsequently induces the 
tautomerization of the carboxamide to the imidol. This tautomerization would 
yield the neutral nucleophilic species which could then react with the 
electrophilic lipid-linked oligosaccharide (Figure 1-7). 
Figure 1-7. Mechanism of Activation for Oligosaccharyl Transferase as Proposed 
by Imperiali.64 
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The mechanistic proposal shown in Figure 1-7 incorporates both the issues 
of specificity and reactivity as well as the absolute requirement for a hydroxyl 
amino acid by integrating substrate structural requirements with participation of 
enzyme active site residues. Thus, the likelihood of an NXT /S sequence to 
undergo glycosylation would be governed by the ability of each potential 
substrate to adopt an Asx-turn conformation within the active site of the enzyme. 
Four tripeptide analogs of 3 were designed to probe different aspects of 
the OT peptide binding site during catalysis; a summary of the kinetic analyses 
of these compounds is listed in Table 1-3.64 Bz-Asp-Leu-Thr-NHMe (8), as 
discussed previously, exhibited no binding to OT. Replacement of the 
asparagine carboxamide with a methyl ester, in Bz-Asp(OyMe)-Leu-Thr-NHMe 
(9), removes the ionizable group from the side chain and affords a tripeptide 
which is not recognized by OT. Incorporation of y-aminobutyrine (Amb) in place 
of asparagine yields Bz-Amb-Leu-Thr-NHMe (10), a peptide with a significantly 
lower pKa at the Amb side chain. Tripeptide 10 is a competitive inhibitor of OT 
with a Ki that is similar to the KM of 3; the increased acidity of the side chain in 
10 apparently facilitates binding to the enzyme and compensates for the peptide 
not having the appropriate functionality to adopt an Asx-turn. Finally, the 
tripeptide Bz-Asn(yS)-Leu-Thr-NHMe (11) is a substrate for OT. This heteroatom 
replacement (CSNH2) increases the acidity of the hydrogen-bond donor site and 
decreases the basicity at the hydrogen-bond acceptor site relative to the 
corresponding oxoamide (CONH2).74,75 Additionally, the sulfur substitution in 
11 introduces steric perturbations into the system by increasing the double bond 
length (C=S > C=O) and atomic radius (S > 0) by approximately 25% relative to 
the corresponding carboxamide.74 The binding of 11 to OT is scarcely affected by 
the thiocarbonyl replacement which is consistent with the ability of this 
compound to adopt an Asx-turn-like conformation. However, the relative 
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maximal velocity of 11 in a standard OT assay is reduced to 8.4% of that 
observed for 3. 
8: X=CO2H 
9: X=CO2Me 
10: X=CH2N H3 + 
11: X=CSNH2 
Table 1-3 - Kinetic Analysis of Tripeptides with Porcine Liver OT.64 
Apparent KM Relative V 
Peptide (mM) (%)a 
Bz-Asn-Leu-Thr-NHMe (3) 0.24 100 
Bz-Asp-Leu-Thr-NHMe (8) 
Bz-Asp(OyMe)-Leu-Thr-NHMe (9) 
Bz-Amb-Leu-Thr-NHMe (10) 
Bz-Asn(yS)-Leu-Thr-NHMe (11) 0.26 8.4 
Ki 
(mM) 
>lOb 
>lOb 
1.0 
apeptide 3 as standard; bno inhibition observed at concentrations below 5 mM. 
Together, the results obtained from this substrate analog study suggest 
that in order for recognition by OT to occur, there is a prerequisite for side chain 
functionality with ionization properties similar to those of the native substrate. 
Tripeptide 10 is readily deprotonated and is a competive inhibitor, while 11 is a 
substrate for the enzyme. For 10, the lower pKa of the nitrogen appears to have 
allowed recognition by OT, despite the loss of the Asx-turn motif. For peptide 
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11, the KM remains similar to that of the native substrate; however, the change in 
electronic properties have resulted in a lower glycosylation rate . These results 
support mechanistic proposals which do not involve the generation of a nitrogen 
anion and are consistent with the mechanism proposed by Imperiali and 
coworkers64 which suggests that an intricate interplay between protonation and 
deprotonation is critical for the enhanced reactivity of the asparagine side chain. 
The microenvironment afforded by the hydrogen-bonding array of the Asx-turn 
provides the ideal arrangement to facilitate tautomerization. The presence of an 
active site base is a central element of this proposal as deprotonation of the 
imidol tautomer would result in the formation of a competent nucleophilic 
species. This active site base remains unidentified. 
1.7 Conformational Consequences of Protein Glycosylation 
As demonstrated above, a great deal of recent research has focused on the 
conformation of the peptidyl acceptor prior to glycosylation. However, since 
glycosylation is a co-translational event, the impact of the modification on the 
final folded protein structure and stability are also of current interest. 
Comparisons between glycosylated and non-glycosylated peptides and proteins 
can offer information on the consequences of the modification on the 
conformation of the peptide and the oligosaccharide. In many cases, the effects 
of N-linked glycosylation on the microenvironment of the asparagine residue has 
been directly observed. Several different techniques are available for analysis of 
glycopeptide structure including NMR76-79 and CD spectroscopies,80-82 molecular 
modeling predictions82,83 and fluorescence energy transfer (FET) experiments.7 
These types of analyses have been performed on proteins and smaller peptide 
fragments . 
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Nuclear Overhauser effects (NOE), amide temperature coefficient and 
deuterium isotope exchange kinetics experiments have all been used to 
investigate the structural implications of protein glycosylation. The structure of a 
glycosylated 22 residue peptide fragment, isolated from human serum 
immunoglobulin Mand containing one NVS glycosylation site, was investigated 
using selected NOE and amide temperature coefficient studies.76 The isolated 
polypeptide contained three .different glycoforms at the asparagine sidechain 
which varied in mannose content from 6 to 9 residues. Comparisons of the NOE 
data from the isolated glycopeptide and the analogous, synthetic, non-
glycosylated peptide revealed that the presence of the oligosaccharide decreased 
the conformational mobility of both the backbone and the side chains of the 
amino acids immediately surrounding the glycosylation site. In addition, the 
amides in this same region were significantly more solvent shielded in the 
glycopeptide. Analysis of the coupling constant between GlcNAcl-ClH and 
Asn9-Nc>H revealed that the protein-glycan linkage is rigid and planar. The 
presence of the three different glycoforms did not effect the resolution of the 
peptide peaks, suggesting that protein conformation is not directly affected by 
the terminal saccharide residues. 76 Additionally, hydrogen isotope exchange 
experiments were used to compare the structures of RNase A and its 
glycosylated counterpart RNase B.77 Although the presence of the 
oligosaccharide did not dramatically affect the global protein conformation, 
glycosylation did enhance the stability of the molecule. This result was 
evidenced by the decreased deuterium/proton exchange rates observed for 
several of the amides, even those buried within the protein and away from the 
oligosaccharide in RNAse B.77 
Disulfide bond equilibria and two-dimensional NMR experiments were 
used to investigate the effects of glycosylation on a 17 residue peptide derived 
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from the nicotinic acetylcholine receptor.79 This peptide is constrained by a 
disulfide bond, with one of the two cysteines in the central position of the sole 
glycosylation site (-NCT-). An analysis of the thermodynamics of disulfide bond 
formation demonstrated that the glycopeptide was more readily oxidized to the 
disulfide than the non-glycosylated peptide. In addition, NMR analysis of the 
non-glycosylated peptide revealed that approximately 50% of the proline residue 
exists as the cis isomer; glycosylation reduced this isomerism to 20% cis. The 
results from this study suggest that asparagine-linked glycosylation can have 
indirect effects on both proline isomerism and disulfide bond formation, two 
processes which are important for protein folding. 79 
Circular dichroism (CD) spectroscopy provides less direct structural 
information than NMR experiments; however, it requires significantly less 
sample and can still be used to observe dramatic conformational differences.80,81 
Analysis of eight pairs of model peptides and glycopeptides by CD has revealed 
that in hydrophobic solvent systems like trifluoroethanol or acetonitrile, 
glycosylation results in a decrease in type I ~-turn character and a concomitant 
increase in type II ~-tum character.82 This trend is reversed when the CD spectra 
are acquired in aqueous environments. One possible explanation for this 
observation is that in the more hydrophobic environments, the oligosaccharide 
interacts with the peptide backbone and side chains through a hydrogen-
bonding array; when the sample is in an aqueous environment, the medium 
provides competition for these hydrogen bonds. 
Fluorescence energy transfer experiments (FET) can also be used to 
investigate the conformational consequences of glycosylation. FET is only 
suitable for peptides which can be modified to incorporate a fluorescent donor 
and acceptor. Generally, the indole side chain of the naturally occurring amino 
acid tryptophan is employed as the donor fluorophore. Similar to CD, FET 
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requires minute quantities of sample (nmoles) and is useful for observing gross 
structural changes in peptide conformations. However, unlike CD, FET can be 
used to determine the distances between acceptor and donor moieties. 
Additionally, FET measurements can be made on the same time scale as that for 
conformational fluctuations within the molecule, so the data are not subject to the 
problems of conformational averaging observed with slower NMR experiments. 
FET has been used to investigate the direct consequences of glycosylation by 
comparing interfluorophore distances in peptides and the corresponding 
glycopeptides.7 For example, FET studies on the glycosylated and non-
glycosylated sequence Ac-Om(8Dns)-Ala-Val-Pro-Asn-Gly-Thr-Trp-Val-NH2 (12, 
based on residues A19-26 of hemagglutinin12,84) revealed the presence of two 
ensembles of populations with distinct interfluorophore distances (Figure 1-8). 
For this peptide, a distribution of conformers, centered around an 
interfluorophore distance of 15A, was observed. Upon glycosylation with a 
chitobiosyl disaccharide, this average interfluorophore distance was reduced to 
9.5A. Glycosylation appeared to induce the formation of a more compact 
structure which approximates the conformation of the glycopeptide within the 
native protein. This result implies that the glycosylation event has a direct 
impact on local peptide conformation and as it is a co-translational process, may 
play a distinct role in the process of protein folding.7 
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Figure 1-8. Dynamic Distribution Plots of 12 and Corresponding Glycopeptide in 
Aqueous Solution? 
1.8. Dissertation Research 
An examination of the current literature readily reveals the recent and 
intense interest in asparagine-linked glycosylation. Advances have been made in 
understanding both the specificity of the mod1fication and of its consequences on 
protein structure and function. However, many questions still remain on how 
nature catalyzes this modification. The research presented in this dissertation 
was designed and executed in an effort to answer some of these questions by 
further characterizing the enzyme oligosaccharyl transferase and examining its 
role in catalysis. 
Chapter two describes a series of chemical modification experiments 
designed to probe the active site of oligosaccharyl transferase for reactive amino 
acid side chains. These experiments identified a specific cysteine in the 
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oligosaccharide binding site. Further investigations, including the development 
of a novel modification reagent, localized this cysteine on the Wbplp subunit of 
OT. 
The role of the required divalent metal cofactor is investigated in chapter 
three. Experiments with a synthetic tripeptide substrate and OT which had been 
reconstituted with several different divalent metals confirmed that, during 
catalysis, the metal binding site is in direct proximity to the peptide substrate. 
This is the first evidence that the metal may play a catalytic role in N-linked 
glycosylation. These studies have also provided insight on how OT directs 
glycosylation to the nitrogen of the asparagine side chain rather than the oxygen; 
this regiochemical control is crucial for the generation of stable glycoproteins in 
VIVO. 
Chapter four discusses the synthesis and kinetic characterization of a new 
class of slow, tight binding inhibitors for OT. The nanomolar binding constants 
of these inhibitors make them more than three orders of magnitude more 
effective than any other previously reported inhibitor of OT. In addition, the 
slow binding nature of the inhibition has implications on the catalytic mechanism 
of OT. 
Finally, chapter five will provide some perspective on how the synthesis 
of the cyclic inhibitors described in chapter four can be applied to the preparation 
of several potential mechanistic inactivators of OT. Originally, a series of linear 
peptide affinity labels were prepared by introducing electrophilic moieties into 
tripeptides in place of the target asparagine residue. However, the electrophilic 
side chains spontaneously cyclized with the peptide amide backbone to generate 
analogs that were no longer useful as mechanistic probes. The cyclic nature of 
the inhibitors in chapter four is readily introduced into peptides via solid phase 
synthesis methods and can be easily adapted to introduce electrophilic groups 
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onto amino acid side chains. The cyclic constraint will prohibit cyclization by 
hindering access to the amide backbone, thereby making this class of mechanistic 
inactivators synthetically accessible. 
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Chapter 2. Chemical Modification Studies of 
Oligosaccharyl Transferase 
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2.1 Introduction 
Studies on enzyme mechanisms have often relied on kinetic assays to 
investigate reaction pathways. Historically, one of the most successful 
methods of characterizing enzyme active sites has been to observe changes in 
activity in the presence and absence of small reactive molecules. When 
combined with the proper controls, the predictable reactivity of these 
chemical modifiers can be used to suggest the identity of specific amino acids 
within the enzyme active site and may provide clues to the reaction 
mechanism utilized by the enzyme.1-3 Commercially available reagants can 
be used to target nearly all of the reactive amino acid side chains including 
cysteine, lysine, histidine, serine, aspartic acid and glutamic acid.2 Successful 
examples of this approach include the use of diethylpyrocarbonate (DEPC) to 
identify catalytic histidines in thermolysin4 and lactate dehydrogenase,5 and 
the modification of the active site cysteine of papain with 5,5'-dithiobis-(2-
nitrobenzoic acid) (DTNB).6 
Chemical modification experiments are most effectively used to 
identify residues positioned within the active site of an enzyme by 
monitoring the rate of inactivation in the presence and absence of the 
substrate(s) recognized by the enzyme. If the substrate protects the enzyme 
from inactivation, then the target amino acid probably resides in or near the 
active site. However, this observation does not automatically point to a 
residue that is directly involved in catalysis as inactivation by chemical 
modification invariably leads to the covalent attachment of a non-native 
chemical group to the enzyme. This variation in the enzyme structure could 
produce a decrease in activity through steric crowding of the active site or 
through the alteration of a crucial catalytic residue and both of these 
possibilities must be considered. For example, a cysteine in creatine kinase 
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was identified following inactivation with several different sulfhydryl 
modifiers including iodoacetamide (1AM), iodoacetic acid (IAA) and p-
chloromercuribenzoic acid. However, when creatine kinase was treated with 
methyl methanethiolsulfonate (MMTS), a cysteine modifier which 
introduces only an additional -S-CH3 group to the enzyme, the enzyme 
remained fully active, suggesting that the previously observed inactivation 
was due to steric occlusion and not mechanistic inactivation.7 
Once an active-site residue has been identified through chemical 
modification studies, additional experiments can be used to further 
characterize the overall environment of the enzyme. Most commonly, these 
experiments include modification of the enzyme with compounds which 
covalently introduce a detectable marker such as a UV chromophore, spin 
label8 or fluorescent group.3,9 Experiments designed to examine these 
markers can then be performed on the inactivated enzyme to provide 
information about the site of modification and sometimes the local 
environment of the active site. For example, the chromophore of DTNB has 
a known extinction coefficient and can be used to quantitate the number of 
free thiols and, when combined with dithiothreitol or ~-mercaptoethanol 
treatment, the total number of disulfides in the enzyme. In addition, cross-
linking agents often take advantage of modifiable residues to covalently link 
catalytic residues or protein subunits.10 
The mechanism of action for asparagine-linked glycosylation, as 
catalyzed by the enzyme oligosaccharyl transferase (OT), is a prime target for 
characterization by chemical modification studies. OT has only recently been 
purified from several sources and, although several subunits have been 
characterized, the enzyme is not yet available in large quantities.11-17 The fact 
that OT is a multi subunit, membrane bound enzyme has hindered the 
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overexpression of native activity, and even with an increase in availability, 
membrane bound enzymes have been notoriously difficult to crystallize.18 
For now, structural and mechanistic information is most readily obtained 
through the use of biochemical and kinetic experiments, including chemical 
modification studies, which require only small amounts of enzyme. 
The reaction catalyzed by OT involves the transfer of an extended 
oligosaccharide from dolichol pyrophosphate to the nitrogen of an asparagine 
residue, an unusual reaction due to the low reactivity of this carboxamide 
side chain. lmperiali and coworkers19 have proposed a mechanism in which 
the asparagine side chain carboxamide tautomerizes to an imidate with 
concomitant deprotonation by an active site basic residue; it is this 
deprotonated imidate which is sufficiently nucleophilic to complete the 
glycosylation event (Figure 2-1). The identity of the proposed active site base, 
shown in Figure 2-1, is unknown. Because this mechanism relies on a base 
which is sufficiently reactive to promote catalysis, the identification of this 
residue is a prime target for chemical modification studies. 
Figure 2-1. The Proposed Mechanism of Action for Oligosaccharyl 
Transferase.19 
Decreases in OT activity produced from chemical modifications can be 
accurately quantified through a radiolabelled assay which measures the 
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transfer of the tritiated disaccharide chitobiose from Dol-P-P-GlcNAc-
[3H]GlcNAc to the tripeptide substrate Bz-Asn-Leu-Thr-NHMe (see Appendix 
A). 20 The availability of exogenous supplies of both substrates facilitates 
substrate protection experiments which can be used to pinpoint the 
positioning of modified residues to either the peptide or oligosaccharide 
binding sites within the enzyme active site. The oligosaccharide substrate 
Dol-P-P-GlcNAc-[3H]GlcNAc is prepared through a combination of chemical 
and enzymatic methods as described in Chapter 1 and in the literature.21 This 
method incorporates a tritium label into the C-6 position of the second N-
acetylglucosamine; the specific activity of the substrate can be readily adjusted 
to enable assays at varied substrate concentrations. The tripeptide 3 can be 
prepared through standard solution phase peptide synthesis protocols. 
In addition to kinetic studies, the recent purification of S. cerevzsiae 
OT 15,22 has enabled experiments which examine the effect of chemical 
modification agents on individual subunits by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis. 
These techniques are powerful tools and, when combined with detailed 
kinetic analyses, can provide additional insight into the exact site of 
inactivation by specific reagents. An example of the purification of OT from 
S. cerevisiae15 , 22 is shown in Figure 2-2 (for more details on the 
characterization of each subunit, see chapter one) . 
This chapter describes an investigation of the active site of OT through 
chemical modification studies; these experiments were designed to probe for 
the proposed active site base. A series of chemical modification reagants were 
screened for their ability to inactivate OT. Those modifiers which produced a 
decrease in enzyme activity were further characterized through substrate 
protection experiments to determine if the modified amino acid was located 
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Figure 2-2. Purification of S. cerevisiae Oligosaccharyl Transferase.15 Lanes 
represent the following protein fractions: a) yeast rnicrosomes; b) NP-40 
solubilized microsomes; c) concanavalin A eluate; d) heparin-agarose eluate; 
e) Q-sepharose eluate; f) hydroxyapatite eluate; and g) hydroxyapatite eluate 
digested with 0.5 unit PNGaseF. The deglycosylated oligosaccharyl transferase 
complex is composed of subunits with apparent molecular weights of 55 kDa 
(Nltlp), 43 kDa (Wbplp), 34 kDa (Ost3p), and 32 kDa (Swplp); PNGaseF 
comigrates with the 34 kDa subunit. 
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in either the peptide or the oligosaccharide binding site. Specifically, these 
experiments identified a reactive cysteine residue at or near the 
oligosaccharide donor binding site. Through the development and 
application of a novel biotinylated chemical modification reagent, this 
residue, and therefore the sugar binding site, was localized to the Wbplp 
subunit of OT. 
2.2 Results and Discussion 
2.2.1 Inactivation of OT with Commercially Available Modification Agents 
The kinetic response of solubilized Saccharomyces cerevisiae OT was 
characterized following treatment with several different chemical modifiers, 
including MMTS, DTNB, p-chloromercuribenzenesulfonic acid (PCMBS), N-
ethylmaleimide (NEM), iodoacetic acid (IAA), iodoacetamide (1AM), DEPC, 
benzoic anhydride (BzAnh), acetic anhydride (AcAnh) and succinic anhydride 
(SuccAnh) (Figure 2-3). These compounds were all chosen for their ability to 
modify potential active site basic residues including cysteine, lysine and 
histidine. Particular attention was paid to compounds designed to react with 
sulfhydryl groups, based on the observation that OT activity decreased 
following exposure to the chemical oxidant m-chloroperbenzoic acid (m-
CPBA). MMTS, DTNB and PCMBS have strong affinities for free sulfhydryl 
groups, independent of the nucleophilicity of the cysteine side chain. The 
remainder of the compounds investigated rely on the presence of a 
nucleophilic moiety, so although they preferentially react with cysteine (with 
the exception of DEPC which prefers histidine), they will also react with 
lysine, histidine and extremely activated serines. Traditionally, IAA and IAM 
are both examined, even though they have similar reactivities, as IAM favors 
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Figure 2-3. Chemical Structures and Target Amino Acids of the 
Commercially Available Modifiers Used to Characterize Oligosaccharyl 
Transferase. 
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more hydrophobic environments whereas IAA favors hydrophilic 
environments. 
Several experiments were performed with each modifier using crude 
solubilized OT. First, different concentrations were examined to determine 
the level required to produce a 50% decrease in enzymatic activity following a 
2 minute preincubation. Second, the rate of inactivation over time was 
examined to verify that the loss in activity was time dependent and not due 
to simple, reversible competitive inhibition. Third, each inactivator was 
reexamined with OT that had been preincubated with either the peptide or 
the sugar substrate. These substrate protection experiments were designed to 
determine if the location of the modified residue was in either of the two 
substrate binding sites. The results from these experiments are summarized 
in Table 2-1. Finally, when appropriate, the inactivated enzyme complex was 
treated with dithiothreitol (DTT, for MMTS and DTNB studies) or 
hydroxylamine (for DEPC studies) to examine whether the inactivation was 
reversible. 
OT activity was inactivated by incubation with MMTS, PCMBS, DTNB, 
DEPC and BzAnh at low to mid micromolar concentrations (90 µM - 750 µM). 
However, NEM was a poor inactivator with 50% inactivation being observed 
at 10 mM; IAA,IAM, AcAnh and SuccAnh did not inactivate the enzyme at 
all . Several trends emerged from this study. First, the sulfhydryl modifiers, 
PCMBS and MMTS, were the most effective inactivators of OT, and activity 
was also strongly effected by DTNB, the only other compound which is 
completely selective for cysteine. Inactivation by DTNB and MMTS was fully 
reversible upon treatment with DTT, confirming the modification of a 
cysteine residue. When analyzed for substrate protection, the effectiveness of 
all three of these compounds as inactivators decreased when the enzyme was 
pretreated with Dol-P-P-GlcNAc2; this substrate protection was observed for 
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Table 2-1. Susceptibility of OT Activity to Chemical Modifiers. 
Chemical 50% Time Substrate Protection 
Reagent Inactivation Dependent Peptide Sugar 
MMTS 100 µM Yes Yes Yes 
PCMBS 90 µM Yes Partial Partial 
DTNB 425 µM Yes No Yes 
NEM 10000 µM Yes Partial Partial 
IAA No inhibition NA NA NA 
IAM No inhibition NA NA NA 
DEPC 200 µM No No No 
BzAnh. 750 µM No ND ND 
AcAnh No inhibition NA NA NA 
SuccAnh No inhibition NA NA NA 
ND - Not determined; NA - Not applicable; 50% Inactivation represents the 
concentration which produced a 50% decrease in activity relative to a control 
after a 2 minute incubation. 
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MMTS even when the inactivator concentration was increased to 500 µM (see 
Figure 2-4). MMTS and PCMBS were also partially deterred by pretreatment 
with the peptide substrate Bz-NLT-NHMe; however, this peptide substrate 
protection disappeared when the concentration of MMTS was increased (see 
Figure 2-5). These results confirmed the presence of a cysteine residue in or 
near the oligosaccharide binding site. 
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Figure 2-4. Oligosaccharide Substrate Protection from Inactivation of Crude 
Oligosaccharyl Transferaseby MMTS. Enzyme activity was measured after 2 
minutes. Preincubation conditions: • - MeOH, no substrate; T - 500 µM 
MMTS, 4.4 µM Dol-PP(GlcNAc)2; ♦ - 500 µM MMTS, no substrate. 
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Figure 2-5. Peptide Substrate Protection from Inactivation of Crude 
Oligosaccharyl Transferase by MMTS. Enzyme activity was measured after 2 
minutes . Preincubation conditions: • - MeOH, no substrate; T - 500 µM 
MMTS, 1.2 mM Bz-NLT-NHMe; ♦ - 500 µM MMTS, no substrate. 
OT activity was only slightly affected by NEM, and no inactivation was 
observed with IAA or 1AM. These inactivators all target nucleophilic 
residues and are therefore particularly useful for cysteine modification, as the 
side chain sulfur is commonly extremely nucleophilic. Although a cysteine 
residue is clearly localized at or near the active site based on the results 
discussed above, this residue does not appear to be nucleophilic, based on its 
reactivity towards these three compounds. The possibility that the decrease in 
nucleophilicity of the cysteine was the result of ligation to the required 
manganese metal cofactor was considered. To examine this hypothesis, OT 
was exhaustively treated with EDTA and O-phenanthroline to remove all 
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metal cations (confirmed by a complete loss in OT activity) . The apoenzyme 
was treated with each of the three inactivators and then reconstituted with 
manganese and examined kinetically. No increase in inactivation was 
observed, demonstrating that the poor reactivity of the cysteine towards these 
inactivators was not due to interference by chelation of the cysteine to a metal 
cation. It appears that the cysteine is unusually non-reactive towards 
electrophiles, for reasons that have not yet been identified, and the enzyme is 
only inactivated by MMTS, DTNB, and PCMBS because of their high affinities 
for sulfur. 
In contrast to the poor inactivation by NEM, OT activity was strongly 
affected by treatment with BzAnh, a modifier which will also react with any 
strong nucleophile. Further examination revealed that this inhibition was 
due to competition and not covalent modification of an amino acid; dilution 
of the enzyme inactivator complex resulted in restoration of enzyme activity. 
It has previously been observed that the peptide substrate Bz-NLT-NHMe is 
much more effective than Ac-NLT-NHMe, suggesting that OT has a specific 
preference for aromatic groups in this position.20 It is possible that BzAnh 
competitively inhibits OT by accessing this aromatic binding pocket; this 
hypothesis is further supported by the inability of AcAnh and SuccAnh, non-
aromatic anhydrides, to inhibit OT activity either competitively or 
irreversibly. 
In general, DEPC reacts preferentially with histidine, to generate an 
ethoxyformylated histidine; this modification can be readily reversed by the 
addition of hydroxylamine. DEPC is unstable at pH 7.5, the optimum pH for 
OT, thus the pH was reduced to 6.0 to sufficiently enhance the stability of the 
modifier without seriously altering the overall activity of the enzyme. OT · 
activity did decrease with DEPC treatment; however, substrate protection 
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experiments by pretreatment with either the peptide or oligosaccharide 
substrate revealed that the modified residue was not in either binding site. 
This inactivation may be caused by placing an obstruction at the entrance to 
the active site, or a modification which is well removed from the active site, 
but which disrupts the overall conformation of the enzyme. Attempts to 
regenerate OT activity through the addition of hydroxylamine were 
unsuccesful as the substrate Dol-P-P-GlcNAc2 was labile to this reagent. 
2.2.2 Design and Synthesis of N-biotinoyl(aminoethane)thiolsulfonate 
The successful modification of a cysteine residue in the Dol-P-P-
GlcNAc2 binding site provided the opportunity for further characterization of 
OT by examining the specific site of modification. Of the reagents which 
adequately and predictably reacted with this cysteine, MMTS was the most 
readily modified to incorporate a detectible tag while maintaining the reactive 
portion of the molecule. An analog of MMTS was designed which contains 
the reactive thiosulfonate moiety covalently attached to a biotin reporter 
group. This reagent, methyl N-biotinoyl-(aminoethane)-thiolsulfonate 
(BMTS, Figure 2-6), should react with the same cysteine that is modified by 
MMTS. The biotin group will provide the ability to visualize the site of 
modification by separating the subunits of the inactivated protein by SDS-
P AGE and analyzing for biotin through a Western blot with an avidin-
horseradish peroxidase conjugation system (Biorad). The synthesis of S-
(aminoethyl) methanethiolsulfonate hydrobrornide has previously been 
reported.23 BMTS was readily prepared from the condensation of this reagent 
with the p-nitrophenyl ester of biotin in the presence of mild base. 
Recrystallization from methanol afforded pure product. 
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Figure 2-6. The Chemical Modification Reagent Methyl N-Biotinoyl(amino-
ethane)thiolsulfonate (BMTS). 
2.2.2 BMTS Modification and Visualization of Wbplp Subunit 
Complete kinetic evaluations of the inhibitory properties of BMTS and 
MMTS were performed with pure OT isolated from S. cerevisiae. The 
purified enzyme complex exhibits slightly different properties than the crude 
enzyme previously characterized. Most notably, the purified enzyme requires 
the addition of 140 mM sucrose and 0.5 mg/mL phosphatidylcholine for 
stabilization, during both the purification and the kinetic assays. Presumably, 
these additives stabilize the enzyme by interacting with the Dol-P-P-GlcNAc2 
binding site; in fact, the presence of these compounds also appears to protect 
OT from inactivation from MMTS or BMTS in a manner which is analogous 
to substrate protection by Dol-P-P-GlcNAc2. This hypothesis was confirmed 
by investigating the ability of DTNB to inactivate solubilized OT under 
analogous conditions, and indeed, the DTNB concentration had to be 
increased from 425 µM to greater than 2 mM for inactivation to be observed 
when the enzyme mixture contained sucrose and PC. In a like manner, 
treatment of crude OT with 500 µM MMTS resulted in a complete loss of 
enzyme activity after only two minutes (Figure 2-4); however, when 
inactivation of pure OT was examined, significantly higher concentrations 
and longer incubation times were required to achieve similar levels of 
inactivation (Figure 2-7). Following MMTS inactivation, enzyme activity 
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could be slowly regenerated over time by treatment with 40 mM DTT at 4°C 
(Figure 2-8) . Attempts to more quickly restore enzyme activity using the 
reagent tributylphosphine were also made.24 This reagant is less hydrophilic 
than DTT and was chosen because it may be able to more readily access 
hydrophobic regions of the modified enzyme. However, these experiments 
were unsuccessful due to the lability of the enzyme in the presence of 
tributylphosphine. 
As predicted, BMTS caused a decrease in OT activity in a manner 
which was very similar to that of MMTS. At a concentration of 2.5 mM, 
BMTS exhibited time dependent inactivation of OT (Figure 2-9) and substrate 
protection when the enzyme was pretreated with the substrate Dol-P-P-
GlcNAc2 (Figure 2-10). To visualize this modification, aliquots of modified 
pure enzyme were first treated with a small burst of MMTS, to limit any non-
specific BMTS interactions. These samples were then incubated with BMTS 
for 0.5, 2, 5, and 30 minutes and quenched with cysteine (to react with the 
remaining BMTS); an additional sample was treated with BMTS for 30 
minutes and then brought to 40 mM DTT. The quenched solutions were 
divided into two parts and loaded onto 12% polyacrylamide gels for 
electrophoresis and transfer to nitrocellulose as described.15One membrane 
was probed with the avidin-biotinylated alkaline phosphatase complex 
(Pierce); the second membrane was treated with anti-Wbplp antiserum 
(provided by M. Aebi, Zurich).25 The results of these Western blots are 
shown in Figure 2-11. Although OT is a multimeric protein complex (see 
Figure 2-2), treatment of OT with BMTS resulted in the modification of 
exclusively the Wbplp subunit. The time dependence of this inactivation is 
clearly visible by the increase in the intensity of the biotin label; in addition, 
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Figure 2-7. Inactivation of Pure Oligosaccharyl Transferase by MMTS. 
Enzyme activity was monitored at various concentrations of MMTS 
( ♦ - control; • - 0.5 mM; T - 1.0 mM; ■ - 2.0 mM; _.. - 4.0 mM). 
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Figure 2-8. DTT Regeneration of Oligosaccharyl Transferase Activity 
Following Inactivation by MMTS. 
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Figure 2-9. Inactivation of Pure Oligosaccharyl Transferase by BMTS. Enzyme 
activity was monitored at various times after the addition of 2.5 mM BMTS. 
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Figure 2-10. Substrate Protection of BMTS Inactivation with Pure 
Oligosaccharyl Transferase. Enzyme activity was measured after 15 minutes. 
Preincubation conditions: • - MeOH, no substrate; T - 2.5 mM BMTS, 4.4 µM 
Dol-PP(GlcNAc)2; ♦ - 2.5 mM BMTS, no substrate. 
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Figure 2-11. Labeling of Oligosaccharyl Transferase Wbplp Subunit by BMTS. 
Top: Time-dependent labeling of oligosaccharyl transferase with 2.5 mM 
BMTS. Aliquots of the BMTS-treated enzyme were prepared and visualized 
as described in the text. Each lane contains an aliquot quenched after a 
different time interval: a) 0.5 minutes, b) 2.0 minutes, c) 5.0 minutes, d) 30.0 
minutes, and e) 30.0 minutes (treated with DTT). 
Bottom: Anti-Wbplp staining of BMTS-treated aliquots. Identical amounts of 
the same samples were probed with antiserum raised against Wbplp25 and 
developed with an anti-rabbit IgG alkaline phosphatase conjugate. The 
samples are: a) 0.5 minutes, b) 2.0 minutes, c) 5.0 minutes, d) 30.0 minutes, 
and e) 30.0 minutes (treated with DTT). 
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the biotin reporter group is completely removed upon treatment with DTT 
(Figure 2-llA). When combined with the fact that pretreatment of OT with 
the substrate Dol-P-P-GlcNAc2 produces substantial substrate protection, these 
results suggest that the sugar substrate binding site can be found on the 
Wbplp subunit, or at the interface of this subunit and the rest of the protein 
complex. 
2.3 Conclusions 
Overall, characterization of OT through the use of commercially 
available chemical modification agents has revealed that a cysteine residue is 
located at or near the binding site for the substrate Dol-P-P-GlcNAc2. It 
remains to be determined if this cysteine is catalytically important. In 
addition, BMTS was designed and synthesized and successfully inactivated 
the purified oligosaccharyl transferase complex. Visualization of this 
inactivation placed the site of modification, and consequently the sugar 
substrate binding site, on the Wbplp subunit. 
These studies were initially designed to probe for an active site base at 
or near the peptide binding site. However, the only reactive residue which 
was identified was placed in the oligosaccharide binding site. Inactivation 
due to the modification of this cysteine was not affected by pretreatment of 
the enzyme with Bz-NLT-NHMe suggesting that this residue is too far 
removed from the peptide binding site to be the active site base. This 
observation does not preclude the presence of an active site base for several 
reasons. First, the residue may not be reactive towards the reagents used in 
this study. This possibility could be examined through further modification 
studies. For example, an aspartic or glutamic acid side chain could function as 
an active site base. These residues would be most readily detected by 
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treatment of the enzyme with a carbodiimide and glycine to modify the 
carboxylate side chains. Second, the base required for deprotonation of the 
imidate may not be provided by an amino acid side chain, and instead may be 
the result of the activation of a water molecule via metal coordination. And 
finally, this catalytic residue may be inactive prior to treatment of the enzyme 
with the peptide substrate. These last two possibilities are most readily 
examined through the use of affinity labels, compounds which resemble the 
peptide substrate but have been altered to contain highly reactive electrophilic 
groups. The synthesis and kinetic evaluation of affinity labels for OT will be 
discussed in detail in chapter five. 
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2.5 Experimental 
2.5.1 Materials 
Solubilized microsomes and pure OT were isolated from 
Saccharomyces cerevisiae by Rahul Pathak as previously described.15 PCMBS, 
MMTS, DEPC, IAA, IAM and NEM were purchased from Sigma. BzAnh and 
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SuccAnh were purchased from Aldrich. AcAnh was purchased from Fisher. 
DTNB was purchased from Calbiochem. 
2.5.2 Chemical Modification of Crude Oligosaccharyl Transferase 
General Enzyme Assay 
In a typical assay, 50,000 dpm [3H]-dolichylpyrophosphoryl-N,N'-
diacetylchitobiose (specific activity 36.5 Ci/mmol) were dried down in a 
micro-centrifuge tube. The radiolabelled sugar21 was redissolved in 10 µL of a 
DMSO solution of 2.5 mM Bz-NLT-NHMe and 90 µL assay buffer (50 mM 
Tris-HCl, pH 7.5, 1.2% Triton X-100, 10 mM MnCl). The reaction was initiated 
by the addition of 100 µL of an enzyme solution prepared by diluting the 
solubilized microsomes (25 µL) to 150 µL with 7.5 µL DMSO and assay buffer. 
Reaction aliquots (4 x 40 µL) were removed at two minute intervals and 
quenched into 1.2 mL of 3:2:1 chloroform/methanol/ 4 mM MgCb. The 
tritiated glycopeptide was separated from the unreacted glycolipid through a 
series of extractions. The upper aqueous layer of the quenched reaction 
mixture was removed and the organic layer was extracted twice with 0.6 mL 
Theoretical Upper Phase with salt (TUP: 12/192/186/2.69 chloroform/ 
methanol/ water/0.25 M MgCb). The combined aqueous layers were 
quantitated for tritium content in 5.5 mL Ecolite (ICN) as disintegrations per 
minute. 
Concentration Dependence Assay 
Stock solutions of PCMBS, NEM, DTNB, IAA, IAM, and the three 
anhydrides were prepared in DMSO; solutions of MMTS were prepared in 
methanol; DEPC solutions were prepared fresh daily in DMSO. Solubilized 
microsomes (25 µL) were combined with 117.5 µL assay buffer and 7.5 µL of 
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the appropriate inactivator solution and incubated at room temperature. (An 
MES/KOH buffer at pH=6.0, with 140 mM sucrose and 1.2% Triton-X, was 
used for all DEPC experiments, rather than the standard buffer described 
above). After two minutes, 100 µL of this mixture were transferred to a 
solution containing the radiolabelled sugar donor and Bz-NLT-NHMe and 
the assay was completed as described above. A corresponding control assay 
was performed for each inactivator in which 7.5 µL DMSO (or MeOH for 
MMTS) was added to the enzyme solution. Each inactivator was examined 
over a range of final concentrations from 50 µM to 10 mM and percent 
inactivation was determined relative to the control. Unless otherwise stated, 
all further experiments were performed at the inactivator concentration 
which produced a 50% drop in enzymatic activity under these conditions. 
The concentration dependence of DTNB was also evaluated under 
conditions where the standard assay buffer had the following additions: 140 
mM sucrose and 0.5 mg/mL or 140 mM sucrose alone or 0.5 mg/mL PC alone. 
Time Dependence of Inactivation 
Solubilized microsomes (50 µL) were combined with 15 µL PCMBS, 
NEM, DTNB, or MMTS solution and 235 µL assay buffer. This solution was 
incubated at room temperature and 100 µL aliquots were removed after 2 and 
15 minutes. Aliquots were assayed as described above. Time dependence was 
determined relative to a control experiment. 
Peptide Substrate Protection - Bz-NLT-NHMe 
Solubilized microsomes (25 µL), 110 µL assay buffer and 7.5 µL 20 mM 
Bz-NLT-NHMe in DMSO were combined and incubated at room temperature 
for several minutes. An aliquot of inactivator (7.5 µL) was added. After two 
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minutes, 100 µL of this mixture was transferred to a solution of Dol-P-P-
GlcNAc2 (50,000 dpm, 36.5 Ci/mmol) in 10 µL DMSO and 90 µL assay buffer; 
the assay was completed as described above. Two controls were performed for 
each inactivator. First, the inactivator was replaced by 7.5 µL DMSO (or 
MeOH). Second, the Bz-NLT-NHME was omitted from the enzyme 
preincubation and the Dol-P-P-GlcNAc2 (50,000 dpm, 36.5 Cimmol) was 
dissolved in 10 µL 10 mM Bz-NLT-NHMe in DMSO and 90 µL assay buffer 
prior to initiation of the assay. 
Preparation of Dol-P-P-GlcNAc2 with Low Specific Activity 
Dol-P-P-[3H]-GlcNAc2 (3H labeled at C-6 position of the ~-1,4 linked 
GlcNAc) was prepared as described previously.21 Material of the desired 
specific activity for each experiment was obtained by the dilution of high 
specific activity UDP-[3H]GlcNAc (36.5 Ci/mmol, NEN) with unlabelled UDP-
GlcNAc, prior to the biosynthetic preparation of the lipid-linked disaccharide. 
Sugar Substrate Protection - Dol-P-P-GlcNAc2 
Aliquots of Dol-P-P-[3H]-GlcNAc2 (200,000 dpm, 0.22 Ci/mmol) were 
dried down under nitrogen, redissolved in 10 µL DMSO and 110 µL assay 
buffer and combined with solubilized microsomes (25 µL). Two solutions 
were combined with 5 µL of either the appropriate inactivator solution (in 
DMSO or MeOH) or DMSO or MeOH. After an incubation time of two 
minutes, the assays were initiated by the addition of 50 µL of a prepared 
solution of 50 µL 2.5 mM Bz-NLT-NHMe and 200 µL assay buffer. As a 
control, 20 µL DMSO, 220 µL assay buffer, 50 µL solubilized microsomes and 
10 µL inactivator were combined and, after a two minute incubation, 150 µL 
of this mixture was transferred to a solution of Dol-P-P-[3H]-GlcNAc2 (200,000 
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dpm, 0.22 Ci/mmol) in 10 µL 2.5 mM DMSO solution of Bz-NLT-NHMe and 
40 µL assay buffer. Aliquots of each assay were removed and quenched as 
described above. 
2.5.3 Synthesis of Methyl N-Biotinoyl-(aminoethane)thiolsulfonate (BMTS) 
Methyl aminoethanethiolsulfonate hydrobromide (44 mg, 0.19 
mmol) 23 and (+)-biotin p-nitrophenyl ester (70 mg, 0.19 mmol) were 
dissolved in 0.4 mL anhydrous dimethylformamide and cooled to 0°C. 
Triethylamine (24µL, 0.19 mmol) was then added dropwise with stirring. 
After 2 hours at this temperature, an additional portion of methyl 
aminoethanethiolsulfonate hydrobromide (10 mg, 0.05 mmol) was added. 
The reaction was then stirred for 2 hours at which time the solvent was 
removed under low pressure at room temperature. The crude residue was 
then redissolved in a minimal volume of warm methanol, filtered and 
cooled to 0°C. The coupled product crystallized readily from the filtrate. 
BMTS was further purified by two additional recrystallizations from 
methanol. The reaction afforded 50 mg (70% yield) of pure white crystalline 
product. 
Mp 108-109°C. MS: [MH+] calcd. for C13H23N3O4S3, 382 obsd. 382. 1H NMR (d1 
-DMF) 8: 1.36-1.76 (m, 6H), 2.19 (t, 2H, J =7.4 Hz), 2.82 (AB, 2H, J = 0, 4.9 and 12.4 
Hz), 3.18 (m, lH), 3.37 (t, lH, J = 6.3 Hz), 3.52 (t, lH, J = 6.0 Hz), 3.58 (s, 3H), 4.28 
(m, lH), 4.45 (m, lH), 6.38 (s, lH), 6.47 (s, lH), 8.14 (t, lH, J = 5.2 Hz). 13C NMR 
(d7-DMF) 8: 26.1, 29.0, 29.1, 36.0, 36.3, 39.1, 40.7, 50.6, 56.4, 60.5, 62.1, 163.7, 173.5. 
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2.5.4 Chemical Modifications of Pure Oligosaccharyl Transferase 
General Enzyme Assay 
Modification of the purified yeast oligosaccharyl transferase with 
MMTS was performed in 50 mM HEPES, pH 7.5, 140 mM sucrose, 0.6% 
Nonidet P-40, 10 mM MnCl2 and 0.5 mg/mL phosphatidylcholine at 25°C and 
a protein concentration of 23.6 µg/mL. MMTS in 6 µL methanol was added to 
114 µL pure enzyme solution to yield final reagent concentrations of O mM, 
0.5 mM, 1.0 mM, 2.0 mM, and 4.0 mM. At various time intervals after MMTS 
addition, 30 µL of the preincubation mixture was diluted to 200 µL into the 
assay buffer containing Bz-NLT-NHMe (10 µL 2.5 mM in DMSO) and Dol-P-P-
GlcNAc2 (200,000 <lorn, 0.22 Ci/mmol). Enzyme activity was quantitated as 
described above for the solubilized microsomes and the loss of catalytic 
activity was monitored over 40 minutes. In the absence of MMTS the 
enzyme maintained full activity over this time period. 
Regeneration of Activity with Dithiothreitol 
Pure oligosaccharyl transferase was treated with MMTS as described 
above and then diluted to 40 mM DTT and stored at 4°C. The regeneration of 
activity was monitored over time by removing aliquots every 24h and 
performing the assay as described above. Unmodified oligosaccharyl 
transferase activity was not affected by the addition of DTT. Attempts to 
completely regenerate enzymatic activity with tributylphosphine24 were 
hindered due to the !ability of the enzyme in the presence of this reagent at 1 
mM concentrations. 
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Inactivation of Pure Oligosaccharyl Trans/erase with BMTS 
BMTS inactivation was carried out as described for MMTS at a final 
concentration of 2.5 mM. Inactivation was also performed in the presence of 
Dol-P-P-GlcNAc2 in order to demonstrate substrate protection by 
preincubating 100 µL of the purified enzyme complex with lxl06 dpm [3H] 
Dol-P-P-GlcNAc2 (0.22 Ci/mmol) for ten minutes. After this time, BMTS (2.5 
mM in MeOH) was added. At 15 minutes, 20 µL of the incubation mixture 
was assayed for transferase activity in 180 µL assay buffer containing 10 µL 2.5 
mM Bz-NLT-NHME in DMSO. As a control, the Dol-P-P-GlcNAc2 in the 
incubation mixture was omitted and an equivalent amount of this substrate 
was added to the assay buffer. 
Visualization of Subunit Containing the Biotin Modification 
An aliquot of purified oligosaccharyl transferase was modified with 
BMTS until the enzyme was completely inactivated. The biotinoylated 
subunit was visualized as previously described.15 
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Chapter 3. Asparagine-Linked Glycosylation: 
Metal Ion Dependence 
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3.1 Introduction 
Oligosaccharyl transferase catalyzes the glycosylation of specific 
asparagine residues within nascent peptides as they emerge into the endoplasmic 
reticulum (ER).1 The ER contains various metal ions and cofactors which can be 
used by OT to facilitate catalysis; this type of cofactor participation often 
provides enzymes with reactivity not normally available from the 20 natural 
amino acids. Because of the potential mechanistic importance of cofactor 
participation, a complete evaluation of the N-linked glycosylation process rests 
on the elucidation of the role of these constituents, including metal ions. 
OT manifests an absolute requirement for certain divalent metal cations 
for activity. In the native enzyme, Mn(II) is considered to be the endogenous 
metal ion;2 however, in reconstitution experiments, magnesium can be 
substituted for manganese with the regeneration of approximately one-third of 
the native activity.3 Manganese-dependent enzymes fall into two categories: 
those which contain a tightly bound manganese and those which are loosely 
associated with their metal cofactor.4 For the latter class of enzymes, which 
includes OT, stimulation of enzyme activity is often observed with the addition 
of exogenous manganese to the enzyme solution. In some cases, other similar 
metal cations may also effect enzyme activity. In light of the potential utility of 
manganese as a spectroscopic probe, particularly in EPR experiments,5 it is 
important to establish if the metal cofactor plays an implicit chemical role in OT 
catalysis, or if it serves simply in a structural capacity. 
A powerful tool for assessing the potential role of a metal ion in enzyme 
catalysis involves the parallel kinetic analyses of substrates and substrate analogs 
that differ only in the metal-coordinating properties of the heteroatoms at or near 
the reacting center. This approach has been used in the presence of different 
metal ions to provide valuable information on the direct catalytic role of the 
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cofactors in the hammerhead RNA self cleavage reaction6 and in 
carboxypeptidase mediated amide hydrolysis.7 In these cases, substrate analogs, 
in which an oxygen near the reactive site was replaced by a sulfur atom, were 
prepared. Kinetic analyses in the presence of different metal ions revealed a 
direct relationship between the identity and thiophilicity of the metal and the 
effectiveness of the substrate, thereby demonstrating that the metal and substrate 
interact during catalysis. 
It has recently been reported that the incorporation of thioasparagine, in 
place of asparagine, affords competent substrates for the glycosylation reaction 
catalyzed by OT.8 The kinetic constants for the tripeptide substrates Bz-Asn-Leu-
Thr-NHMe (1) and Bz-Asn()6)-Leu-Thr-NHMe (2) were determined with porcine 
liver OT. These two substrates exhibited similar binding constants (KM); 
however, the thioasparagine tripeptide 2 was a less efficient substrate with an 
approximate tenfold drop in maximum velocity (V maJ when compared to the 
Vmax of 1.8 Because 2 is an adequate substrate for OT and because sulfur and 
oxygen exhibit different metal binding affinities, this subtle replacement 
provides an ideal platform for the examination of the role of the required metal 
cofactor. 
1: X=O 
2: X=S 
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This chapter describes a series of experiments designed to identify and 
elucidate interactions between the peptide substrate and the required metal 
cofactor during OT mediated catalysis. Comparative kinetic analyses were 
performed on Bz-Asn-Leu-Thr-NHMe (1) and Bz-Asn()'S)-Leu-Thr-NHMe (2) 
with OT that had been independently reconstituted with four different metal 
cations. These studies revealed that specific features of the metal cofactor, 
particularly the ionic radius and thiophilicity, directly affect the substrate 
behavior of the peptide. In addition, a detailed analysis of the glycosylation 
products of 2 confirmed that glycosylation occurs predominantly or exclusively 
on the nitrogen of the thioasparagine side chain suggesting that, in natural 
systems, OT may play a specific role in directing the regiochemistry of 
glycosylation. 
3.2 Results and Discussion 
3.2.1 Oligosaccharyl Transferase Metal Cation Cofactor Requirements 
The metal cofactor requirements for oligosaccharyl transferase, isolated 
from both porcine liver and S. cerevisiae sources, were investigated (Table 3-1). 
Table 3-1. Oligosaccharyl Transferase Activity with Various Metal Cations. 
S. cerevisiae Porcine Liver 
Metal Activity(%) Activity(%) 
Mn2+ 
Fe2+ 
Co2+ 
Mg2+ 
Ca2+ 
100 
84 
32 
32 
13 
100 
50 
0 
20 
34 
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The ability of various metal cations to reconstitute OT activity was 
examined by adding exogenous metal stocks to solubilized apoenzyme and 
assaying for OT activity with the standard peptide Bz-Asn-Leu-Thr-NHMe (1). 
For these studies, the S. cerevisiae enzyme was solubilized as previously 
described;9 the porcine enzyme was solubilized by a modification of the 
procedure described for the canine pancreas enzyme.10 Each apoenzyme was 
prepared by treating the solubilized enzyme with the chelating resin Chelex 
(BioRad) until a standard assay for OT activity (see Appendix A) revealed that a 
complete loss in enzyme activity had been achieved. Chelex is a resin bound 
form of EDTA, and its use removed the need for dialysis and greatly increased 
the availability of apoenzyme, particularly with the porcine enzyme which was 
unstable during extensive dialysis. Wild type enzyme activity could be 
regenerated by the addition of exogenous manganese. After solubilization in a 
detergent buffer with sucrose and phosphatidylcholine, the two sources of 
apoenzyme were stable for several months at-80°C. 
In each case, a final metal cation concentration of 10 mM was utilized to 
insure maximum enzyme activity. Wild type activity was observed with 
manganese ion concentrations ranging from 1 mM to 20 mM. The addition of 
several divalent metal cations, including magnesium, iron, cobalt, and calcium, 
resulted in the reconstitution of enzyme activity (see Table 3-1). Surprisingly, 
cobalt effectively reconstituted S. cerevisiae OT activity; however, it was 
ineffective with the porcine liver enzyme; the cause of this variation is currently 
unknown. Divalent zinc, nickel, cadmium, mercury, copper, lead and trivalent 
aluminum were also examined. However, these cations did not reconstitute 
enzyme activity. These studies suggest that OT has a distinct preference for 
metal cations which can adopt octahedral coordination geometries. 
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3.2.2 Kinetic Constants for 1 and 2 with Reconstituted Oligosaccharyl 
Transferase 
The kinetic constants for compounds 1 and 2 have previously been 
determined with porcine liver oligosaccharyl transferase in the presence of 
manganese.8 Compound 1 is also an excellent substrate for yeast OT;11 however, 
analysis of the thioamide 2 with the yeast enzyme revealed that 2 is not 
glycosylated and instead behaves as a competitive inhibitor with an approximate 
Ki of 100 µM. This observation is consistent with the observed differences in 
kinetic responses of the two enzyme sources. Typically, peptide substrates bind 
the S. cerevisiae enzyme more tightly (lower KM) than the porcine enzyme; 
however, they are glycosylated less efficiently (lower Vmax)- Although the 
thioamide 2 is recognized by the yeast enzyme, its V max is too low to be detected 
(as manifested by the competitive inhibition kinetics). Because of the poor 
substrate behavior of 2 with yeast OT, all further studies were performed with 
the porcine liver enzyme. 
To examine interactions between the metal cation and the peptide 
substrate during OT mediated catalysis, kinetic analyses on 1 and 2 were 
performed in the presence of four different divalent metal ions: Mn2+, Fe2+, 
Mg2+, and Ca2+. These metals were chosen because they produce significant 
rates of turnover with 1 (Table 3-1) and they represent a wide range of ionic radii 
(0.64A to 0.99A), as well as different affinities for sulfur 
(Fe2+>Mn2+>>Mg2+:::::Ca2+). Each enzyme assay was run at a final metal 
concentration of 10.5 mM which was well within the range of maximum activity 
for each of the four metals. Since the kinetic experiments did not control for Fe2+ 
oxidation, the possible effects of Fe3+ were also considered. Control experiments 
indicate that enzyme activity is not reconstituted with Fe3+. Furthermore, in the 
presence of 10 mM Fe2+, concentrations of Fe3+ below 0.5 mM did not inhibit 
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enzyme activity. Partial inhibition of OT activity due to the oxidation of Fe2+ to 
Fe3+ was observed after 6 - 8 hours of incubation in the preparative product 
synthesis; this inhibition would not be significant on the 20 minute time scale of 
the kinetic experiments. 
Each set of kinetic data was obtained from the same stock of apoenzyme 
to allow for comparison between data sets. The concentration of Dol-P-P-
GlcNAc-[3H]-GlcNAc was maintained at 12.6 nM for each kinetic experiment. 
This concentration is well below the reported KM of 1.2 µM for the lipid-linked 
substrate.3 The possibility that the KM could vary when the enzyme was 
reconstituted with the various metals was considered. However, when the Dol-
P-P-GlcNAc-[3H]-GlcNAc concentration was increased to 41.3 µM (above KM) 
for the glycopeptide synthesis, similar trends in relative velocities were observed. 
Kinetic constants were calculated based on data obtained from a Hanes 
plot (S/V vs. S where S equals the peptide concentration and V is the relative 
maximum velocity observed at each concentration).12 These constants were not 
calculated when peptide 2 was examined with OT and magnesium or calcium, 
because under these conditions, the substrate behavior was too poor. Figures 3-1 
through 3-8 show representative kinetic data for each peptide and metal cation 
combination. In addition to the kinetic analyses of 1 and 2, background rates for 
each metal were assessed in the absence of peptide substrate. These rates were 
very low and may be due either to glycosylation of endogenous proteins or to 
metal mediated breakdown of the glycosyl donor. Control experiments 
indicated that the background rates are suppressed in the presence of the 
tripeptide substrates; therefore, the rate data were used directly for calculation of 
the kinetic constants without correction. 
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Figure 3-1. Kinetic Analysis of Bz-Asn-Leu-Thr-NHMe (1) with MnCl2, (A) 
Relative rates of glycosylation with increasing concentrations of 1 (0, 0.05 mM; 
IJ.., 0.10 mM; ♦, 0.25 mM; ■, 0.5 mM; "lff, 0.75 mM; e, 1.0 mM) in the presence of 
10.5 mM MnClz. Apoenzyme was also assayed without added metal cations (Ll, 
0.5 mM Bz-Asn-Leu-Thr-NHMe (1)). (B) Hanes plot of 1 with MnClz. 
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Figure 3-2. Kinetic Analysis of Bz-Asn()S)-Leu-Thr-NHMe (2) with MnCl2. (A) 
Relative rates of glycosylation with increasing concentrations of 2 (0, 0 mM; Ji., 
0.125 mM; ♦, 0.25 mM; ■, 0.5 mM; T, 1.0 mM; e, 2.0 mM) in the presence of 10.5 
mM MnCb. (B) Hanes plot of 2 with MnCl2. 
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Figure 3-3. Kinetic Analysis of Bz-Asn-Leu-Thr-NHMe (1) with Fe(NH4)z(SO4)2. 
(A) Relative rates of glycosylation with increasing concentrations of 1 (0, 0 mM; 
.a., 0.10 mM; ♦, 0.25 mM; ■, 0.5 mM; 'lff, 1.0 mM; e, 2.0 mM) in the presence of 10.5 
mM Fe(NI-4)2(SO4)2. (B) Hanes plot of 1 with Fe(NH4)z(SO4)2. 
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Figure 3-4. Kinetic Analysis of Bz-Asn(')'S)-Leu-Thr-NHMe (2) with 
Fe(NHi)2(S04)2 . (A) Relative rates of glycosylation with increasing 
concentrations of 2 (0, 0 mM; A, 0.125 mM; ♦, 0.25 mM; ■, 0.5 mM; T, 1.0 mM; e, 
2.0 mM) in the presence of 10.5 mM Fe(NH4)2(S04)2. (B) Hanes plot of 2 with 
Fe(NH.i)2(S04)2. 
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Figure 3-5. Kinetic Analysis of Bz-Asn-Leu-Thr-NHMe (1) with MgCb. (A) 
Relative rates of glycosylation with increasing concentrations of 1 (0, 0 mM; .A., 
0.25 mM; ♦, 0.5 mM; ■, 1.0 mM; "'ff, 2.0 mM; e, 5.0 mM) in the presence of 10.5 
mM MgCl2. (B) Hanes plot of 1 with MgCb, 
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Figure 3-6. Kinetic Analysis of Bz-Asn(yS)-Leu-Thr-NHMe (2) with MgCb, 
Relative rates of glycosylation with increasing concentrations of 2 (0, 1.0 mM; .A., 
2.0 mM; ♦, 5.0 mM) in the presence of 10.5 mM MgCl2. 
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Figure 3-7. Kinetic Analysis of Bz-Asn-Leu-Thr-NHMe (1) with CaCh. (A) 
Relative rates of glycosylation with increasing concentrations of 1 (0, 0 mM; 
.A.,0.10 mM; ♦, 0.25 mM; ■, 0.5 mM; T, 1.0 mM; e, 2.0 mM) in the presence of 10.5 
mM CaCl2. (B) Hanes plot of 1 with CaCI2. 
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Figure 3-8. Kinetic Analysis of Bz-Asn()'S)-Leu-Thr-NHMe (2) with CaCl2, (A) 
Relative rates of glycosylation with increasing concentrations of 2 (0, 1.0 mM; •, 
2.0 mM; ♦, 5.0 mM) in the presence of 10.5 mM CaCb. 
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The Michaelis-Menten constants for both 1 and 2, with OT and each metal 
ion, are listed in Table 3-2 for comparison. These results represent constants 
obtained from a typical set of experiments. 
Table 3-2. Kinetic Parameters for Bz-Asn-Leu-Thr-NHMe (1) and Bz-Asn()'S)-
Leu-Thr-NHMe (2) with OT Reconstituted with Various Divalent Metal Cations. 
Bz-Asn-Leu-Thr-NHMe (1) Bz-Asn()'S)-Leu-Thr-NHMe (2) 
Apparent Vmax Apparent Vmax 
Metal Ion KM (µM) (dpm/min) KM (µM) (dpm/min) 
Mn2+ 380 4550 380 326 
Fe2+ 650 2120 680 703 
Ca2+ 1100 4800 NA No Rate 
Mg2+ 2500 2930 >5000 <100 
NA - Not applicable 
The substrate behaviors of 1 and 2 with OT and the various metal cations 
were very distinct (Figure 3-9). Oligosaccharyl transferase activity, when 
regenerated with manganese, produces the optimum kinetic parameters with 
compound 1. However, the KM values obtained for 1 and 2 in the presence of 
Mn2+ were found to be similar (380 µMeach); thioamide 2 was a less effective 
substrate because its V max is approximately one order of magnitude lower than 
that of the corresponding oxygen containing peptide 1. When enzymatic activity 
was restored with iron, 1 and 2 still exhibited similar binding constants (650 µM 
and 680 µM, respectively). Notably, thioamide 2 was turned over at a rate which 
was only three times slower than 1, and in fact, the relative maximum velocity 
for 2 doubled when manganese was replaced with iron. The trend in the kinetic 
parameters for calcium and magnesium is even more dramatic. While the amide 
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substrate 1 is turned over with reasonable efficiency in the presence of each of 
these metals, the thioasparagine peptide 2 is not glycosylated at all in the 
presence of calcium and is very poorly glycosylated in the presence of 
magnesium (Figure 3-9). 
The kinetic constants calculated for each peptide in the presence of the 
four different divalent metal cations followed distinct trends (Table 3-1). The 
metal ion substitution studies reveal that the asparagine-containing tripeptide is 
efficiently turned over in the presence of several metal cations (Mn2+, Fe2+, Mg2+, 
and Ca2+). For the thioasparagine peptide (2), the thiophilicity of the metal 
cation directly correlates with the efficiency of turnover. Both iron and 
manganese resulted in active complexes, and iron, the most thiophilic metal, 
yielded the highest relative rates. In contrast, when the enzyme is reconstituted 
with the oxophilic cations, magnesium and calcium, the thioasparagine peptide 
is very poorly glycosylated. The kinetic constants also appear to be correlated 
with the size of the metal cation. With peptide 1, iron and magnesium (ionic 
radii of 0.66 and 0.64 A, respectively) produced the lowest turnover rates and 
calcium and manganese (0.99 and 0.80 A, respectively) produced the highest 
rates. A different effect was observed with peptide 2 and this may be due to the 
fact that sulfur substitution imposes its own steric perturbations. Both the 
heteroatom covalent radius and the carbon-heteroatom bond length increase by 
about 25% on changing from oxygen to sulfur.13 In the case of calcium and 
peptide 2, both binding and turnover were undetectable and this may be due to 
both steric effects between the bulky sulfur and the calcium ion as well as the low 
thiophilicity of the metal. When these trends are examined together, they 
suggest that the metal cation and the peptide substrate are in proximity and may 
directly interact during the catalytic process of N-linked glycosylation. 
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Figure 3-9. Relative Rates of Bz-Asn-Leu-Thr-NHMe (1) and Bz-Asn('yS)-Leu-
Thr-NHMe (2) with Different Metal Cations. Final metal concentrations were 
10.5 mM (• - Fe(NH4)z(SO4)2; ■ -MnCb; ♦ - MgCb; • - CaCb). Peptide 
concentrations were 1.0 mM. (A) Relative rates of Bz-Asn-Leu-Thr-NHMe (1) . 
(B) Relative rates of Bz-Asn('yS)-Leu-Thr-NHMe (2). Peptide concentration was 
l.0mM. 
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3.2.3 Regiochemistry of Asparagine-Linked Glycosylation 
The kinetic experiments on peptides 1 and 2, described above, suggest that 
the metal cation is in direct proximity to the peptide substrate during catalysis. 
The conclusions drawn from these experiments relied on the assumption that 
glycosylation of the thioasparagine 2 produced a glycopeptide product (4a) 
which is directly analogous to 3, the glycopeptide product of 1. However, it has 
previously been proposed that, during the N-linked glycosylation process, the 
peptide substrate underogoes a tautomerization to an imidol (see Figure 1-7), 
and this nucleophilic species completes the glycosylation reaction.8 The 
analogous tautomerization of 2 produces a thioimidol (Figure 3-10), with two 
reactive nucleophiles and the potential to complete the glycosylation process 
through alkylation at two different sites, the nitrogen or the sulfur. 
Thioimidol 
Figure 3-10. Proposed Tautomerization of Bz-Asn()'S)-Leu-Thr-NHMe (2) within 
the Active Site of Oligosaccharyl Transferase. 
Because of the potential ambiguity introduced by tautomerization of the 
thioamide side chain, the possibility that glycosylation of 2 occurred on the sulfur 
of the thioamide substrate, rather than the nitrogen, had to be considered; this 
unusual modification would produce the glycopeptide product 4b (Figure 3-11). 
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Figure 3-11. Predicted Glycosylation Products for Oxoamide 1 and Thioamide 2. 
GlcNAcGlcNAc indicates chitobiose; asterisk indicates the presence of a tritium 
radiolabel. 
Several experiments were designed and implemented to confirm the 
identities of glycopeptides 3 and 4 (a orb). Prior to analysis, each glycopeptide 
was synthesized on a preparative scale by incubating the appropriate peptide 
with OT and low specific activity Dol-P-P-GlcNAc-[3H]GlcNAc. The products 
were purified and characterized by HPLC. The enzymatic synthesis of 3 yielded 
a chromatogram with only two peaks, the starting material 1 and the product 3. 
The radiolabeled product eluted approximately 2 minutes earlier than the 
starting material. The retention time and the presence of the tritium label were 
consistent with the formation of a glycosylated product. Mass spectral analysis 
confirmed the identity of the product peak. 
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For the turnover of peptide 2, products resulting from glycosylation at 
both sulfur and/ or nitrogen were considered. For clarity, the isolated material is 
designated as 4, and the two potential products are designated as 4a for nitrogen 
glycosylation and 4b for sulfur glycosylation (Figure 3-11). Enzymatic synthesis 
of 4 produced an HPLC chromatogram which contained the desired 
glycopeptide as well as several small side products and starting material. The 
radioactivity quantitatively eluted with the glycopeptide peak approximately 4 
minutes earlier than the corresponding peptide. These results were independent 
of the divalent metal ion (Mn2+ or Fe2+) used to prepare the glycopeptide. 
Control experiments, in the absence of enzyme, indicated that the observed side 
products result from the normal decomposition of 2; this breakdown is most 
likely due to succinimide formation with the amide nitrogen of the adjacent 
amino acid.14 The rate of decomposition was insignificant on the time scale of 
the kinetic experiments and was only observed during the longer glycopeptide 
synthesis and isolation procedures. Mass spectral analysis of the purified 
product afforded the correct molecular weight but could not be used to 
distinguish between the two possible products (4a and 4b) which have the same 
molecular formula . Capillary zone electrophoresis of 4 yielded one major peak 
(94%). 
Since 4 was only available in microgram quantities, the glycosylation 
regiochemistry had to be assessed through the use of analytical methods which 
were amenable to HPLC and TLC characterization. Treatment of 4 with mercuric 
acetate and with Raney nickel were chosen as promising options, because each of 
the reaction products obtained from these conditions could be predicted and 
were synthetically accessible for comparison. The chemical transformations that 
were investigated and the predicted products following treatment of compounds 
4a or 4b are summarized in Figure 3-12 and Figure 3-13. 
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Figure 3-12. Predicted Chemical Reactivity of Glycopeptide 4a. GlcNAcGlcNAc 
indicates chitobiose; asterisk indicates the presence of a tritium radiolabel. 
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Figure 3-13. Predicted Chemical Reactivity of Glycopeptide 4b. GlcNAcGlcNAc 
indicates chitobiose; asterisk indicates the presence of a tritium radiolabel. 
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Mercuric acetate has previously been shown to convert thioamides to their 
corresponding oxoamides in organic solvents;15,16 model reactions on N-
ethylthioacetamide indicated that mercuric acetate would effect the same 
conversion in water. As determined by HPLC analysis (Figure 3-14), treatment 
with mercuric acetate converted compound 4 to glycopeptide 3 (Figure 3-14C). 
When the radioactivity was quantified, 71 % of the tritium label was found to 
coelute with the product glycopeptide (3 ). The remaining 29% or the 
radioactivity eluted in a broad peak which was not visible at 228 or 254 nm, 
suggesting the presence of a carbohydrate fragment. As a control, compound 3 
was also treated with mercuric acetate. In this case, no reaction occurred and the 
radiolabel quantitatively eluted with 3. These results are consistent with at least 
71 % of the glycosylation occurring on the nitrogen of the thioasparagine side 
chain (4a). The reactivity of 4b in the presence of mercuric acetate was not 
predicted. 
Raney nickel reductively cleaves carbon-sulfur bonds in both 
aqueous and organic media. As illustrated in Figure 3-12, treatment of 4a with 
Raney nickel would be expected to afford a labile product which, in the presence 
of water, would hydrolyze to chitobiose (5, Sigma) and Bz-Amb-Leu-Thr-NHMe 
(6, Amb: a-aminobutyrine). HPLC analysis (Figure 3-15) of the Raney nickel 
products indicated the presence of 6, when compared to an authentic sample.8 
Furthermore, TLC analysis indicated that 40-50% of the radiolabel was converted 
from 4 to chitobiose (5). In addition, the Raney nickel treatment resulted in the 
production of 15-25% glycopeptide 3, presumably through a mechanism similar 
to that of mercuric acetate in which the thiocarbonyl is converted to an 
oxocarbonyl. The desulfurization of 4b by Raney nickel would be expected to 
yield two products (7 and 8, Figure 3-12). The imine, 7, if formed, should 
hydrolyze to the aldehyde 9 which is in equilibrium with the cyclic 
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Figure 3-14. HPLC Analysis Following Treatment of 4 with Mercuric Acetate. 
Aliquots were counted for radioactivity at one minute intervals. Asterisk 
denotes radiolabel. (A) Bz-Asn(-yS)[GlcNAcGlcNAc]-Leu-Thr-NHMe (4). (B) Bz-
Asn[GlcNAcGlcNAc]-Leu-Thr-NHMe (3). (C) Treatment of Bz-Asn(-yS)[GlcNAc-
GlcNAc]-Leu-Thr-NHMe (4) with mercuric acetate. 
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Figure 3-15. HPLC Analysis Following Treatment of 4 with Raney Nickel. 
Asterisk denotes radiolabel. (A) Bz-Asn(yS)[GlcNAcGlcNAc]-Leu-Thr-NHMe 
(4). (B) Bz-Asn[GlcNAcGlcNAc]-Leu-Thr-NHMe (3). (C) Bz-Amb-Leu-Thr-
NHMe (6). (D) Treatment of Bz-Asn(yS)[GlcNAcGlcNAc]-Leu-Thr-NHMe (4) 
with Raney nickel. 
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aminal 10. The second product would be 1-deoxychitobiose (8).17 Both 8 and 10 
were synthesized for comparison. Compound 10 was not visible by HPLC 
analysis. In the TLC analysis, compound 8 was not observed; however, an 
unidentified radiolabeled product was present which accounted for 25-35% of 
the radioactivity. Again, these results are consistent with 4a as the predominant 
glycosylation product. 
Mercuric acetate and Raney nickel analysis of 4 indicates that at least 70% 
of the glycosylation product is alkylated at the nitrogen (4a). The identity of the 
remaining 30% has yet to be confirmed. The possibility that the product 4b was 
produced, but was labile under the reaction conditions, was also considered. 
This reaction course would be manifested by the appearance of increased levels 
of peptide 1 or the corresponding glycopeptide 3. HPLC analysis revealed that 
hydrolysis of 4 to afford 1 or 3 did not occur. This observation, in combination 
with the chemical reactivity studies, confirmed that 4a, with alkylation occurring 
at the nitrogen, is the predominant glycosylation product of 2. 
In general, amide functional groups can undergo alkylation on the 
nitrogen or the oxygen to afford amide or imidate products respectively. In 
solution, the relative distributions of these two products vary depending on the 
nature of the electrophile and the reaction conditions.18 In model systems, 
electrophilic attack on thioamides occurs preferentially at sulfur.19 In the 
"normal" asparagine-linked glycosylation process, it is clear that the reaction is 
predominantly localized at nitrogen. In nature, this regiochemical control is 
important because the corresponding O-alkylated imidate products would be too 
labile to be viable in a physiological context. Therefore, in these experiments it 
was imperative to establish whether the regiochemical control with the unnatural 
thioamide substrate paralleled that of the amide substrate. A detailed analysis of 
the glycosylated thioasparagine-containing peptide did not indicate the presence 
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of sulfur alkylation products as would be manifested either by the production of 
a labile product that spontaneously hydrolyzed to the corresponding asparagine-
containing tripeptide or by formation of a stable product that could be converted 
to known authentic samples via Raney nickel or mercuric acetate treatment. In 
fact, at least 70% of the glycosylated species was directly identified as the N-
linked glycopeptide. The results from these regiochemical studies suggest that 
the catalytic machinery of OT participates in directing glycosylation to the 
appropriate site on the asparagine side chain, to generate stable and 
physiologically viable glycoprotein products. 
3.3 Conclusions 
In enzyme catalyzed glycosylation of asparagine, the distinct preference 
for manganese over magnesium argues against a specific role for the metal cation 
in coordination to the pyrophosphoryl moiety of the lipid-linked carbohydrate 
substrate. 20 The results of the comparative studies on asparagine and 
thioasparagine-containing tripeptides discussed in this chapter provide the first 
compelling evidence that the metal cofactor is proximal to the peptide binding 
site. This observation suggests the intriguing possibility that the metal cation is 
an integral part of the catalytic machinery of OT. In the future, connections 
between the divalent metal cation and catalysis can be further investigated by 
using the manganese center as a spectroscopic probe for EPR experiments to 
evaluate the interactions of the enzyme with asparagine and thioasparagine 
substrates. This information will be important in future considerations of the 
mechanism of asparagine-linked glycosylation. 
It has recently been reported that the fidelity of asparagine-linked 
glycosylation may be related to the ability of the peptide substrates to adopt an 
Asx-turn conformation.11 The hydrogen bonding network seen in this motif, 
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along with participation of the enzyme, are believed to direct the modification to 
the nitrogen of the bidentate functional group in the natural substrates. 
Although thioamides preferentially undergo sulfur alkylation in model 
systems, 19 the observation that enzyme-catalyzed thioamide glycosylation 
proceeds predominantly or exclusively at the nitrogen is consistent with the 
environment of the functional group playing an important role in targeting the 
alkylation to the correct heteroatom despite the inherent chemical tendencies of 
the system. Thus, it appears that the environment provided by OT acts in concert 
with the peptide substrate and the metal cofactor to control the regiochemistry of 
N-linked glycosylation while concomitantly catalyzing this complicated process. 
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3.5 Experimental Methods 
3.5.1 Enzyme Assays and Determination of Kinetic Constants 
General Methods 
Unless otherwise noted, mass spectral analyses were determined by the 
University of California-Riverside Mass Spectroscopy Facility using standard 
Fast Atom Bombardment (F AB) protocols. Tritium quantification was obtained 
in disintegrations per minute (dpm) on a Beckman LS-S000TD scintillation 
counter. HPLC purification and analysis were on a Beckman Dual Channel 
System operating with Sytem Gold software with an analytical grade, C-18 
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reverse phase column (25cm x 4.6mm). Proton NMR spectra were acquired on a 
Bruker AM-500 MHz spectrometer. 
Buffers and Solutions 
Buffer A contained 50 mM Hepes, pH 7.4, 1.2% Triton X-100. Buffer B 
contained 50 mM Hepes, pH 7.4, 140 mM sucrose, 1 % NP-40, 0.5 mg/mL PC. 
Buffer C contained 50 mM Hepes, pH 7.4, 1 mM DTT, 500 mM NaCl, 140 mM 
sucrose, 0.1 mM AEBSF, 2 µg/mL leupeptin and 4 µg/mL pepstatin. Buffer D 
contained 50 mM Hepes, pH 7.4, 1 mM DTT, 50 mM NaCl, 140 mM sucrose, 0.1 
mM AEBSF, 2 µg/mL leupeptin, 4 µg/mL pepstatin and 0.1 % NP-40. Buffer E 
contained 50 mM Hepes, pH 7.4, 1 mM DTT, 500 mM NaCl, 140 mM sucrose, 1 % 
NP-40, 1 mg/mL PC, 0.1 mM AEBSF, 2 µg/mL leupeptin and 4 µg/mL 
pepstatin. Theoretical Upper Phase (TUP, 12:192:186:2.69 chloroform/methanol/ 
water/0.25 M MgCb) 21 . 
Peptide Synthesis 
Peptides 1 and 2 were synthesized by standard solution phase coupling 
methods. Bz-Asn('yS)-Leu-Thr-NHMe (2) was prepared as previously described 
by converting ~-cyanoalanine to thioasparagine by sequential treatment with 
saturated ammonia in ethanol followed by hydrogen sulfide.8 
Glycolipid Synthesis 
Dol-P-P-[3H]-GlcNAc-GlcNAc (3H labeled at C-6 position of the ~-1,4 
linked GlcNAc) was prepared as described previously.22 Material of the desired 
specific activity for each experiment was obtained by appropriate dilution of 
high specific activity UDP-[3H]GlcNAc (ca. 36 Ci/mmol, NEN) prior to the 
biosynthetic preparation of the lipid-linked disaccharide. 
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Glycopeptide Synthesis 
Five samples of Dol-P-P-GlcNAc-[3H]-GlcNAc (200,000 dpm, 0.011 
Ci/mmol) were each dissolved in 20 µL 5 mM Bz-Asn-Leu-Thr-NHMe in DMSO. 
Buffer B was added to each sample in 75 µL aliquots. The glycosylation reaction 
was initiated by the addition of 100 µL solubilized porcine apoenzyme (see 
below) and 5 µL 600 mM MnCl2. After agitation for four hours at room 
temperature, the five reactions were quenched together into 6 mL 3/2/1 
chloroform/methanol/4 mM MgClz. The aqueous layer was removed and the 
organic layer washed with 2 x 3 mL TUP. The combined aqueous layers were 
washed with 1 mL chloroform and then dried under a stream of nitrogen. The 
resulting residue was partially purified by gradient elution with acetonitrile from 
a SepPak cartridge (C-18, Millipore). The product was detected by monitoring 
for radioactivity which typically eluted from the cartridge between 15% and 25% 
acetonitrile in water. Final purification was accomplished by reverse phase 
HPLC (on a C-18 analytical column, 25 cm x 4.6 mm) with a 0.1 % 
TFA/acetonitrile/water gradient from 15% - 20% acetonitrile over 25 minutes. 
Typically, 1,000,000 dpm Dol-P-P-GlcNAc-[3H]-GlcNAc afforded 250,000 dpm 
pure Bz-Asn(GlcNAc-[3H]-GlcNAc)-Leu-Thr-NHMe(3) . 
A similar procedure was utilized for the preparation of Bz-
Asn("y5)(GlcNAc-[3H]-GlcNAc)-Leu-Thr-NHMe (4). Dol-P-P-GlcNAc-[3H ]-
GlcNAc was dissolved in 5 µL DMSO and 15 µL of a 10 mM DMSO solution of 2 
and combined with 75 µL Buffer Band 100 µL of the solubilized porcine 
apoenzyme. The reaction was initiated by the addition of 5 µL 600 mM MnClz or 
600 mM Fe(NH4)z(SO4)2. The reactions were agitated for 12 hours at room 
temperature and then quenched and purified as described above. HPLC analysis 
indicated the preparation of one radiolabeled product (4) and several non-
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radiolabeled side products. Utilization of the two different divalent metals 
yielded identical HPLC chromatograms. 
The syntheses of non-radiolabeled glycopeptides 3 and 4 were 
accomplished as described above. Dol-P-P-GlcNAc-GlcNAc was prepared 
enzymatically from UDP-GlcNAc and Dol-P-P-GlcNAc by using protocols 
identical to those developed for the synthesis of radiolabeled material.22 The 
progress of the reaction was estimated by monitoring a parallel reaction using 
radiolabeled UDP-[3H]GlcNAc at identical concentrations. Products were 
purified by HPLC and elution times were identical to the corresponding 
radiolabeled analogs. The product identities were further verified by mass 
spectroscopy. Molecular weights for the two unlabeled glycosylated peptides, 3 
and 4, were determined by MALDI-Time of Flight mass spectroscopy using a 2,5-
dihydroxybenzoic acid matrix. Calculated molecular weight for 3: 869.9 (MNa+: 
892.9). Observed MNa+: 893.5. Calculated molecular weight for 4: 885.9 (MNa+: 
908.9) . Observed MNa+: 909.6. The purified glycopeptide 4 was also analyzed 
for purity by capillary zone electrophoresis. The results indicate that the sample 
obtained in the HPLC purification migrates as predominantly (94%) one peak. 
The solution state stabilities of 2 and 4 under the reaction conditions used 
throughout these experiments were assessed as follows. Four control 
experiments, A-D, were prepared by combining 5 µL 600 mM MnCl2, 5 µL 
DMSO and 155 µL Buffer A. Experiments A-C contained 15 µL 10 mM 2 in 
DMSO and experiment D contained 15 µL 10 mM 1 in DMSO. Experiment A was 
initiated by the addition of 20 µL solubilized apoenzyme. Experiment B was 
initiated by the addition of 20 µL Buffer A. Experiment C was prepared in the 
presence of 50,000 dpm Dol-P-P-GlcNAc-[3H]-GlcNAc, and was also initiated by 
the addition of 20 µL solubilized apoenzyme. Experiment D was again initiated 
by the addition of 20 µl solubilized apoenzyme. Experiments A-D were agitated 
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for 12 hours, quenched and purified as described above. HPLC traces for all four 
reactions were obtained. 
Mercuric Acetate Reactions 
Pure, radiolabeled glycopeptides 3 and 4 (50,000 dpm each, 0.011 
Ci/mmol) were dissolved in 20 µL acetonitrile and mercuric acetate (80 µL of a 1 
mg/mL water solution) was added to each glycopeptide. The reactions were 
agitated overnight and filtered through microcentrifuge filters (5000 rpm x 40 
minutes). Filtered samples were used immediately or stored at -80°C until ready 
for HPLC analysis. 
Raney Nickel Reactions 
The glycopeptide (3 or 4, 50,000 dpm, 0.011 Ci/mmol) was dissolved in 
150 µL water and excess activated Raney nickel in ethanol was added (20 µL of 
an approximately 1:1 Raney nickel:ethanol slurry). After three hours of agitation, 
a second aliquot of Raney nickel (20 µL) was added and the reaction was shaken 
for an additional 3 hours. The reaction was centrifuged briefly to settle the 
catalyst and the supernatant was removed. The catalyst was washed four times 
with 200 µL 20% acetonitrile in water. The supernatants were pooled and any 
remaining catalyst was removed through centrifugation. The final supernatant 
was dried under a stream of nitrogen and redissolved in water for HPLC and 
TLC analysis. 
HPLC Analysis 
Mercuric acetate and Raney nickel reactions were examined by analytical 
HPLC. Fractions were collected over one minute intervals and quantitated for 
3H content. Absorbances were monitored at 228 nm and 254 nm. 
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TLC Analysis 
Raney nickel reactions were applied to TLC plates (250 µM, glass, EM 
Science) in 10,000 dpm fractions and dried under vacuum. The plate was 
developed six times in 65 /35 / 4/ 4 chloroform/ methanol/water/ 15M 
ammonium hydroxide.23 Compound 3 (Rf"" 0.6), chitobiose (5, Rf= 0.33) and 2-
acetamido-1,5-anhydro-4-O-(2-acetamido-2-deoxyglucopyranosyl)-2-deoxy-glu-
citol (8, Rf = 0.53)17 were included on the same TLC plate for comparison. The 
plate was analyzed for 3H content by removing the silica in 0.5 cm portions . 
Each sample was suspended in 1 mL water and counted in 6 mL Ecolite. Non-
radiolabeled lanes were visualized by heating the TLC plate after immersion in a 
5% H2SO4 methanolic solution. 
Saccharomyces cerevisiae Oligosaccharyl Transferase 
A solubilized preparation of the yeast enzyme was prepared as previously 
described.9 Prior to assaying, the crude enzyme was diluted seven-fold with 
buffer A and the MnCl2 concentration was brought to 10 mM. A 200,000 dpm 
aliquot of Dol-P-P-GlcNAc-[3H]-GlcNAc (specific activity 36.5 Ci/mmol) was 
brought to dryness in a microcentrifuge tube. The lipid-linked donor was then 
redissolved in 10 µL DMSO, 10 µL 20 mM Bz-Asn(yS)-Leu-Thr-NHMe (2) in 
DMSO and 30 µL buffer A. The assay was initiated by the addition of 150 µL of 
the diluted enzyme. Four time points were obtained by removing 40 µL aliquots 
at 2 minute intervals. Each aliquot was quenched in a solution of 1.2 mL 3/2/1 
chloroform/methanol/4 mM MgCb. The aqueous layer was removed and the 
organic layer was washed twice with 0.6 mL TUP. The aqueous layers were 
combined and counted (dpm) in 5 mL Ecolite (ICN). 
In order to determine whether 2 is a competitive inhibitor for OT activity, 
three samples of Dol-P-P-[3H]-GlcNAc-GlcNAc (50,000 dpm, 36.5 Ci/mmol) 
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were each redissolved in 10 µL 1 mM Bz-Asn-Leu-Thr-NHMe in DMSO and 155 
µL buffer B (with 10 mM MnCb) . An additional 10 µL of DMSO or of a 1 mM or 
a 10 mM DMSO solution of Bz-Asn(-yS)-Leu-Thr-NHMe were added to each of 
the three reaction mixtures to bring the final concentration of 2 to O mM, 50 µM 
and 500 µM, respectively. Each assay was initiated by the addition of 20 µL 
undiluted, solubilized yeast OT. Time points were obtained as described above. 
Porcine Liver Oligosaccharyl Transferase 
Crude porcine liver microsomes were prepared from fresh pig liver 23 and 
solubilized by a modified version of the procedure published for the 
solubilization of canine pancreatic microsomes.1° Crude liver microsomes (30 
mL, 30% v /v glycerol suspension) were diluted to 150 mL with buffer C. This 
mixture was incubated at 0°C for 20 minutes and centrifuged for 60 minutes at 
2.5 x 105 g. The pellets were resuspended in 150 mL buffer D. This mixture was 
incubated for 20 minutes at 0°C and then centrifuged for 60 minutes at 2.5 x lQS 
g. The pellets were resuspended in 50 mL buffer E and centrifuged, following a 
20 minute incubation, for 60 minutes at 1.4 x lQS g. The supernatant was divided 
into two portions (25 and 20 mL) and stored at -80°C. 
Apoenzyme for metal reconstitution experiments was prepared as follows. 
The solubilized porcine microsomes (25 mL) were gently thawed and treated 
twice with Chelex resin (BioRad) at 4°C for five minutes each. A brief 
centrifugation (2 minutes at 2000 rpm) facilitated the separation of the resin from 
the supernatant. The solution was then brought to a final concentration of 5 mM 
EDTA and incubated for 5 minutes at 4°C. This solution was dialyzed twice 
against 500 mL buffer E for 30 minutes each time. The apoenzyme could be 
stored at -80°C for several months without loss of activity. Regeneration of 
activity was obtained by the addition of exogenous MnCl2, MgCl2, CaCl2 or 
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Fe(N~)2(S04)2 at concentrations in excess of 2 mM. Other divalent metal 
cations, including ZnCl2, NiCb, CdCl2 and C0Cl2, failed to restore activity. A 
two-fold dilution of this enzyme was used for all experiments. This dilution 
resulted in 56% conversion of Bz-Asn-Leu-Thr-NHMe (1) to 3 in 8 minutes with a 
peptide concentration of 1 mM and 200,000 dpm Dol-P-P-GlcNAc-[3H]-GlcNAc 
(specific activity 36.5 Ci/mmol). 
Determination of Kinetic Constants for 1 and 2 
In a typical experiment, six aliquots of Dol-P-P-GlcNAc-[3H]-GlcNAc 
(200,000 dpm, specific activity 36.5 Ci/mmol) were blown dry under a stream of 
nitrogen in small eppendorf tubes. A DMSO solution of Bz-Asn('yS)-Leu-Thr-
NHMe was added in 20 µL aliquots to each of five of the eppendorfs to yield 
final peptide concentrations of 2 mM, 1 mM, 500 µM, 250 µMand 125 µM. A 
blank was prepared in the same manner using 20 µL DMSO. Buffer A was added 
to each tube in 75 µL aliquots. The solubilized porcine apoenzyme (700 µL) was 
combined with 35 µL of a 400 mM solution of MnCb, MgCb, CaCb or 
Fe(N~h(S04)2 and 105 µL of this solution was used to initiate each assay. 
Aliquots (40 µleach) were removed after appropriate intervals and were treated 
as described above. The organic layers were dried and the remaining 
proteinaceous residue was redissolved in 200 µL Solvable (NEN), agitated for 30 
minutes and counted in 6 mL Formula 989 (New England Nuclear). The amount 
of radioactivity present in the aqueous extracts was normalized against the total 
radioactivity (aqueous and organic) for each sample. Each set of kinetic values 
(KM and V maJ was determined separately from the same batch of solubilized 
apoenzyme and peptide concentrations were varied as needed. 
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3.5.2 Synthetic Protocols and Physical Data - Bz-aminal-Leu-Thr-NHMe (10) 
Synthesis of Boc-Hse(OBn)-Leu-Thr-NHMe : 
OBn 
Boe-N(~ yJ,:~HMe 
H O = H 0 
'r 
Boc-Hse(OBn) (50.3 mg, 163 µmoles) was dissolved in 600 µL THF. DCC 
(36.7 mg, 178 µmoles, 1.1 eq) and p-nitrophenol (25.8 mg, 186 µmoles, 1.14 eq) 
were added. The solution was stirred for four hours and then filtered to remove 
DCU. The activated ester was briefly purified via silica gel chromatography and 
used immediately (53.6 mg, 125 µmoles). TFA-Leu-Thr-NHMe (51.4 mg, 149 
µmoles, 1.2 eq) was dissolved in 600 µL DMF and combined with triethylamine 
(39 µL, 282 µmoles, 2.2 eq). This solution was added to the activated Boc-
Hse(OBn) p-nitrophenol ester and stirred for 16 hours. The resultant tripeptide 
was purified by silica gel chromatography to yield 65 mg (121 µmoles, 68% yield) 
Boc-Hse(OBn)-Leu-Thr-NHMe. TLC: Rt = 0.45 in 5/1 chloroform/methanol. 
MS calculated for C27f41N4O7 (MH+) 537.6, observed 537.3. 1H-NMR Ott (500 
MHz, CDC!J): 7.31 (m, SH), 7.23 (d, lH, J = 8.2 Hz), 7.09 (d, lH, J = 6.7 Hz), 6.91 
(d, lH, J = 5.3 Hz), 4.48 (s, 2H), 6.06 (d, lH, J = 3.4 Hz), 4.36 (d, 2H, J = 7.1 Hz), 
4.23 (dd, lH, J = 11.6 Hz, 5.2 Hz), 3.61 (m, lH), 3.66 (m, lH), 2.08 (m, lH), 2.77 (d, 
3H, J = 4.8 Hz), 1.99 (m, lH), 1.63 (m, 2H), 1.25 (s, lH), 1.43 (s, 9H), 1.49 (m, lH), 
1.12 (d, 3H, J = 6.4 Hz), 0.89 (dd, 6H, J = 9.3 Hz, 6.3 Hz). 
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Synthesis of Bz-Hse(OBn)-Leu-Thr-NHMe: 
OBn 
} O yOH 
Bz-N-\r~~N~NHMe 
H O = H 0 
' Boc-Hse(OBn)-Leu-Thr-NHMe (61.8 mg, 115 µmoles) was dissolved in 2 
mL dichloromethane and 2 mL trifluoroacetic acid and stirred for 20 minutes. 
The TFA was removed under a stream of nitrogen and the resultant oil was 
lyophilized from water to afford a fluffy white powder which was redissolved in 
550 µL DMF. The p-nitrophenyl ester of benzoic acid was added (33 mg, 136 
µmoles, 1.2 eq) along with triethylamine (23 µL, 166 µmoles, 1.5 eq). The reaction 
was complete after 6 hours at which time the DMF was removed under vacuum. 
The product was purified by silica gel chromatography to yield 48 mg (84.9 
µmoles , 76% yield) Bz-Hse(OBn)-Leu-Thr-NHMe. TLC: Rt = 0.5 in 5/1 
chloroform/methanol. MS calculated for C29H40N4O6 (MH+) 541.6, observed 
541.3. 1H-NMR OH (500 MHz, CDCl3): 8.10 - 6.95 (m, 14H), 4.71 (dd, 1 H, J = 5.1 
Hz, 12.0 Hz), 4.51 (s, 2H), 4.52-4.45 (m, lH), 4.39 (m, 2H), 4.10 (m, lH), 3.84 (m, 
lH), 3.74 (m, lH), 2.78 (d, 3H, J = 4.8 Hz), 2.22 (m, 2H), 1.69 (m, lH), 1.60 (m, lH), 
1.51 (m, lH), 1.14 (d, 3H, J = 6.4 Hz), 0.88 (d, 3H, J = 6.5 Hz), 0.86 (d, 3H, 6.4 Hz) . 
Synthesis of Bz-Hse-Leu-Thr-NHMe: 
OH 
} O yOH 
Bz-N-\r~~N~NHMe 
H O = H 0 
' Bz-Hse(OBn)-Leu-Thr-NHMe (14 mg, 26 µmoles, 1 eq) was dissolved in 1 
mL methanol. The flask was purged with nitrogen. Approximately 2 mg 
palladium over carbon were introduced to the flask and the flask was purged 
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again and evacuated. Hydrogen gas was introduced into the flask from a balloon 
and the reaction was stirred for 30 minutes. The solution was filtered over celite 
and dried down to afford 10 mg (22.2 µmoles, 86% yield) Bz-Hse-Leu-Thr-
NHMe. TLC: Rf = 0.46 in 5/1 chloroform/methanol. MS calculated for 
C22H32N4O6 (MH+) 450.5 observed 451.3. 1H-NMR Of-I (500 MHz, CDCl3): 8.10 
(d, lH, J = 6.7 Hz), 7.75 (m, 3H), 7.53 (d, lH, J = 8.2 Hz), 7.49-7.37 (m, 4H), 7.24 
(m, lH), 4.71 (m, lH), 4.34 (m, lH), 4.25 (m, 2H), 3.68 (m, 2H), 2.72 (d, 3H, J = 4.7 
Hz), 2.1 (m, lH), 1.9 (m, lH), 1.67 - 1.53 (m, 3H), 1.1 (m, 3H), 0.88 (d, 3H, J = 4.4 
Hz), 0.83 (d, 3H, J = 4.2 Hz). 
Synthesis of Bz-Hse(OBn)-Leu-Thr(TBDMS)-NHMe: 
OBn 
) O OTBDMS 
Bz-N\r~yl~~NHMe 
H O =- H 0 
i 
Bz-Hse(OBn)-Leu-Thr-NHMe (48 mg, 88.8 µmoles, 1 eq) was dissolved in 
1 mL anhydrous acetonitrile. The solution was chilled in an ice bath and 
pyridine (34 µL, 422 µmoles, 5 eq) and TBDMS-triflate (48 µL, 209 µmoles, 2.5 eq) 
were added. The reaction was slowly warmed to room temperature and stirred 
for 90 minutes. The reaction was then quenched with saturated ammonium 
chloride and the product was extracted into chloroform. The product was 
purified by silica gel chromatography to yield Bz-Hse(OBn)-Leu-Thr(TBDMS)-
NHMe (40 mg, 61.1 µmoles, 69% yield). TLC: Rf = 0.32 in 10/1 
chloroform/methanol. MS calculated for C35H54N4O6Si (MH+) 655.9, observed 
655.4. 1H-NMR ◊H (500 MHz, CDCl3): 7.87 - 6.77 (m, 14 H), 4.66 (m, lH), 4.45 (s, 
2H), 4.43 (m, lH), 4.15 (m, 2H), 3.95 (m, lH), 3.71 (m, lH), 2.71 (d, 3H, J = 4.7 Hz), 
2.17 (m, lH), 2.11 (m, lH), 1.60 - 1.41 (m, 3H), 1.01 (d, 3H, J = 6.3 Hz), 0.81 - 0.74 
(m, 15 Hz), 0.02 (s, 3H), -0.02 (s, 3H). 
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Synthesis of Bz-Hse-Leu-Thr(TBDMS)-NHMe: 
OH 
) O yOTBDMS 
Bz-N\r~J~~NHMe 
H O ~ H 0 
i 
Bz-Hse(OBn)-Leu-Thr(TBDMS)-NHMe (13 mg, 19.9 µmoles) was 
dissolved in approximately 1 mL methanol. Reaction vessel was purged with 
nitrogen and Pd(OH)2 was added. Reaction vessel was purged again and 
evacuated. Hydrogen gas was introduced from a balloon for one hour with 
stirring. The reaction was monitored by TLC and, when complete, filtered over 
celite and dried down to afford Bz-Hse-Leu-Thr(TBDMS)-NHMe (10 mg, 17.7 
µmoles, 89.0% yield). TLC: Rf = 0.56 in 9 /1 ethyl acetate/methanol. MS 
calculated for C2sf-LisN4O6Si (MH+) 565.8, observed 565.3. 1H-NMR ◊H (500 
MHz, CDCl3): 7.83 - 7.44 (m, 6H), 6.85 (d, lH, J = 4.8 Hz), 4.95 (m, lH), 4.41 (m, 
lH), 4.33 (m, lH), 3.85(m, lH), 3.77 (m, lH), 2.80 (d, 3H, J = 4.8 Hz), 2.25 (m, lH), 
1.94 (m, lH), 1.70 (m, 3H), 1.06 (d, 3H, J = 6.3 Hz), 0.89 (m, 15 H), 0.13 (s, 3H), 0.11 
(s, 3H). 
Synthesis of 9 and 10: 
H rO OH 
sz-w\r~Jl~~NHMe 
H O ~ H 0 
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OH 0 OH 
Bz- ~~NJN ~NHMe 
H O ~ H 0 
i 
10 
Chromium (VI) trioxide (23.3 mg, 233 µmoles, 13.1 eq) and pyridine (35 
µL, 434 µmoles, 24.5 eq) were combined with 0.5 mL anhydrous dichloromethane 
and chilled to 0°C. The yellow-brown mixture was stirred for 15 minutes and a 
0.5 mL solution of Bz-Hse-Leu-Thr(TBDMS)-NHMe (10.0 mg, 17.7 µmoles, 1 eq) 
in anhydrous dichloromethane was added via cannula. The solution turned 
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black and was allowed to stir for 20 minutes at 0°C. The solution was 
immediately passed over several columns of silica gel in 9 / 1 ethyl 
acetate/methanol to completely remove the chromium. The remaining residue 
(3.1 mg) was dissolved in 30 µL acetonitrile and a 2% HF solution in acetonitrile 
(11.6 µL) was added. After 60 minutes, an additional 5.5 µL HF solution was 
added. The reaction was stirred for 90 minutes and then brought to dryness. 
The product was purified by analytical HPLC on a 10% to 30% gradient of 
acetonitrile in water (0.1 % TFA). MS calculated for C27H44N4O7 (MH+) 449.5, 
observed 449. 
Additionally, the impure product (1 mg, 2.2 µmoles, leq) was treated with 
excess sodium borohydride (0.88 mg, 23 mmoles) in methanol for 45 minutes and 
reexamined by HPLC. The product was quantitatively reduced to Bz-Hse-Leu-
Thr-NHMe. 
3.5.3 Synthetic Protocols and Physical Data - Reduced Chitobiose (8) 
Synthesis of 2-acetamido-3,6-Di-0-acetyl-4-0-(2-acetamido-3,4,6-tri-0-acetyl-2-
deoxygluco-pyranosyl)-1-chloro-1-deoxy-D-glucopyranoside: 
~~?I 
OAc~ fi)AcNH 
AcO AcNH 
The disaccharide 2-acetamido-3 ,6-Di-O-acety l-1-chloro-1-deoxy-4-O-(2-
acetamido-3 ,4,6-tri-O-acety l-2-deoxyglucopyranosyl)-D-gl u copyr anosi de was 
prepared from octaacetyl-chitobiose (56.5 mg, 83.7 µmoles) as previously 
described.17 Further purification was performed on silica gel for a final yield of 
26 mg (39.8 µmoles, 47.5% yield). TLC: Rf = 0.49 in 9 /1 ethyl acetate/methanol. 
1H-NMR 8H (500 MHz, CDCb): 6.15 - 6.10 (m, 2 H, H-1 and N-H'), 5.94 (d, lH, J 
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= 7.5 Hz, N-H), 5.29 (m, lH, H-3), 5.21(m, lH, H-3'), 5.03 (m, lH, H-4'), 4.61 (m, 
lH, H-1'), 4.45 - 4.35 (m, 4H, H-2, H-6A, H-6B, H-6A'), 4.18 (m, lH, H-5), 4.02 (m, 
lH, H-6B'), 3.87 - 3.77 (m, 2H, H-2' and H-4), 3.65 (m, lH, H-5'), 2.15 - 1.94 (m, 
21H, acetyl CH3's). 
Synthesis of 2-acetamido-3 ,6-Di-O-acetyl-1,5-anhydro-4-0-(2-acetamido-3 ,4,6-tri-O-
acetyl-2-deoxyglucopyranosyl)-2-deoxy-o-glucitol: 
OAc 
OAcs f;j AcNH 
AcO AcNH 
The heptaacetyl chloride (5.4 mg, 8.3 µmoles) was dissolved in dry toluene 
(1.1 mL) with 2 mg AIBN. Tributyl tin hydride (64 µL) was added and the 
reaction was heated at 90 °C for 11 hours. Toluene was removed and the product 
was separated from remaining starting material by silica gel chromatography for 
a final yield of 1.5 mg (2.4 µmoles, 29.2% yield). TLC: Rf = 0.30 in 9 /1 ethyl 
acetate/methanol. 1H-NMR ◊H (500 MHz, CDCl3): 5.99 (d, lH, J = 9.0 Hz, N-H'), 
5.87 (d, lH, J = 7.4 Hz, N-H), 5.16 (m, lH, H-3'), 5.06 (m, lH, H-4'), 4.93 (m, lH, 
H-3), 4.51 (d, lH, J = 8.4 Hz, H-1'), 4.39 - 4.27 (m, 3H, H-6A, H-6B, H-6A'), 4.14 -
4.10 (m, 2H, H-6B', H-2), 4.03 (d, lH, J = 12.4 Hz, H-lA), 3.93 (m, lH, H-2'), 3.64 
(m, 2H, H-4, H-5'), 3.48 (m, lH, H-5), 3.12 (m, lH, H-lB), 2.19 - 1.94 (m, 21H, 
acetyl CH3's). 
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Synthesis of 2-acetamido-1,5-anhydro-4-0-(2-acetamido-2-deoxyglucopyranosyl)-2-
deoxy-glucitol: (8) 
Car 
OH~ 
~ AcNH 
HO AcNH 
8 
The protected disaccharide 2-acetamido-3 ,6-Di-O-acety l-l,5-anhydro-4-O-
(2-acetamido-3 ,4,6-tri-O-acetyl-2-deoxyglucopyranosyl)-2-deoxy-D-gl uci to l (1.5 
mg, 2.4 µmoles) was dissolved in 0.5 mL 3/2 chloroform/methanol. A 50 µL 
aliquot of an anhydrous solution of sodium methoxide (750 mM) was added to 
the disaccharide solution. After 20 minutes, the reaction was complete by TLC. 
The solution was neutralized with Dowex-50 pyridinium-HCl, filtered and 
brought to dryness to quantitatively yield the deprotected disaccharide. TLC: Rf 
= 0.08 in 65/35/4/4 chloroform/methanol/water/15 M ammonium hydroxide. 
MS calculated for C16H2sN2O12 (MH+) 409, (MNa+) 431, observed 409 and 431. 
1H-NMR ◊H (500 MHz, d6-DMSO): 7.74 (d, lH, J = 7.83 Hz, N-H), 7.68 (d, lH, J = 
9.52 Hz, N-H'), 4.29 (d, lH, J = 8.51 Hz, H-1'), 3.74 - 3.17 (br. m, llH), 3.03 (m, 
2H), 2.91 (m, lH, H-lB), 1.74 (s, 3H, acetyl CH3), 1.71 (s, 3H, acetyl CH3). 1H 
NMR Chemical Shifts obtained from Double Quantum Filtered COSY, d6-DMSO, 
(o ppm): 7.74 (N-H), 7.68 (N-H'), 4.29 (H-1'), 3.64 (H-lA), 3.55 (H-2), 3.41 (H-2'), 
3.38 (H-3), 2.84 (H-lB). 
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Chapter 4. Design and Evaluation of Potent Inhibitors of 
Asparagine-Linked Glycosylation 
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4.1 Introduction 
One of the most powerful tools in the field of mechanistic enzymology 
is the analysis of substrate analogs as a means of probing an enzyme active 
site. A great deal of information can be acquired by monitoring changes in 
kinetic behavior following the introduction of seemingly minute alterations 
into the chemical structure of an enzyme substrate. For example, as 
demonstrated in chapter three of this dissertation, the generation of alternate, 
non-native substrates and their subsequent kinetic evaluation can be used to 
contribute to a picture of an enzyme's active site environment during the 
catalytic process. Similarly, knowledge of substrate specificities can be used to 
design compounds which no longer behave as substrates and potentially 
inhibit enzyme activity. By kinetically examining the mode of inhibition, 
these compounds can provide further information about an enzyme active 
site and its mechanistic machinery. 
In addition to providing information about the mode of action of a 
specific enzyme, inhibitors are often invaluable as therapeutic and 
biotechnological agents.1 Compactin, which targets the enzyme 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMG-CoA reductase) is a prime 
example.2 HMG-CoA reductase catalyzes the rate determining step in de 
nova cholesterol biosynthesis; compactin specifically targets and inhibits this 
enzyme and is therefore a potentially powerful anti-hypercholesterolemic 
agent.2, 3 In addition to its therapeutic benefits, compactin has been used to 
produce inhibitor resistant cell lines which dramatically overexpress HMG-
CoA reductase, thus enabling further biochemical studies.4 
Protein glycosylation has recently gained attention as a critical 
biological modification5-7 with diverse ramifications including effects on 
protein stability and folding,8 cellular targeting and sorting,9 and intercellular 
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recognition.6 Asparagine-linked glycosylation10 is the predominant protein-
carbohydrate modification in eukaryotic cells.11 Because of the widespread 
and varied roles played by N-linked glycoproteins, inhibitors which interfere 
with the biosynthesis of these biomolecules would have immediate potential 
as biotechnological tools and potential chemotherapeutic agents.12 
The biosynthetic pathway which leads to the development of 
functional asparagine-linked glycoproteins is catalyzed by a series of enzymes 
within the endoplasmic reticulum and the golgi apparatus.13 These enzymes 
can be divided into three different functions: Those involved in the 
biosynthesis of the lipid-linked tetradecasaccharide donor Dol-P-P-GlcNAQ-
Man9-Glc3 (I, Figure 4-1), 2) that which catalyzes the transfer of this 
tetradecasaccharide to an asparagine within a nascent protein (II, Figure 4-1), 
and 3) those involved in the modification of the oligosaccharide following 
transfer to the protein (III, Figure 4-2). Each individual step in this 
biosynthetic pathway represents a potential target for inhibition. Several 
inhibitors of specific enzymes in the assembly of the lipid-linked donor and 
in the processing of N-linked glycoproteins have been identified and 
characterized; some of these compounds are illustrated in conjunction with 
the relevant enzymatic steps in Figures 4-1 and 4-2. 
Enzyme inhibitors classically fall into two different categories: 
irreversible inactivators and reversible, competitive inhibitors. 1 An 
irreversible inactivator binds to and then reacts with the substrate binding site 
to form a covalent bond between the inactivator and the enzyme. Covalent 
modification results in time-dependent, irreversible inactivation of the 
enzyme activity. (The use of this type of inactivatior to investigate 
oligosaccharyl transferase will be discussed in chapter five of this 
dissertation.) Alternatively, a reversible, competitive inhibitor typically binds 
124 
®-Dolichol 
j OH 0 0 RHC=c~N 
H H ofo o 
NHAc 
HOH2C OH 
HN~ 
OH ~ .. J 
0 N 
0 
®-®- Dolichol 
j 
HO OH GlcNAc-®-®-oolichol OH 
j 
GlcNAc2-®--®-Dolichol Tunicamycin V 
Man j 
~ Man- GlcNAc2-®-®-Dolichol 
Man- Man- Man 
Man-Man_ j 
.Man 
Man- Man : Man- GlcNAc2-®-®-Dolichol 
Man-Man-Man 
M~-Ma~ j 
.Man 
Man- Man ~ Man-GlcNAc2-®-®-Dolichol 
(Glcb-Man-Man-Man 
Man-Man_ j OT 
M M .Man an- an ' 
/ 
Man- G lcNAc2 - Asn-Protein 
Glc - Glc- Glc - Man- Man- Man 
I 
II 
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Elbein).14 I. Biosynthesis of the donor Dol-P-P-GlcNAc2-Man9-Glc3; each step 
is catalyzed by a different glycosyl transferase. II. Oligosaccharyl transferase 
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to an enzyme active site with a binding affinity similar to, or more effective 
than, that of the native substrate. Competitive inhibition can often be 
reduced by an increase in the concentration of the competing substrate, by 
dilution of the enzyme-inhibitor complex, or by dialysis to remove the 
inhibitor. The inhibitors of protein glycosylation shown in Figures 4-1 and 4-
2 are all reversible, competitive inhibitors, with varying degrees of affinity for 
their specific enzymes. These compounds effectively compete for the 
substrate binding site, resulting in a reduction in enzyme activity without 
covalent modification. 
Currently, the only pre-transfer inhibitor of N-linked protein 
glycosylation that demonstrates activity at a practical concentration is the 
microbial product tunicamycin (I, Figure 4-1).19, 20 Tunicamycin does not 
specifically target OT, but rather functions by inhibiting the first step in the 
assembly of the complex, lipid-linked oligosaccharide donor (Dol-P-P-
(GlcNAc)2-(Man)9-(Glc)3) that provides the oligosaccharide moiety for all 
asparagine-linked glycoproteins.21 Although tunicamycin is active at low 
nanomolar concentrations, its use is limited because several cell cycles are 
required before the supply of the lipid-linked donor is sufficiently depleted to 
arrest protein glycosylation. Therefore, the effect of tunicamycin on protein 
glycosylation is neither specific nor immediate. The processing inhibitors 
shown in Figure 4-2 inhibit specific enzymes which manipulate the 
oligosaccharide sequence following protein synthesis and therefore do not 
completely abolish the glycosylation process. These inhibitors can be used to 
produce glycoproteins with elongated or truncated oligosaccharide chains that 
are not normally found in mature glycoproteins. The clinical potential of 
several of these inhibitors is currently being investigated.12 
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Despite the centrality of asparagine-linked glycosylation, no potent 
inhibitors for oligosaccharyl transferase, the enzyme that catalyzes the first 
committed step in this process, have been reported (II, Figure 4-1). Two 
peptidyl inhibitors for this step have previously been synthesized; however, 
characterization of their inhibitory constants revealed that they were only 
poor inhibitors of OT.22, 23 Appropriately designed inhibitors of this enzyme 
would be particularly useful because they could provide further insight into 
the mechanism of action of OT; they could be used to induce the 
overexpression of the active OT complex, a target which has remained 
elusive;24 and they could facilitate further investigations into the complex 
roles of glycoproteins by enabling the preparation of oligosaccharide depleted 
proteins. In addition, inhibitors of this process could provide new leads for 
the development of novel therapeutic strategies.12, 25 
This chapter describes the development of a new class of reversible, 
competitive inhibitors for oligosaccharyl transferase. These constrained 
peptidyl compounds exhibit nanomolar binding constants and slow, tight 
binding inhibition, suggesting that they may ressemble the transition state of 
the N-linked glycosylation reaction. In addition, these compounds were 
examined for their ability to specifically inhibit OT isolated from different 
sources and these studies revealed that they are selective for OT which has 
been isolated from the yeast S. cerevisiae. 
4.2 Results and Discussion 
4.2.1 Design and Synthesis of Cyclic Inhibitors For Oligosaccharyl Transferase 
During the process of N-linked glycosylation, oligosaccharyl transferase 
catalyzes a reaction between two different substrates, a nascent polypeptide 
and a lipid-linked tetradecasaccharide; analogs of either of these two 
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substrates could be potential inhibitors. Unlike the compounds shown in 
Figures 4-1 and 4-2 which are all sugar analogs, the two reported inhibitors for 
OT are both peptidyl compounds.22, 23 The most effective of these two 
inhibitors is the tripeptide Bz-Amb-Leu-Thr-NHMe (1).23 In this peptide, the 
required asparagine residue, within the consensus sequence Bz-Asn-Leu-Thr-
NHMe, has been replaced with a y-aminobutyrine (Amb) amino acid; this 
modification increases the acidity of the side chain amine; however, it no 
longer contains the carbonyl group required to complete the hydrogen 
bonding array of the Asx-turn, the conformation that has been implicated in 
conferring substrate ability to peptides (see Figure 1-4).23 
1 : X = CH2N H3 + 
2: X = C(O)NH2 
Peptide 1 inhibits porcine liver OT with a Ki ( ~ 1 mM) that is slightly 
lower than the KM of the competing substrate Bz-Asn-Leu-Thr-NHMe (250 
µM, 2).23 This decrease in affinity is most likely associated with the second 
peptide's inability to adopt a formal Asx-turn. The absence of the side chain 
carbonyl in the Amb residue does not preclude access to an Asx-turn-like 
form, but it does remove the crucial and defining stabilization factor. 
However, the observation that inhibition occurs, albeit weakly, when an 
asparagine residue is replaced with an Amb residue provided a starting point 
for the design of a more potent inhibitor of OT. 
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Previously, it has been reported that the incorporation of a constrained 
Asx-turn into a tripeptide substrate (3) results in a tenfold improvement in 
binding affinity (KM) for OT.26 In an effort to improve the inhibitory 
behavior of 1, it was of interest to introduce a similar constraint into an Amb 
containing tripeptide. The cyclic, constrained peptide 4, in which the 
asparagine side chain of 3 was replaced with an Amb residue was therefore 
designed and synthesized for biochemical studies. 
0 
HN,~ HN O 
H2N H0,,,.0NHMe 
CH3 O 
3 
The syntheses of 3 and 4 proceed through the incorporation of the 
unnatural amino acid a-aminodecanedioic acid (Add) into the appropriate 
tripeptide prior to cyclization; the synthesis of 3 has been previously 
reported. 26 The ring closure, which introduces the required constraint, 1s 
effected by activating the Add side chain carboxylic acid as a 
pentafluorophenyl ester for base-induced condensation with the amino 
terminus of the tripeptide. Following synthesis and purification, tripeptides 3 
and 4 were each analyzed with OT isolated from S. cerevisiae; peptide 3 is a 
substrate with a KM of 78 µM, whereas 4 is an effective competitive inhibitor 
of the enzyme with a Ki of 50 µM. Thus, the introduction of the cyclic 
constraint produced an inhibitor 4 that can obtain a conformation which 
resembles an Asx-turn and therefore exhibits an improved Ki (as compared to 
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1) which is essentially identical to the binding affinity of the analogous 
substrate 3. 
Several additional modifications were considered in an effort to 
further develop peptide 4. These alterations were specifically designed to 
improve the synthetic accessibility of the inhibitor while simultaneously 
enhancing its binding affinity for OT. Most notably, it was believed that an 
increase in the length of the tripeptide backbone of 4 to a hexapeptide would 
offer several advantages. OT recognizes an extended peptide chain during in 
vivo glycosylation, and statistical studies of N-linked glycoproteins suggest 
that glycosylation is modulated by the identity of the residues flanking the 
consensus sequence.27 These observations suggest that interactions between 
OT and extended binding substrate determinants can be exploited to improve 
binding affinity. Thus, the preparation of a cyclic hexapeptide, analogous to 4, 
should generate a structure which exhibits improved recognition by OT and is 
therefore more effective as an inhibitor. 
The decision to increase the length of the peptide inhibitor prompted 
the need for the development of a solid phase synthesis method. The cyclic 
constraint could be incorporated through the introduction of an orthogonally 
protected cysteine residue and a bromohexanoyl cap on the N-terminus of the 
hexapeptide (Figure 4-3). Deprotection of the cysteine thiol and subsequent 
nucleophilic displacement of the bromine would yield the desired product,28 
with a conservative thioether replacement for one of the methylene groups 
in 4. The cyclic hexapeptide cyclo[SHex-Amb-Cys]-Thr-Val-Thr-Nph-NH2 (5, 
Nph = p-nitrophenylalanine) was chosen as the most promising inhibitor for 
evaluation with OT. This peptide contains the inhibitory portion of 4 with 
the addition of three residues on the C-terminal side of the original sequence. 
Val and Thr were selected to follow the consensus sequence based on the 
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statistical analysis of Gavel and von Heijne27 which suggests that these 
residues are prevalent in these two positions in native glycoproteins. The 
Nph residue was included to provide a diagnostic chromophore to facilitate 
purification and quantification of the final cyclic compound. In a deviation 
from 4, the formation of a thioether was selected to introduce the cyclic 
constraint. 
ys, 
H :,H O ~S-8-t-Bu 
3 N 
H 0 
HN 
CH3 
5. X = S 
6. X = 8=0 
Figure 4-3. Scheme for the Solid Phase Preparation of 5 and 6. 
Two additional potential inhibitors were prepared for further 
evaluation and for comparison to 5. The thioether of 5 was oxidized to a 
sulfoxide ( 6) as it has previously been demonstrated that constrained 
thioethers and sulfoxides can favor different conformations and may 
therefore exhibit different inhibitory properties.29 The possibility that two 
diastereomeric sulfoxides were generated during this reaction was considered; 
however, only one product was observed by HPLC analysis, suggesting that a 
single diastereomer was formed. The unconstrained analog 7, with the 
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peptide sequence NCX-hexanoyl-Amb-Cys(S-S-tert-butyl)-Thr-Val-Thr-Nph-
NH2 (7, not shown), was also synthesized. 
Compounds 5 and 6 were readily prepared using standard Fmoc-based 
solid phase peptide synthesis procedures (Figure 4-4). The Amb residue was 
incorporated into the peptide as Fmoc-Amb(Boc). This amino acid can be 
prepared from Fmoc-Gln in one step via a Hofmann rearrangement using 
Pb(OAc)4 in tert-butanol. 30 In order to introduce the required conformational 
constraint, an orthogonally protected cysteine residue Fmoc-Cys(S-S-tert-
butyl) was incorporated into each peptide28 and the N-terminus of the 
completed peptide was capped with 6-bromohexanoic acid. The cysteine side 
chain was deprotected by treatment with tributylphosphine and the 
cyclization was affected via alkylation at the C-6 carbon of the hexanoic acid. 
Direct cleavage from the resin at this stage afforded peptide 5. The related 
product, 6, was generated by mild oxidation (H202) prior to cleavage from the 
solid support.29 The linear analog 7 was prepared through standard methods 
and the N-terminus was capped with hexanoic acid; the cysteine side chain 
remained fully protected. Each peptide was readily purified by HPLC and the 
identity was confirmed by mass spectroscopy and amino acid analysis . Peptide 
5 was also examined by proton NMR; the ten methylene protons of the 
hexanoic acid all appeared as diastereotopic protons thereby establishing the 
introduction of the cyclic constraint. 
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NHr Amb(Boc)-Cys(S-StBu)-Thr(OtBu)-Val-Thr(OtBu)-Nph-'8 
Bromohexanoic acid ( 4.8 eq) 
DIPCDI (4.8 eq) 
TEA (1 eq) 
BrHex-Amb(Boc)-Cys(S-StBu)-Thr(OtBu)-Val-Thr(OtBu)-Nph-'I 
Tributylphosphine (excess) 
BrHex-Amb(Boc)-Cys-Thr(OtBu)-Val-Thr(OtBu)-Nph-~ 
a. 1,1,3,3-TMG 
b. Cleavage from resin 
a. 1,1,3,3-TMG 
b. 30 % H20 2 
c. Cleavage from resin 
5 6 
~ - denotes solid support 
Figure 4-4. Solid Phase Synthesis and Cyclization of 5 and 6. Compounds 5 
and 6 were purified by reverse phase HPLC on a C1s column with a water/ 
acetonitrile/0.1 % TFA gradient; (1,1,3,3 -TMG: 1,1,3,3-tetrarnethylguanidine). 
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4.2.2 Kinetic Evaluation of 5, 6 and 7 
Each of the compounds (5 - 7) was evaluated using Saccharomyces 
cerevisiae oligosaccharyl transferase in a series of competitive assays with the 
standard tripeptide substrate Bz-Asn-Leu-Thr-NHMe (2). 31 For each 
experiment, the precise concentration of each inhibitor was determined 
through quantitative amino acid analysis of stock solutions. Initial 
experiments revealed that all three peptides exhibit slow, tight binding kinetic 
behavior against OT, as evidenced by the curvature of the data in Figure 4-5. 
This kinetic phenomenon is unusual and is often associated with a slow, 
structural reorganization of the enzyme/inhibitor complex to a species that 
may more closely resemble the transition state in the reaction coordinate.32 
Two different possibilities may account for this behavior with peptides 5 - 7. 
It has been proposed that asparagine glycosylation occurs following 
tautomerization with concomitant deprotonation of the asparagine side chain 
(see Figure 1-7).23 This process requires an active site base positioned in 
proximity to the asparagine side chain; the pKa of the Amb side chain ( ~ 9) is 
significantly reduced from that of an asparagine carboxamide and the slow 
binding behavior of peptides 5 - 7 may be due to deprotonation of the side 
chain to the neutral amine. Alternatively, or simultaneously, the unusual 
kinetic behaviors of these three peptides may be due to the peptides slowly 
accessing a more appropriate conformational space, perhaps analogous to an 
Asx-turn. 
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5 10 15 20 25 30 35 
Time (min) 
Figure 4-5. Inhibition of Oligosaccharyl Transferase by Compounds 5 - 7 (.&. -
no inhibitor; ♦ - 800 nM linear inhibitor 7; ■ - 200 nM cyclic sulfoxide 
inhibitor 6; • - 200 nM cyclic thioether inhibitor 5). 
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Each Ki was determined by preincubating OT with the appropriate 
peptide inhibitor at 4 °C for 30 minutes prior to the competitive assay. The 
slow binding kinetic behavior of these peptides necessitated this 
preincubation to allow the inhibitors and the enzyme to completely 
equilibrate prior to analysis. Several concentrations were examined for each 
inhibitor (Figures 4-6, 4-7 and 4-8). From this data, a concentration was 
selected which induced a moderate drop (~50%) in OT activity (as measured 
by the rate of glycosylation) in the presence of 50 µM of the competing 
substrate Bz-Asn-Leu-Thr-NHMe (1, 2xKM). The values for Ki were 
calculated for 6 and 7 as described by Segel33 by inserting this concentration 
([I]) into equation 3-1. This equation is most accurate under conditions where 
the enzyme rate is decreased by 50% (i = 0.50) in the presence of the inhibitor. 
(3-1) 
[I] - i[I] 
i represents the percent inhibition as compared to the rate of a control. 
[I] represents the inhibitor concentration. 
[S] represents the concentration of the competing substrate ([SJ = 50 µM). 
KM represents the binding constant for the competing substrate 2 (KM = 25 µM). 
A summary of the kinetic data for peptides 5 - 7 is given in Table 4-1; 
several related compounds have been included for comparison. The 
calculated Ki for 5 (37 nM) shows that this constrained peptide is at least three 
orders of magnitude more potent than any previously reported inhibitor of 
OT, 22, 23 including 123 and 4. This enhancement in potency is due to the 
collective exploitation of the specific structural features which were 
incorporated into the design, including the introduction of the cyclic 
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Figure 4-6. Concentration Dependence of 5 with Oligosaccharyl Transferase 
and Bz-Asn-Leu-Thr-NHMe (Concentration of 5: • - 0 nM; T - 7.5 nM; ■ - 75 
nM; ♦ - 750 nM; e - 7.5 µM) . 
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Time (min) 
Figure 4-7. Concentration Dependence of 6 with Oligosaccharyl Transferase 
and Bz-Asn-Leu-Thr-NHMe (Concentration of 6: A - 0 nM; T - 9.7 nM; ■ - 97 
nM; ♦ - 970 nM; • - 9.7 µM). 
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Time (min) 
Figure 4-8. Concentration Dependence of 7 with Oligosaccharyl Transferase 
and Bz-Asn-Leu-Thr-NHMe (Concentration of 7: .&. - 0 nM; T - 10 nM; ■ - 100 
nM; ♦ - 1 µM; • - 10 µM). 
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constraint and the exploitation of extended binding sites. The 3.5-fold 
difference in affinity between 5 and the cyclic sulfoxide 6 is attributed to the 
unique conformational preferences of the thioether 5. 
Table 4-1. Kinetic Constants for Inhibitors of OT 
Peptide 
Bz-NLT-NHMe (2) 
123 
4 
5 
6 
7 
25 
1000000 
sooooa 
37b 
130C 
360C 
a Not slow binding. b Ki was determined from a progress curve analysis (see 
text), k0 n = 2.4 x 104 s-1 M-1, koff = 8.9 x 10-4 s-1; for comparison, a value of 18 
nM was obtained using equation 1. c Kis were determined using equation 1. 
As the most potent inhibitor, the slow binding kinetic behavior of 5 
was more precisely delineated through a detailed kinetic evaluation using a 
progress curve analysis (Figures 4-9) for the determination of kon and k0 ££.34 
These constants were determined by examining the rate of inhibition of 5 at 
several different concentrations. (Figure 4-9A shows a representative set of 
slow binding data; these curves were obtained from a single experiment.) A 
value for kobsd was determined for each concentration by fitting the data in 
Figure 4-9 (and other experiments) to equation 3-2.34 
(3-2) 
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Uft - (uf- ui)[l - exp(-kobsdt)] 
Dpm = ---------- + Dpm0 
kobsd 
Dpm represents disintegrations per minute. 
Dpmo represents dpm at t = 0. 
Uf and Ui represent the final and initial velocities (estimated from the data for 
each individual experiment). 
Values for Kon and Koff were determined from a replot of the calculated kobsd 
vs. inhibitor concentration, using equation (3-3). 
(3-3) 
[I] = [5]. 
[S] = [2] = 37.5 µM. 
KM=25µM . 
The value for Ki given in Table 4-1 is the ratio of the Koff and K0 n34 and was 
determined from average values for kobsd over several experiments (Figure 4-
9B, 1 - 4 measurements were made at each inhibitor concentration). The low 
nanomolar Ki for 5 makes it the most potent inhibitor of OT identified to 
date. In addition, the slow binding kinetic behavior of this compound may, 
in the future, shed light on the mechanism of action of asparagine-linked 
glycosylation. 
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Figure 4-9. Characterization of the Slow, Tight Binding Inhibition of 
Oligosaccharyl Transferase by 5. A. Inhibition of OT Activity by Compound 5 
(.a. - no inhibitor; • - 37.5 nM inhibitor; ■ - 75 nM inhibitor; ♦ - 150 nM 
inhibitor; T - 300 nM inhibitor). B. Plot of kobsd (calculated from part A) vs . 
inhibitor concentration. 
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Peptides 5 and 6 represent a new class of potent inhibitors for 
oligosaccharyl transferase, with the cyclic thioether 5 being the most effective. 
These compounds represents the culmination of a logical plan designed to 
systematically improve the affinity of 1 (Ki = 1 mM). The binding affinities 
for the two cyclic peptides have been enhanced to nanomolar levels through 
the incorporation of several different experimental observations. Most 
notably, the combination of the cyclic constraint and the extension in length 
to a hexapeptide seem to act in concert to produce compounds which are 
substantially more effective than their truncated linear (1) or cyclic (4) 
analogs. 
4.2.3 Species Selectivity and Enzyme Specificity 
The enzyme oligosaccharyl transferase has been characterized from 
several different species and shows structural homology throughout 
eukaryotic evolution.35 It was therefore of interest to examine whether 
inhibitors 5 and 6 demonstrate any species selectivity. The two constrained 
peptides were examined as inhibitors against S. cerevisiae and porcine liver 
OT (Figures 4-10 and 4-11, respectively) . The percent inhibition was 
determined by measuring any decrease in the rate of OT mediated 
glycosylation in the presence of various concentrations of each inhibitor. 
Notably, in each case, inhibition of yeast OT was approximately three-fold 
more effective. Since extended binding interactions from the C-terminal 
residues contribute significantly to enzyme binding,27 these results suggest 
that it may be possible to manipulate and enhance this species selectivity by 
simple changes in the inhibitor primary sequence. This possibility is 
currently being investigated in the Imperiali group. 
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Figure 4-10. Species-Selectivity and Enzyme-Specificity of 5. Cyclic peptide 5 
was examined as an inhibitor against OT isolated from S. cerevisiae and 
porcine liver sources to determine its species selectivity. Enzyme specificity 
was examined through an assay of GalNAc-transferase36 in the presence of 5. 
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Figure 4-11. Species-Selectivity of 6. Cyclic peptide 6 was examined as an 
inhibitor against OT isolated from S. cerevisiae and porcine liver sources to 
determine its species selectivity. 
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As a final control, the ability of 5 to specifically inhibit N-linked rather 
that O-linked glycosylation was assessed by monitoring its activity against the 
common O-linked glycosylation enzyme, polypeptide N-acetyl 
galactosamin y 1 transferase ( GalN Ac-transferase). 36 This enzyme catalyzes the 
transfer of GalNAc from UDP-GalNAc to threonine residues within peptides; 
a consensus sequence has not been identified. As 5 contains two threonine 
residues, it was also evaluated for substrate activity. As expected, the 
inhibitor 5 showed no measurable activity against this enzyme even at 
elevated concentrations (Figure 4-10). 
4.3 Conclusions 
The investigations presented in this chapter all represent in vitro 
analyses of a new class of cyclic inhibitors, using solubilized sources of 
oligosaccharyl transferase; the in vivo efficacies of the compounds remain 
unevaluated. One problem that has not yet been addressed experimentally is 
the possibility that compounds such as 5 and 6 will not be able to access OT in 
vivo. OT is sequestered on the lumenal side of the endoplasmic reticulum 
(ER) 13 and is therefore likely to be inaccessible to extracellular antagonists. 
Thus, for this new class of inhibitors to be effective for in vivo studies, they 
must be able to cross the cell wall and be transported into the ER. Variations 
of the core structure of 5 are currently under consideration in the Imperiali 
group in an effort to design an inhibitor which gains access to the ER. 
Glycoproteins play critical biological roles in all eukaryotic cells. 
Because of the importance of these glycoconjugates, potent and specific 
inhibitors of N-linked protein glycosylation may find diverse applications. 
This chapter has described the design and evaluation of a new class of slow, 
tight binding inhibitors that exhibit nanomolar binding constants for the 
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enzyme oligosaccharyl transferase. The modular nature of these inhibitors 
provides immediate opportunities for structural diversification through 
combinatorial synthesis,37-39 making this class of cyclic peptides the first 
example of a readily available and adaptable family of potent protein 
glycosylation inhibitors. These compounds present a platform which can be 
easily modified for the further development of specific glycosylation 
inhibitors as diagnostic tools to evaluate the role of glycoproteins in biological 
systems and as potential therapeutic agents.25 These compounds may prove 
to be valuable tools for future studies designed to elucidate the roles of 
glycosylation in complex cellular processes. 
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4.5 Experimental Methods 
4.5.1 Solid Phase Synthesis of Cyclic Inhibitors 5 and 6 
Synthesis of Fmoc-Amb(Boc) 
A heterogeneous mixture of Fmoc-Gln-OH (2.3 mmol, 0.85 g) and 
anhydrous tert-butanol (15 mL) was placed in a dry flask, degassed under 
reduced pressure and placed under nitrogen. The mixture was warmed to 75 
°C and lead tetraacetate (4.6 mmol, 2.05 g) was added. The dark orange 
mixture was allowed to stir at 75 °C for 1 hour and was warmed to 80 - 85 °C 
for an additional 45 min, during which time the color lightened to pale 
brown. To the cooled (20 °C) mixture was added ether (50 mL) and NaHCO3 
(1 g). The suspension was allowed to stir for 20 min. The solids and salts 
were removed by filtration through a plug of silica gel followed by rinsing 
with CHCb/MeOH/ AcOH: 96/4/1. The foam obtained upon removal of the 
solvent was purified by silica gel chromatography (CHCl3/MeOH/ AcOH : 
96/ 4/1, Rt 0.25). The product was obtained as a white powder (0.437 g, 43%) 
upon removal of solvent and crystallization in petroleum ether: mp 73.5 -
75.5 °C, [a]D25 + 3.9 ° (c 1.0, CHCl3), Rt 0.36 (CHCb/MeOH/ AcOH : 95/5/1); 
1H-NMR 8tt (300 MHz, CDCb) 7.78 (d, 2H, J = 7.7 Hz, Fmoc arom), 7.60 (d, 2H, 
J = 6.8 Hz, Fmoc arom), 7.39 (t, 2H, J = 7.7 Hz, Fmoc arom), 7.32 (t, 2H, J = 7.7 
Hz, Fmoc arom), 6.65 - 5.17 (four br s, 2H, NH<X and NHY), 4.40 (m, 3H, CH<X 
and Fmoc CH2), 4.23 (t, lH, J = 6.6 Hz, Fmoc 9-CH), 3.50 - 3.00 (m, 2H, CH2~), 
2.36, 2.00 (m,m, 2H, CH2Y), 1.46 (s, 9H, Boe CH3); 13C-NMR 8 (75 MHz, CDCl3) 
143.7, 141.3, 127.7, 127.1, 125.1, 120.0, 80.3, 67.1, 66.9, 51.4, 47.2, 36.7, 28.3. IR Vmax 
(thin film, NaCl) 3327, 2969, 1702, 1518, 1445, 1361, 1249, 1165, 1054, 908, 735. 
HRMS calcd for C24H27N2O6 (MH-) 439.187 g/mol, found 439.187. 
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Fmoc-Thr(OtBu)-Val-Thr(OtBu)-Pal-Peg Resin 
The C-terminal tetrapeptide for compounds 5 and 6 was prepared using 
standard solid phase synthesis protocols and 9-fluorenylmethoxycarbonyl 
(Fmoc) protecting group chemistry on a Millipore 9050 Peptide Synthesizer 
with Enhanced Monitoring. Unless otherwise stated, all Fmoc protected 
amino acids were purchased from Perseptive Biosystems (USA). The peptide 
was generated on Pal-Peg Resin (1.0 g, 0.170 meq/ g) to afford a C-terminal 
carboxamide upon cleavage. Each coupling cycle was conducted with 3 
equivalents of each amino acid and HOBT coupling chemistry. The final 
deprotection cycle was omitted to generate Fmoc-Thr(OtBu)-Val-Thr(OtBu)-
Pal-Peg Resin. 
Fmoc-Cys(SStBu)-Thr(OtBu)-Val-Thr(OtBu)-Pal-Peg Resin 
Fmoc-Thr(OtBu)-Val-Thr(OtBu)-Pal-Peg resin (34 µmoles) was washed 
twice (30 seconds) with DMF and then treated twice with 20% 
piperidine/DMF (3 minutes). Following an extensive wash with DMF, a 
solution of Fmoc-Cys(SStBu)-OH (48.8 mg, 113 µmoles, 3 eq, CalBiochem, 
USA), HOBT (19.1 mg, 125 µmoles, 3.6 eq) and diisopropylcarbodiirnide 
(DIPCDI, 16.5 µL, 112 µmoles, 3.3 eq) in 2 mL DMF was added to the resin and 
agitated for 2 hours. The resin was washed with DMF and treated twice with 
10 mL of the following capping solution: 180 mL DMF, 20 rnL 
dichlorornethane, 5.7 mL acetic anhydride (29 mM) and 8.13g HOBT (26 rnM). 
The resin was rinsed twice with DMF and twice with dichloromethane. 
Fmoc-Amb(Boc)-Cys(SStBu)-Thr(OtBu)-Val-Thr(OtBu)-Pal-Peg Resin 
Fmoc-Cys(SStBu)-Thr(OtBu)-Val-Thr(OtBu)-Pal-Peg resin (34 µmoles) 
was washed twice (30 seconds) with DMF and then treated twice with 20% 
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piperidine/DMF (3 minutes) . Following an extensive wash with DMF, a 
solution of Fmoc-Amb(Boc)-OH (46.8 mg, 110 µmoles, 3.2 eq), HOBT (16.7 mg, 
109 µmoles, 3.2 eq) and diisopropylcarbodiimide (DIPCDI, 16.5 µL, 112 µmoles, 
3.3 eq) in 2 mL DMF was added to the resin and agitated for 2 hours. The 
resin was washed with DMF and then treated twice with the capping solution 
described in the previous solution. Following capping of all unreacted amino 
groups, the resin was washed twice with DMF and twice with 
dichloromethane. 
BrHex-Amb(Boc)-Cys(SS tBu)-Thr(OtBu)-Val-Thr( OtBu)-Pal-Peg Resin 
Fmoc-Amb(Boc)-Cys(SStBu)-Thr(OtBu)-Val-Thr(OtBu)-Pal-Peg resin 
(34 µmoles) was washed twice (30 seconds) with DMF and then treated twice 
with 20% piperidine/DMF (3 minutes) . Following an extensive wash with 
DMF, the resin was combined with a solution of bromohexanoic acid (32 mg, 
164 µmoles, 4.8 eq), DIPCDI (24 µL, 163.5 µmoles, 4.8 eq) and triethylamine (22 
µL, 159 µmoles , 4.7 eq) in 3 mL DMF for 1.5 hours. Resin was filtered and 
recombined with a solution of bromohexanoic acid (33.6 mg, 172 µmoles, 5.0 
eq), DIPCDI (24 µL, 163.5 µmoles, 4.8 eq) in 2 mL DMF and agitated overnight. 
Resin was filtered and washed with DMF and dichloromethane. 
Solid Phase Cyclization of Hexapeptides 
Cyclization was afforded according to the method of Virgilio and 
Ellman.28 A 5/3/2 solution (15 mL) of n-propanol/DMF/water was prepared 
and bubbled with nitrogen for 15 minutes. A 10 mL aliquot of this solution 
was combined with the resin bound BrHex-Amb(Boc)-Cys(SStBu)-Thr(OtBu)-
Val-Thr(OtBu)-Pal-Peg resin (34 µmoles) for ten minutes and then removed 
via filtration. The S-t-butyl protecting group was removed under a nitrogen 
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atmosphere by combining the resm with an additional 15 mL of the 
deoxygenated n-propanol solution and 375 µL tributyl phosphine. After 6 
hours, the resin was filtered and the filtrate was quenched with a bleach 
solution. The resin was washed twice with methanol and twice with 
dichloromethane. A solution of DMF was bubbled under a stream of 
nitrogen. Cyclization was afforded by washing the resin with 10 mL DMF and 
then combining the resin with an additional 15 mL DMF and 375 µL 1,1,3,3-
tetramethylguanidine and agitating the mixture for 20 hours . Resin was 
washed extensively with DMF and dichloromethane to yield cyclo[SHex-
Amb(Boc)-Cys]-Thr(OtBu)-Val-Thr(OtBu)-Nph-Pal-Peg resin. 
Cleavage and Deprotection 
Cleavage and deprotection was accomplished by shaking cyclo[SHex-
Amb(Boc)-Cys]-Thr(OtBu)-Val-Thr(OtBu)-Nph-Pal-Peg resin with 95/5 /5 
trifluoroacetic acid/ dimethyl sulide/water (1 mL) for four hours. The resin 
was filtered and rinsed with TFA. The filtrate was concentrated under a 
stream of nitrogen and then triturated 3 times with ether to remove the 
excess dimethyl sulfide. The impure peptide (6 mg) was lyophilized 
overnight from water. The peptide was purified by HPLC with a 
acetonitrile /water/ 0.1 % TF A gradient ranging from 35% to 55% acetonitrile 
over 20 minutes. The product was detected by monitoring absorbance 
changes at 228 nm and 280 nm. Cyclo[SHex-Amb-Cys]-Thr-Val-Thr-Nph-NH2 
5 eluted with a retention time of 8.4 minutes. The product was pure by HPLC 
and proton NMR. Final yield was approximately 400 µg. 1H-NMR <>tt (500 
MHz, DMSO-d6) 8.45 (d, lH, J = 8.4 Hz, NH), 8.09 (d, 2H, J = 8.3 Hz, Nph arom), 
8.00 (d, lH, J = 8.4 Hz, NH), 7.92 (d, lH, J = 8.6 Hz, NH), 7.65 (m, 6H, three NH 
and NH3+), 7.49 (d, 2H, J = 8.4 Hz, Nph arom), 7.45 (s, NH2), 7.22 (s, NH2), 4.94 
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(br s, lH, Tor OH), 4.84 (br s, lH, Tor OH), 4.65 (m, lH, CHa), 4.52 (m, 2H, two 
CHa), 4.28 (m, lH, CHa), 4.29 (m, 2H), 3.93 (br s, 2H), 3.19 (d, lH, J = 4.0 Hz), 
3.17 (d, lH, J = 4.3 Hz), 2.93 (dd, lH, J = 13.7, 9.1 Hz), 2.85 (dd, lH, J = 13.9, 7.1 
Hz), 2.78 (br m, 3H), 2.35 - 2.42 (br m, obscured by solvent), 2.18 (m, lH), 2.11 
(m, lH), 2.02 (m, lH), 1.92 (m, lH), 1.78 (m, lH), 1.68 (br s, lH), 1.48 - 1.22 (m, 
~8H), 0.98 (m, 6H), 0.75 (m, 6H). HRMS calcd for C35H55N 9O11S (MH+) 
810.3820 g/mol, found 810.3858 g/mol. Quantitative amino acid analysis 
confirmed the presence of each amino acid (except cysteine) in the appropriate 
ratios (see below). 
Oxidation of Cyclic Thioether 5 to Cyclic Sulfoxide 6 
Cyclo[SHex-Amb(Boc)-Cys ]-Thr( OtBu)-Val-Thr( OtBu)-Nph-Pal-Peg 
resin (approximately 10 mg) was combined with 75 µL n-propanol, 75 µL 
dichloromethane and 30 µL 30% hydrogen peroxide. Mixture was agitated for 
five hours, washed with water and dichloromethane and cleaved as described 
above with 200 µL 95/5/5 trifluoroacetic acid/dimethyl sulide/water. 
Following trituration and lyophilization, the reaction products were analyzed 
by HPLC on an analytical column with a gradient of acetonitrile from 20% to 
30% over 20 minutes. The sulfoxide product eluted with a retention time of 
10.9 minutes, compared to a retention time of 17.1 minutes for the thioether 
starting material. Only one new peak was observed following oxidation 
suggesting that only one diastereomer is generated or the two diastereomers 
coelute under these conditions. Approximately 150 µg of the sulfoxide 6 were 
purified. LRMS calcd for C35H55N9O12S (MH+) 826 g/mol, found 826 g/mol. 
Quantitative amino acid analysis verified the presence of each amino acid 
(except cysteine) in the appropriate ratios (see below). 
Hexanoyl-Amb(Boc)-Cys(SStBu)-Thr(OtBu)-Val-Thr(OtBu)-NH2 (7) 
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Fmoc-Amb(Boc)-Cys(SStBu)-Thr(OtBu)-Val-Thr(OtBu)-Pal-Peg resm 
(50 µmoles) was washed twice (30 seconds) with DMF and then treated twice 
with 20% piperidine/DMF (3 minutes). Following an extensive wash with 
DMF, the resin was combined with a solution of hexanoic acid (30 µL, 240 
µmoles, 4.8 eq), DIPCDI (35 µL, 240 µmoles, 4.8 eq) and triethylamine (7 µL, 50 
µmoles, 1 eq) in 3 mL DMF and agitated overnight. The resin was filtered and 
washed with DMF and dichloromethane and cleaved from the resin as 
described above. Peptide was purified by HPLC. Quantitative amino acid 
analysis verified the presence of each amino acid (except cysteine) in the 
appropriate ratios (see below). 
4.5.2 Enzymatic Evaluation of Cyclic Inhibitors 
Determination of Peptide Solution Concentrations by Quantitative Amino 
Acid Analysis 
Following HPLC purification, the water/ acetonitrile solutions of cyclic 
peptides 5 and 6 were quantitated by measuring the solutions absorbance 
between 250 nm and 300 nm on a Beckman DU7500 Spectrophotometer in a 1 
cm cell. Using an extinction coefficient of 9340 mol-1 cm-1, the concentration 
of each solution was estimated using Beer's Law. Based on this 
concentration, the cyclic peptides were aliquoted into microcentrifuge vials in 
10 nmole portions. 
For the final concentration determination, a 10 nmole aliquot of each 
cyclic peptide was redissolved in 100 µL 50% acetonitrile/water /0.1 % TFA. 
The linear peptide 7 was dissolved in 200 µL DMSO to yield an approximate 
concentration of 840 µM as determined by UV analysis . An aliquot of this 
solution (10 µL, 7.56 µg) was dried under vacuum and redissolved in 100 µL 
50% acetoni trile /water/ 0 .1 % TF A. These three solutions were submitted to 
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Kristine Swiderick at the amino acid analysis facility at the City of Hope for 
analysis . The concentration was determined by quantitative amino acid 
analysis for valine. The 10 nmole aliquot of 5 contained 6.04 µg peptide (7.5 
nmoles); the 10 nmole aliquot of 6 contained 8.0 µg peptide (9.7 nmoles); The 
9 nmole aliquot of the linear peptide 7 contained 4.70 µg peptide (5.6 nmoles). 
Solutions of the two unnatural amino acids, Fmoc-Amb(Boc) and 
Fmoc-Nph, were also analyzed as standards by the amino acid analysis facility 
at the City of Hope. The results from these experiments were combined with 
the analyses of peptides 5 - 7 to confirm the presence of each of the amino 
acids in the expected ratios (1 Amb, 2 Thr, 1 Val, 1 Nph); cysteine is not readily 
observed by quantitative amino acid analysis. 
General Assay for Competitive Inhibition - Oligosaccharyl Transferase 
Final peptide concentrations ranged from 7.5 nM to 7.5 µM for peptide 
5; from 9.7 nM to 9.7 µM for peptide 6; and from 10 nM to 10 µM for peptide 7. 
Assays were compared to control experiments which did not contain the 
inhibitor peptides. Porcine liver and S. cerevisiae OT were isolated as 
previously described.31, 36, 40 The solubilized yeast (150 µL) and the crude 
porcine (20 µL) OT were diluted to final volumes of 1200 µL with assay buffer 
(50 mM Hepes, pH 7.5, 140 mM sucrose, 1 % Triton X-100, 0.5 mg/mL 
phosphatidylcholine, 10 mM MnCb). Solutions of each peptide were 
prepared in DMSO at concentrations which would yield the appropriate final 
concentration following the 20-fold dilution of the assay. 
A 200 µL portion of each enzyme was combined with 13.3 µL Bz-NLT-
NHMe (10 mM and 1 mM stock solutions in DMSO for porcine and S. 
cerevisiae assays, respectively), 13.3 µL of the appropriate inhibitor solution or 
DMSO (control) and 13.4 µL assay buffer. These solutions were equilibrated 
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on ice for 30 minutes. The assays were initiated by transferring 180 µL of the 
equilibrated enzyme solution into eppendorfs containing 50,000 dpm 
dolichol-PP-GlcNAc2 (36.5 Ci/mmol) and 20 µL assay buffer. Following 
initiation, aliquots were treated as previously described .31 
General Assay for Competitive Inhibition - Polypeptide N-Acetyl-
galactosaminyl Transferase 
Solubilized GalNAc-transferase (100 µL) was suspended in 112.5 µL of 
buffer (100 mM imidazole/HCl, pH 7.5, 1% Triton-X) . Ac-PDAATAAPL-NH2 
was added (12.5 µL of a 8 mM solution) with 12.5 µL inhibitor or DMSO 
(control). Following preincubation, the assay was initiated by the addition of 
12.5 µL of a 2.5 mM solution UDP-GalNAc (0.1 µCi) and completed as 
previously described.36 
Determination of Kinetic Constants - Approximate Ki 
The ICso, or the concentration of each peptide which produced a 50% 
decrease in OT activity, was determined through standard competitive assays 
in the presence of 50 µM Bz-NLT-NHMe (2x KM). The values for Ki were 
calculated as described by Segel33 by inserting the results from these 
experiments into the following equation: Ki = ([I]-i[I]) / (i + [S]i/KM); [I] = 
concentration of inhibitor peptide; i = percent observed inhibition; [S] = 50 
µM; KM = 25 µM. This equation is most accurate when i = 0.5. 
Determination of Kinetic Constants - Precise Ki, Kon and Koff 
Peptide 5 was further evaluated for slow binding inhibition of 
oligosaccharyl transferase. OT (S. cerevisiae solubilized microsomes,40 210 
µL) was diluted with 3.57 mL assay buffer (50 mM Hepes, pH 7.5, 140 mM 
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sucrose, 1 % Triton X-100, 0.5 mg/mL phosphatidylcholine, 10 mM MnCb). 
Radiolabeled dolichol-P-P-GlcNAc2 (DPPC) was prepared as previously 
described (1.2 x lQ6 dpm, 60 Ci/mmol per assay).41 Each aliquot was diluted 
with unlabeled DPPC and dissolved in 540 µL enzyme solution. The final 
DPPC concentration was 160 nM. Assays were initiated by the addition of 60 
µL of a DMSO solution containing 375 µM Bz-NLT-NHMe and the 
appropriate concentration of 5. Following initiation, aliquots of each assay 
were quenched and quantitated as previously described.31 Compound 5 was 
examined over a range of concentrations from 37.5 nM to 300 nM. 
Values for kobsd were calculated for each peptide concentration by 
fitting the data to the equation Dpm = Uft - (Df-Di)[l-exp(-kobsdt)]/kobsd + 
Dpmo.34 Values for Kon and Koff were determined from a replot of the 
calculated kobsd vs. inhibitor concentration, using the equation kobsd = koff + 
kon[I] / (1 + [S]/Km).34 
4.5.3 Solution Phase Synthesis of cyclo[Amb-Add]-Thr-NHMe (4) 
The experimental protocols described in this section were developed 
and accomplished by Dr. Jeffrey R. Spencer and have been included for 
completeness. 
Synthesis of Boc-Gln-Add(All)-OH (SIII.97) 
A chilled (- 20 °C) solution of HCl•H-L-Add(All)-OH (2.3 mmol, 0.67 g) 
and HOBt (2.5 mmol, 0.34 g) in DMF (9 mL) was treated with NMM (2.3 
mmol, 0.25 mL). An additional 0.15 mL (1.4 mmol) of NMM was added to 
adjust the mixture pH to 7-8. The ester Boc-Gln-ONp (2.5 mmol, 0.93 g) was 
added, and the reaction was allowed to proceed 20 min at - 20 °C and 18 hours 
at 20 °C. The mixture was then chilled (0 °C), treated with additonal Boc-Gln-
ONp (0.27 mmol, 0.10 g) and allowed to proceed 8 hours more. This step was 
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repeated. After removal of the solvent under reduced pressure, the residue 
obtained was suspended in AcOEt (400 mL) and washed with several portions 
(10 mL) of 1 N NaHSO4 and H2O (2x10 mL) and dried (MgSO4) . The residue 
obtained upon removal of the solvent under reduced pressure was purified 
by silica gel chromatography (CHCl3/MeOH/ AcOH: 90/10/1 ➔ 85/15/1). The 
dipeptide was obtained as a white powder (0.71 g, 64%) after the addition and 
removal under reduced pressure of toluene and hexanes: mp 65.5 - 68 °C, 
[a]D25 + 7.1 ° (c 0.3, CHCb), Rf 0.14 (CHCb/MeOH/ AcOH: 90 / 10/1); 1H-NMR 
OH (300 MHz, DMSO-d6) 7.60 (br s, lH, NH), 7.03 (d, 2H, J = 165 Hz, Gln NH2d), 
6.98 (d, lH, J = 8.2 Hz, NH), 5.88 (m, lH, CH2-CH=CH2), 5.23 (ddd, 2H, J = 26.8, 
20.7, 1.8 Hz, CH2-CH=CH2), 4.53 (d, 2H, J = 6.1 Hz, CH2-CH=CH2), 4.00 (m, lH, 
CHCX), 3.85 (m, lH, CHCX), 2.29 (t, 2H, J = 7.4 Hz, Add CH28), 2.07 (m, 2H, Gln 
CH2Y), 1.83 (m, lH, Gln CH~d), 1.65 (m, lH, Gln CH~u), 1.65-1.50 (m, 4H, Add 
CH2~ and CH2Y), 1.37 (s, 9H, Boe CH3), 1.22 (br s, SH, Add CH2); 13C-NMR o (75 
MHz, DMSO-d6) 174.0, 172.5, 171.0, 155.2, 132.8, 117.6, 78.0, 64.2, 54.0, 52.8, 33.4, 
31.9, 31.6, 28.8, 28.7, 28.5, 28.2, 27.7, 24.9, 24.5. IR Vrnax (thin film NaCl) 3306, 
2930, 1733, 1661, 1569, 1451, 1418, 1367, 1247, 1170. FAB MS m/z: 508 (MNa+); 
FAB HRMS calcd for C23H39N3OsNa (MNa+) 508.2635, found 508.2653. 
Synthesis of Boc-Gln-Add(All)-Thr(tBu)-NHMe (SIII.99) 
To a solution of Cbz-Thr(tBu)-NHMe (0.93 mmol, 0.30 g) in MeOH/1 % 
HOAc (10 mL) was added 10% Pd/C (0.045 g). Hydrogen was introduced at 
atmospheric pressure at 20 °C, and the mixture allowed to react 1 hour. The 
catalyst was removed by filtration and the solvent removed under reduced 
pressure. Toluene (2 x 10 mL) was added and removed under reduced 
pressure. A mixture of the amino component and Boc-Gln-Add(All)-OH 
(0.83 mmol, 0.40 g) in DMF (3.3 mL) was chilled to - 40 °C under nitrogen. 
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The mixture was treated with NMM (0.83 mmol, 0.091 mL) and after 5 min, 
HOAt (0.81 mmol, 0.11 g) and EDC (0.83 mmol, 0.16 g) were added. After 30 
min at - 40 °C, the reaction was allowed to warm to 20 °C and proceed for 18 
hours. The solvent was removed under reduced pressure. The residue 
obtained was suspended in 400 mL of AcOEt and washed with 0.5 M NaHCO3 
(10 mL), saturated NaHCO3 (3 x 10 mL), H2O (10 mL), 1 N NaHSO4 (3 x 10 mL), 
saturated NaCl (3 x 10 mL) and dried (Na2SO4). The solvent was removed 
under reduced pressure, and the tripeptide was obtained as a white powder 
(0.45 g, 83%): mp 174 - 176.5 °C, [o:]D 25 +2.3° (c 0.2, CHCl3), Rf 0.62 
(CHC!J/MeOH/ AcOH: 85/15/3); 1H-NMR OH (300 MHz, DMSO-d6) 7.95 (d, 
lH, J = 8.3 Hz, NH), 7.58 (d, lH, J = 4.8 Hz, NHCH3), 7.48 (d, lH, J = 8.9 Hz, NH), 
7.00 (d, 2H, J = 138 Hz, Gln NH28), 6.98 (d, lH, J = 8.3 Hz, NH), 5.89 (m, lH, 
CH2-CH=CH2), 5.23 (ddd, 2H, J = 26.2, 19.2, 1.7 Hz, CH2-CH=CH2), 4.53 (d, 2H, J 
= 5.6 Hz, CH2-CH=CH2), 4.31 (m, lH, CHa), 4.14 (dd, lH, J = 8.6, 2.9 Hz, CHa), 
3.90 (m, 2H, CHa and Thr CHP), 2.58 (d, 3H, J = 4.6 Hz, NCH3), 2.30 (t, 2H, J = 
7.6 Hz, Add CH28), 2.07 (m, 2H, Gln CH2Y), 1.80 (m, lH, Gln CHP<l), 1.65 (m, lH, 
Gln CHPu), 1.65-1.50 (m, 4H, Add CH2P and CH2Y), Add 1.36 (s, 9H, Boe CH3), 
1.23 (br s, 8H, Add CH2), 1.08 (s, 9H, tBu CH3), 0.95 (d, 3H, J = 6.5 Hz, Tor CH3Y); 
13C-NMR o (75 MHz, DMSO-d6) 173.7, 172.5, 172.0, 171.5, 169.9, 155.2, 132.8, 
117.6, 78.0, 73.5, 67.0, 64.2, 57.7, 54.1, 52.5, 33.3, 31.7, 31.6, 28.6, 28.4, 28.2, 28.1, 
28.0, 27.6, 25.6, 25.0, 24.5, 19.5. IR Ymax (thin film, NaCl) 3293, 2929, 1732, 1641, 
1550, 1522, 1390, 1236, 1172, 1095. FAB MS m/z: 656 (MH+); FAB HRMS calcd 
for C32HssNsO9 (MH+) 656.4235, found 656.4238. 
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Synthesis of Boc-Gln-Add(OH)-Thr(tBu)-NHMe (SIII.100) 
A mixture of Boc-Gln-Add(All)-Thr(tBu)-NHMe (0.50 mmol, 0.33 g) 
and AcOH (2.4 mmol, 0.14 mL) in anhydrous THF (5 mL) was treated with 
PdCb(PPh3)2 (0.016 mmol, 0.011 g). The heterogeneous, bright yellow mixture 
became homogeneous and darker upon the rapid addition of nBu3SnH (0.52 
mmol, 0.14 mL). After 30 min, a white precipitate began forming and 
increased as the reaction was allowed to proceed another 5 hours. Additional 
nBu3SnH (0.056 mmol, 0.015 mL) was added. After 1 hour, the solvent was 
removed under reduced pressure and hexanes was added and removed. A 
pale yellow solid was isolated by filtration from a suspension in hexanes. The 
carboxylic acid was purified by recrystallization from hot AcOEt/hexanes and 
obtained as a white powder (0.23 g_, 77%): mp 172.0 - 175.0 °C, [a]o25 - 13.7 ° (c 
0.3, MeOH), Rf 0.10 (CHCb/MeOH/ AcOH : 95/5/3); 1H-NMR ◊H (300 MHz, 
DMSO-d6) 11.95 (s, lH, COOH), 7.92 (d, lH, J = 7.9 Hz, NH), 7.50 (m, 2H, NH 
and NHCH3), 7.08 (d, 2H, J = 117 Hz, Asn NH2Y), 7.00 (d, lH, J = 7.9 Hz, Asn 
NH), 4.24 (m, 2H, two CHa), 4.12 (m, lH, CHa), 3.92 (m, lH, Thr CH~), 2.58 (d, 
3H, J = 4.8 Hz, NHCH3), 2.35 (m, 2H, Asn CH2~), 2.17 (m, 2H, Ada CH28), 1.53 
(m, 4H, two Ada CH2), 1.36 (s, 9H, Boe CH3), 1.22 (m, 8H, four Ada CH2), 1.07 
(s, 9H, tBu CH3), 0.96 (d, 3H, J = 6.6 Hz, Thr CH3Y); 13C-NMR o (75 MHz, 
DMSO-d6) 174.5, 174.0, 171.5, 171.4, 169.9, 155.1, 78.2, 73.5, 66.9, 57.8, 52.7, 51.3, 
37.1, 33.7, 31.8, 28.6, 28.5, 28.4, 28.1, 28.0, 25.7, 25.0, 24.5, 19.6. IR Vmax (KBr) 3310, 
2905, 1687, 1639, 1538, 1453, 1389, 1219. FAB MS m/z: 602 (MH+); FAB HRMS 
calcd for C23H52N5O9 (MH+) 602.3765, found 602.3784. 
Synthesis of cyclo[Gln-Add]-Thr-NHMe (SIV.05-06, 09) 
A mixture of Boc-Gln-Add(OH)-Thr(tBu)-NHMe (0.30 mmol, 0.185 g) 
and DMF (1.0 mL) was chilled (- 15 °C) under nitrogen. To the mixture was 
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added DCC (0.46 mmol, 0.094 g). After 15 min at - 15 °C, the mixture was 
treated with a solution of pentafluorophenol (0.76 mmol, 0.14 g) in AcOEt 
(0.15 mL), and the reaction was allowed to proceed for 30 min at - 15 °C and 
another 12 hours at 20 °C. After the solvent was removed under reduced 
pressure, a solid material containing DCU was obtained. The 
pentafluorophenyl ester was extracted by suspension of the solid material in 
AcOEt followed by removal of the solid by filtration. Additional 
pentafluorophenyl ester was recovered by recrystallizing the solid in warm 
AcOEt/CHCb and retaining the "liquid phase. The organic layers were pooled 
and a pale yellow residue was obtained upon removal of the solvent under 
reduced pressure. The pentafluorophenyl ester was obtained as a white solid 
(0.233 g, with trace DCU impurities) following crystallization in 1/1 
ether/hexanes and filtration: TLC Rf 0.28 (CHCl3/MeOH/ AcOH : 95/5/3). 
To a heterogeneous mixture of the protected compound Boc-Gln-
Add(OPfp)-Thr(tBu)-NHMe (0.13 mmol, 0.10 g) and CH2Cl2 (5 mL) was added 
TFA (5 mL) with dissolving of the solid material. The homogeneous mixture 
was allowed to stir 1.75 hours at 20 °C. After the solvents were removed 
under a stream of nitrogen, additional CH2Cb (2 x 30 mL) was added and 
removed under reduced pressure to assist in removing excess TFA. The 
residue obtained was stored under reduced pressure for 4 hours. 
The residue was then chilled (0 °C) under nitrogen and dissolved in 
chilled (0 °C), freshly distilled DMF (125 mL). After 15 min at O °C, the 
mixture was allowed to warm to 4 - 6 °C and stir for 6 days. A 0.64 M TEA 
solution was prepared from freshly distilled TEA (0.089 mL) and freshly 
distilled DMF (0.911 mL) . After the first 24 hours, the reaction mixture was 
treated at 24 hours intervals with 0.050 mL of the TEA solution (0.032 mmol 
TEA). The progress of the reaction was monitored by RP HPLC (analytical, 10 
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➔ 80% MeCN /H2O, 0.1 % TFA over 25 min., retention time 9.4 min) . The 
solvent was removed under reduced pressure. A solid material (0.065 g) was 
obtained after the residue was suspended in and centrifuged out of ether 
(three times) to assist in crystallization and removal of pentafluorophenol. 
The crude material was fractionated in batches of 17 mg with a pre-packed 
reversed phase (C1s) column (Waters, SepPak) employing a gradient elution 
of O ➔ 40% MeCN /H2O. The cyclic compound eluted in the range of 5 ➔ 12% 
MeCN /H2O. After removal of solvent by lyophilization, the purified cyclic 
compound was obtained as a fluffy white powder (0.048 g, 74%): mp 287 - 290 
°C dee., analytical HPLC (10 ➔ 80% MeCN /H2O, 0.1 % TFA over 25 min.) 
retention time 9.4 min, Rt 0.19 (CHCb/MeOH/ AcOH : 85/15/3); lH-NMR 8H 
(300 MHz, DMSO-d6) 8.31 (d, lH, J = 9.0 Hz, NH), 7.74 (d, lH, J = 5.1 Hz, NH-
Me), 7.66 (d, lH, J = 9.0 Hz, NH), 7.63 (d, lH, J = 9.0 Hz, NH), 7.02 (d, 2H, J = 150 
Hz, Gln NH2°), 4.85 (br s, lH, Thr OH), 4.35 (m, 2H, two CHa), 4.10 (dd, lH, J = 
8.6, 5.0 Hz, CHa), 3.90 (m, lH, Thr CH~), 2.57 (d, 3H, J = 4.9 Hz, N-CH3), 2.10, 
1.90 (m,m, 2H, Add CH2~), 2.04 (t, 2H, J = 7.9 Hz, Add CH28), 1.90, 1.68 (m,m, 
2H, Gln CH2Y), 1.68 - 1.05 (m, 12H, five Add CH2 and Gln CH2~), 0.98 (d, 3H, J = 
6.0 Hz, Thr CH3Y) . FAB MS m/z: 442 (MH+); FAB HRMS calcd for 
C20H36NsO6 (MH+) 442.2666, found 442.2691. 
Synthesis of cyclo[Amb-Add]-Thr-NHMe (4 , SIV.13) 
A heterogeneous mixture of the cyclic compound cyclo[Gln-Add]-Thr-
NHMe (0.017 mmol, 7.6 mg) in 2/1: MeCN /H2O (0.10 mL) was treated at 20 °C 
with [bis(trifluoroacetoxy)iodo]benzene (0.026 mmol, 11.0 mg). The reaction 
was allowed to proceed at 20 °C for 1 hour and was warmed to 50 °C for 15 
min. After more 2/1 : MeCN /H2O (0 .020 mL) was added, the mixture was 
allowed another 3.5 hours at 50 °C. The mixture was then treated with an 
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additional portion of [bis(trifluoroacetoxy)iodo]benzene (0.0093 mmol, 4.0 mg) 
and 2/1 : MeCN/H2O (0.060 mL) and warmed (50 °C) for 2 hours more. To 
the cooled mixture was added 0.1 M HCl (1 mL). The acidic layer was washed 
with ether (3 x 1 mL) to remove [bis(trifluoroacetoxy)iodo]benzene and 
iodobenzene. A solid material was removed from the aqueous layer by 
centrifugation, and the crude compound was obtained following removal of 
the aqueous solvent by lyophilization. The crude solid was fractionated with 
a pre-packed reversed phase (C1s) column (Waters SepPak) employing a 
gradient elution of O ➔ 20% MeCN /H2O. The cyclic compound eluted in the 
range of 5 ➔ 7.5% MeCN /H2O. After removal of the solvent by 
lyophilization, the purified cyclic compound was obtained as a fluffy white 
powder (3.1 mg, 44%): mp 245.5 - 247.5 °C dee., analytical HPLC (10 ➔ 80% 
MeCN I H2O, 0.1 % TFA over 25 min.) retention time 8.5 min, Rf 0.39 
(CHCl3/MeOH/ AcOH: 6/4/1); 1H-NMR ◊H (300 MHz, DMSO-d6) 8.43 (d, lH, J 
= 8.4 Hz, NH), 7.74 (m, 6H, three NH and NH3+), 4.85 (d, lH, J = 5.5 Hz, Thr 
OH), 4.43 (m, 2H, two CHo:), 4.10 (dd, lH, J = 8.3, 4.1 Hz, CHo:), 3.92 (m, lH, Thr 
CHP), 2.75 (t, 2H, J = 10.7 Hz, Dab CH2Y), 2.57 (d, 3H, J = 5.2 Hz, N-CH3), 2.29, 
1.80 (m,m, 2H, Add CH2P), 1.97 (m, 4H, Add CH28 and Dab CH2P), 1.65 - 1.20 
(m, lOH, five Add CH2), 0.98 (d, 3H, J = 6.4 Hz, Thr CH3Y). FAB MS m/z: 414 
(MH+); FAB HRMS calcd for C19H36NsOs (MH+) 414.2716, found 414.2716. 
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Chapter 5. Affinity Labels for Oligosaccharyl Transferase: 
Future Directions 
168 
5.1 Introduction 
The 20 natural amino acids provide enzymes with different reactive 
functionalities which are used to construct the catalytic machinery of 
enzymes. As demonstrated in chapter two, these amino acid side chains can 
often be identified and localized to an enzyme active site through the use of 
nonspecific chemical modification reagents. A related and frequently more 
powerful approach is to synthetically introduce an electophilic site into a 
natural substrate to generate a selective affinity label. Affinity labels are 
compounds which resemble the natural substrate sufficiently to bind to the 
enzyme active site with near native affinity. However, the introduction of an 
electrophilic moiety provides the opportunity for alkylation of a reactive 
amino acid within the enzyme active site.1 When combined with site-
directed mutagenesis or digestion by limited proteolysis and sequencing of the 
modified protein, affinity labels can often be used to identify amino acids 
which are directly involved in enzyme-mediated catalysis. 
In the design of affinity labels, the most common form of modification 
includes the introduction of a halo- or diazo-ketone as the reactive 
electrophile; these modifications produce labels which are ideal for the 
identification of active site bases or nucleophiles. For example, 3-bromo, 3-
chloro and 3-iodo-1-hydroxy-2-propanone phosphate (Figure 5-1, 1), 
halogenated analogs of the substrate dihydroxyacetone phosphate (Figure 5-1, 
2), were used to characterize triosephosphate isomerase (TIM).2 These three 
compounds irreversibly inactivated the enzyme; the site of alkylation was 
identified as a highly reactive glutamate (Glu-165) and it was later confirmed 
that this residue is directly involved in TIM mediated catalysis .3 Similarly, 
the compound 6-diazo-5-oxonorleucine (Figure 5-1, DON, 3) has been used to 
characterize several of a family of amidotransferases which catalyze the 
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transfer of ammonia from glutamine to other substrates.4 DON is a direct 
analog of glutamine (Figure 5-1, 4) wherein the carboxamide side chain has 
been replaced by a reactive diazoketone; it irreversibly inactivates many of 
these enzymes by alkylating a crucial cysteine residue.5, 6 Figure 5-1 shows the 
chemical structure of each of these inactivators adjacent to the relevant 
substrate; the effectiveness of these labels can be directly attributed to their 
structural similarity to the corresponding substrate. 
Triosephosphate lsomerase 
Affinity Label 
X = Br, Cl, I 
3-Halo-1-hydroxy-2-
propanone phosphate 
1 
Substrate 
Dihydroxyacetone phosphate 
2 
Glutamine Amidotransferases 
Affinity Label 
6-Diazo-5-oxonorleucine (DON) 
3 
Substrate 
Glutamine 
4 
Figure 5-1. Structural Similarities Between Substrates and Affinity Labels for 
Two Different Enzyme Systems. 
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Modification of oligosaccharyl transferase by peptide affinity labels has 
been attempted and reported in the literature on two occasions with mixed 
results. Lennarz and coworkers synthesized a tripeptide photoaffinity label 
based on the OT substrate Ac-Asn-Xaa-Thr-NHMe. 7 In their label, Xaa 
consisted of a lysine residue which had been modified at the £-amino group 
with p-azidobenzoic acid (5) . Upon irradiation at 254 nm to generate the 
reactive nitrene, this compound selectively modified one protein within the 
endoplasmic reticulum. However, further scrutiny revealed that protein 
disulfide isomerase had been targeted and identified instead of OT.8 
Although p-azidobenzoyl groups are frequently used as photoaffinity 
labels, the placement of this moiety in 5 has several drawbacks which, when 
considered together, significantly decrease the chances of selectively 
modifying OT. First, the consensus sequence for OT is -Asn-Xaa-Thr/Ser-
with very little sequence specificity for the central amino acid. Thus, the 
photoreactive functionality of 5 is placed in a position which does not appear 
to specifically interact with the OT peptide binding site. Second, tripeptides 
with an acetylated N-terminus typically exhibit poor affinities for OT.9 In 
addition, the use of a lysine side chain further lengthens the distance between 
the enzyme binding site and the photolabile group. The stringent sequence 
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specificity of OT and the bulky nature of the p-azidobenzoyl group preclude 
the positioning of this moiety in place of the asparagine or threonine residues 
of the consensus sequence. 
A second affinity label for OT has been reported which replaces the 
threonine residue in the consensus sequence with an epoxide ring to yield 
Arg-Asn-Gly-Asn-Gly-Vepx-Ala-Val-OMe (6, Vepx = vinyl glycine based 
epoxide).10 The epoxide moiety was introduced into the peptide by oxidative 
treatment with m-chloroperoxybenzoic acid (m-CPBA). This modification is 
significantly more specific than that of 5, in that the reactive group is placed 
in one of the two positions of high sequence selectivity and it introduces only 
minimal structural perturbations . Time dependent inhibition of 
oligosaccharyl transferase was observed when OT was treated with an impure 
form of this peptide. Further attempts to purify and characterize the inhibitor 
resulted in peptide cleavage on the C-terminal side of the epoxide ring; the 
possibility that inhibition was being induced by a contaminant, such as m-
CPBA, was never eliminated. 
Currently, the favored mechanism for oligosaccharyl transferase 
catalyzed protein glycosylation (see chapter one) involves deprotonation of an 
asparagine side chain by an active site base (Figure 5-2).11 Based on this 
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mechanism, successful glycosylation would occur only if this putative base is 
in direct proximity to the asparagine side chain during the catalytic process. 
As of yet, affinity labels which have been designed to probe this region have 
not been reported. Tripeptide affinity labels, which incorporate electrophilic 
modifications into the asparagine side chain of the consensus sequence, are 
ideal compounds to facilitate the investigation and identification of this 
active site base. 
Figure 5-2. Proposed Mechanism of Action of Oligosaccharyl Transferase with 
Positioning of an Active Site Base Near the Asparagine Side Chain. 
This chapter describes the design and investigation of several different 
peptidyl affinity labels for oligosaccharyl transferase which may be divided 
into three separate groups: a-methyl substituted ketones, epoxides and 
peptides incorporating an organomercurial functionality. The synthesis of 
the a-methyl ketone analogs proved futile because the introduction of 
electrophilic groups to the side chain of asparagine resulted in side chain to 
main chain cyclization. This cyclization generated peptides which were no 
longer effective analogs of the consensus sequence and were therefore no 
longer potential affinity labels. The second series of affinity labels (epoxides) 
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was prepared and kinetically evaluated without success; however, these 
compounds contained less conservative structural modifications and less 
reactive electrophilic centers than the original designs. The third set of 
affinity labels (organomercurial containing peptides) were prepared and 
evaluated. These compounds were unsuccessful as affinity labels of OT. 
However, the reactivity of this type of compound is limited by being highly 
specific for cysteine residues. Finally, a discussion has been included which 
addresses possible explanations for the lack of reactivity of residues within the 
peptide binding site as well as prospects for the synthesis of more potent 
affinity labels. 
5.2 Results and Discussion 
5.2.1 Analogs of -Asn-Xaa-Thr-: a-Methyl Ketone Substituted Affinity Labels 
Initially, three different synthetic targets were chosen as potential 
affinity labels for OT. Compounds 7, 8, and 9 are all analogs of the substrate 
Bz-Asn-Leu-Thr-NHMe (10) which have been modified at the asparagine 
carboxamide to contain an a-diazomethyl, an a-chloromethyl or an a-
fluoromethyl ketone as a reactive electrophilic group. 
Bz-.... N 
H 
R 
7: R = CHN2 
8: R = CH2CI 
9: R = CH2F 
10: R = NH2 
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The proposed synthesis for each of these tripeptides is shown in Figure 
5-3. Bz-Asp-Leu-Thr-NHMe (11) was treated with oxalyl chloride to yield the 
aspartic acid chloride 12. It was predicted that this reactive tripeptide could be 
treated with diazomethane to yield 712 which could be quenched with 
chloride ions or pyridinium poly (HF)13 to afford the two halomethyl ketones 
8 and 9, respectively. Analysis of the oxalyl chloride reaction revealed that 12 
underwent cyclization with the peptide backbone to form the succinimide 13 
in greater than 35% yield. In addition to 13, several other side products were 
observed which most likely result from further hydrolysis of the succinimide. 
Treatment of this reaction mixture with diazomethane did not induce the 
formation of 7. 
The ability of asparagine and aspartic acid side chains to cyclize with the 
peptide backbone has been well documented in the literature and has been 
implicated in the normal aging process of proteins .14, 15 This process often 
results in the deamidation of asparagine and the generation of aspartatic acid 
and isoaspartic acid containing peptides. In nature, this structural breakdown 
occurs slowly with peptides often having half lives of years.14 Activation of 
the aspartic acid side chain to generate 12 appears to have greatly accelerated 
this process, inducing rapid cyclization in high yields, thereby prohibiting the 
formation of 7, 8 and 9. In addition, it is probable that if peptides 7, 8 and 9 
could be prepared without the intermediacy of 12, they would immediately 
cyclize to form six-membered rings (rather than the five-membered 
succinimide ring formed from the acid chloride). Regardless, these cyclic 
compounds are not potential affinity labels as they no longer resemble the 
substrate 10 and the electrophilic center has been removed. 
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Figure 5-3. Synthetic Scheme for Affinity Labels 7, 8, and 9. 
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5.2.2 Analogs of -Asn-Xaa-Thr-: Epoxide Affinity Labels 
Because of the problems encountered during the synthesis of 7, 8 and 9, 
a new family of potential affinity labels, containing an epoxide as the 
electrophile, was designed and evaluated. Typically, epoxides are less reactive 
than the corresponding acid halides and a-substituted ketones discussed 
above and are therefore less potent as affinity labelling reagents. However, 
they are readily synthesized and are still reactive towards strong nucleophiles 
such as the thiol group of cysteine or the £-amino group of lysine. In the 
design of affinity labels for OT, where the electrophile needs to be 
incorporated into an amino acid side chain, it was believed that the less 
reactive epoxide moiety would prove to be an asset by prohibiting 
unfavorable cyclizations between the peptide backbone and the electrophilic 
amino acid side chain. 
Four epoxide peptides were selected for the initial investigations with 
oligosaccharyl transferase (14 - 17). Each of these peptides contains an epoxy 
amino acid in place of the asparagine or threonine residue in the OT 
consensus sequence (-Asn-Xaa-Thr-). Two different amino acids were selected 
(Epx and Vepx) with side chains that differ by only one methylene group. It 
was predicted that by using both of these amino acids in similar peptide 
affinity labels, slightly different regions of the enzyme's peptide binding site 
could be investigated; this could substantially increase the chance of 
successful enzyme inactivation by one of the compounds. To introduce the 
epoxides, the non-natural amino acids allyl glycine and vinyl glycine were 
chosen to be synthetically incorporated into the desired position of the 
peptide sequence. Oxidation of these residues would generate the two 
epoxide amino acids, in a mixture of diastereomers (Epx and Vepx, 
respectively). 
177 
Epx Vepx 
The first three inhibitors were designed to examme the asparagine 
position of the consensus sequence. Bz-Epx-Leu-Thr-NHMe (14) is a direct 
analog of the tripeptide substrate Bz-Asn-Leu-Thr-NHMe (10) . Ac-Ser-Phe-
Epx-Leu-Thr-Val-Thr-NH2 (15) contains the consensus sequence flanked by 
four amino acids (two on each side); these residues were selected based on the 
statistical analysis of Gavel and von Heijne16 and were chosen to enhance 
recognition of the inhibitor by OT. Finally, Bz-Vepx-Leu-Thr-Phe-OMe (16) 
was prepared in case the active site base is not appropriately positioned to 
react with 14. The fourth epoxide peptide contains a more conservative 
modification which replaces the required threonine with Vepx (Bz-Asn-Leu-
Vepx-Phe-OMe, 17); this peptide was designed to reexamine the previously 
reported inhibition of OT by 6. 10 
Prior to oxidation, the precursor peptides to 14, 16 and 17 were prepared 
through standard solution phase synthesis protocols; the precursor to peptide 
15 was prepared by solid phase synthesis methods. Two different methods for 
the oxidation of the allyl glycine and vinyl glycine residues were evaluated. 
Initially, m-CPBA was utilized as described by Bause. 10 This method 
presented two complications. During m-CPBA oxidation to generate 15, the 
peptide fragment Leu-Thr-Val-Thr-NH2, where the N-terminal amine of the 
leucine had been oxidized, was isolated indicating that peptide backbone 
cleavage had occurred. Cleavage of the peptide backbone appeared to progress 
178 
0 
H ~H H 0 
NyAN NHMe 
0 = H 0 r 
14 
179 
during purification, similar to the breakdown reported by Bause.1° Kinetic 
evaluation of the impure peptide was hindered by the presence of intact m-
CPBA which effectively inactivates the enzyme (presumably by oxidizing the 
cysteine residue in the sugar substrate binding site, see chapter two). Because 
of this complication, dimethyldioxirane (DMDO),17, 18 which decomposes to 
acetone during purification,19 was examined as an alternative oxidant. The 
conditions for DMDO oxidation are neutral and mild and, in each case, the 
reaction proceeded in nearly quantitative yield to produce pure product. 
Peptides 14 - 17 were evaluated as inhibitors of oligosaccharyl 
transferase. Each epoxide was combined with the enzyme (prior to addition 
of the substrate 10) and the enzyme was analyzed for activity after several 
different incubation times. To maximize potential inactivation, the 
inhibitors were examined at high concentrations (2.5 mM - 5.0 mM) relative 
to the competing substrate 10 (200 µM). The rate of inactivation was 
determined by comparing the OT activity of these enzyme mixtures to an 
analogous control experiment that did not contain any of the inhibitors. In 
each case, the enzyme activity remained constant over time, indicating that 
the epoxide inhibitors do not effectively inactivate OT. Figure 5-4 shows a 
comparison of the rates obtained when OT was treated with peptide 15 versus 
the relevant control; nearly identical results were obtained with the other 
three epoxide peptides (14, 16 and 17). 
The most remarkable result obtained from this series of inhibitors was 
the inability of 17 to inactivate the enzyme. This peptide contained a Vepx 
residue in place of the threonine, a conservative modification which has been 
previously reported to result in the inactivation of OT.10 However, in a direct 
contradiction to the previous report, 17 did not inactivate the enzyme. The 
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Figure 5-4. Treatment of OT with Epoxide Peptide 15 (■ , 2.5 mM 15 during 
preincubation; e, control, no inhibitor). 
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compound examined by Bause (6) was utilized in an impure form 
immediately following oxidation; one possible explanation for the earlier 
results is that inactivation was induced by residual m-CPBA and not by 
alkylation of an active site nucleophile upon epoxide ring opening. This 
hypothesis is supported by the observation that treatment of OT with pure m-
CPBA does result in a substantial loss in enzyme activity over time. A 
reexamination of the precise peptide sequence previously evaluated, using 
DMDO as the oxidant, would need to be accomplished to confirm this 
hypothesis. 
The epoxide peptides proved disappointing as affinity labels for OT; 
however, these results suggest that the previous claims are not valid . Most 
importantly, Epx and Vepx are not good analogs of asparagine and it is 
therefore likely that they are not bound by OT with appreciable affinity. In 
addition, the epoxide is not highly reactive and ring opening would most 
likely only occur if a cysteine or a highly nucleophilic lysine was present in 
the peptide binding site, a possibility that is not supported by the results of the 
chemical modification studies presented in chapter two. The lack of reactivity 
of these epoxide affinity labels towards OT does not rule out the presence of a 
histidine or an aspartic or glutamic acid as the active site base. 
5.2.3 Analogs of -Asn-Xaa-Thr-: S-Mercury Affinity Labels 
One final series of potential affinity labels was prepared based on a 
report that cysteine residues could be modified by compounds which contain 
an appropriately positioned organomercurial group (R-S-Hg+) .20 When 
incubated with an enzyme, the high affinity of mercury for sulfur can induce 
a reaction with cysteine side chains to form R-S-Hg-S-Cys-Enz. Competition 
studies can be used to determine whether the cysteine side chain resides in 
182 
the enzyme active site. Two peptides were chosen to test against OT, in which 
either the asparagine or the threonine of the consensus triad was replaced 
with a cysteine. These peptides were synthesized through standard solid 
phase synthesis procedures and, following cleavage and purification, treated 
with mercuric nitrate to generate 18 and 19. 
Peptides 18 and 19 were evaluated as potential inhibitors of 
oligosaccharyl transferase. Competing interactions between chloride anions 
and the mercury cation in each peptide were observed to interfere with the 
ability of these compounds to react with enzymic cysteine residues by the 
formation of R-S-HgCl. Thus, following an initial evaluation, an OT 
preparation was developed which contained dramatically decreased levels of 
chloride anions. This enzyme source was used for all further studies. 
Inhibition of OT activity was observed when the enzyme was treated 
with each mercury peptide; however, enzyme activity did not decrease with 
183 
time and different preparations of the peptides produced dramatic variations 
in the degree of inhibition observed. Further evaluation revealed that this 
inhibition was due to competition for the manganese binding site by residual 
mercury (II) nitrate and not the direct result of the mercury-containing 
peptides. Again, the fact that these peptides were ineffective as affinity labels 
is not surprising as peptides 18 and 19 do not closely mimic the consensus 
triad and therefore may not even be recognized by OT. Additionally, this type 
of affinity label is designed to specifically target cysteine side chains and the 
chemical modification studies presented in chapter two strongly suggest that a 
reactive cysteine is not located in or near the peptide binding site of OT. 
5.3 Conclusions and Future Directions 
The design and evaluation of nine different affinity labels has been 
accomplished. Of the inhibitors that were successfully prepared, none 
produced a significant decrease in OT activity, even when examined at 
elevated concentrations. Unfortunately, these compounds were all limited in 
reactivity and their final structures were significantly removed from that of 
the consensus sequence normally recognized by OT.21 With the high degree 
of substrate specificity exhibited by OT,22 it is not surprising that these 
compounds were unsuccessful as potential affinity labels. The a-substituted 
methyl ketone containing peptides 7, 8 and 9 were the most promising of the 
affinity labels considered. Their structures contained straightforward and 
subtle modifications based on the simple substrate 10. However, these 
compounds could not be prepared as described and therefore could not be 
evaluated kinetically. Further structural alterations would need to be 
considered to develop these peptide analogs into useful affinity labelling 
reagents. 
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It has recently been reported that the introduction of a constrained asx-
turn into a peptide substrate for OT results in a tenfold enhancement in 
binding to the enzyme active site.23 This cyclization has been incorporated 
into the design of the potent OT inhibitors discussed in chapter four and a 
solid phase method of synthesis for these compounds has been developed. 
This method of cyclization could be readily adapted to generate cyclo[SHex-
Asp-Cys]-Thr-Val-Thr-Nph-NH2 (20) as a precursor to several different 
affinity labels. The synthetic procedures shown in Figure 5-3 could be used to 
convert peptide 20 into constrained analogs of 7 - 9 (21 - 23, respectively). 
Steric hindrance caused by the cyclic constraint should eliminate or 
dramatically decrease succinimide formation, thereby making the preparation 
of these compounds feasible. 
20: R = o-
21: R = CHN2 
22: R = CH2CI 
23: R = CH2F 
Cyclic peptides 21 - 23 offer the potential to be powerful affinity labels of 
oligosaccharyl transferase. These compounds more closely resemble the 
consensus sequence than any of the other labels designed and presented in 
this chapter. In addition, the electrophilic modification is located precisely in 
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the position of interest within the asparagine side chain. Thus, these 
compounds would be ideally suited to probe for the active site base shown in 
Figure 5-2. 
Modification of this active site base has proven particularly challenging 
and its identity remains elusive. Chemical modification studies (chapter two) 
have failed to position any reactive residues within the peptide binding site 
and the more specific affinity labels have also been unable to provide new 
information. However, one additional possibility needs to be considered. It 
has been demonstrated that the required metal cofactor for asparagine-linked 
glycosylation is positioned in direct proximity to the asparagine carboxamide 
during catalysis (chapter three); this observation suggests that the divalent 
manganese may play a distinct role in mediating the glycosylation event. 
Could the elusive active site base be an activated metal bound water 
molecule? If this were the case, then irreversible modification of OT by an 
affinity label or a chemical modification reagent would not be observed 
because the modified water could be replaced by a new water molecule to 
regenerate active enzyme. Although unusual, catalytically competent water 
molecules have been observed in other enzymatic systems1 and such a 
possibility is decidedly consistent with the failed attempts to covalently 
modify a base within the active site of oligosaccharyl transferase. 
A metal bound water or hydroxide anion is an interesting mechanistic 
option that deserves scrutiny. Compounds 21 - 23 could also be used to 
examine this possibility by incubating these peptides in aqueous solution with 
and without OT. In the presence of OT, a reactive water or hydroxide ion 
would manifest itself by increasing the rate at which these peptides are 
converted to the a-hydroxy ketone. These rates could be readily determined 
by HPLC analysis of the aqueous peptide solutions. Such experiments could 
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shed a great deal of light on the mechanistic machinery of oligosaccharyl 
transferase. 
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5.5 Experimental Methods 
5.5.1 Analogs of Bz-Asp-Leu-Thr-NHMe - Halomethyl Ketone Affinity Labels 
Boc-Leu-Thr-OMe 
Boe-Leu-OH (1.4568 g, 5.8 mmol, 1 eq) and Thr-OMe (0.9895 g, 5.8 
mmol, 1 eq) were dissolved in 29.2 mL THF. HOBT (5-hydroxybenzotriazole, 
0.9416 g, 7.0 mmol, 1.2 eq), dicyclohexylcarbodiimide (DCC, 1.4362 g, 7.0 mmol, 
1.2 eq) and triethylamine (1.2 mL, 8.7 mmol, 1.5 eq) were added to this 
solution. A precipitate of dicyclohexylurea formed and the reaction was left 
stirring overnight. The mixture was filtered and brought to dryness. 
Purification was afforded by silica gel chromatography in chloroform. Yield: 
1.9559 g, 5.65 mmol, 97%. Rt 0.73 (CHCb/MeOH: 10/1). 1H-NMR OH (500 
MHz, CDCl3): 6.85 (br s, lH), 5.05 (br s, lH), 4.62 (d, lH), 4.35 (m, lH), 4.13 (m, 
lH), 3.77 (s, 3H), 1.74 (m, 2H), 1.45 (s, 9H), 1.23 (d, 3H), 0.95 (m, 6H). 
Boc-Asp(OBn)-Leu-Thr-OMe 
Boc-Leu-Thr-OMe (1.9559 g, 5.65 mmol) was dissolved in 20 mL 
methylene chloride with 8 mL trifluoroacetic acid. The solution was stirred 
for 1 hour until the amino terminus was completely deprotected. The 
solution was dried under a stream of nitrogen and lyophilized from water 
overnight to quantitatively yield the TFA salt of the dipeptide. This salt was 
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dissolved in 16 mL DMF. Triethylamine (1.7 mL, 1.8 eq) and the p-
nitrophenyl ester of Boe-Asp-OH (Boc-Asp-OpNP, 3.3792 g, 7.6 mmol, 1.3 eq) 
and were added to the solution which was left stirring for 16 hours. The 
solvent was removed by distillation and the product was purified on a 3/7 
ethyl acetate/hexane silica gel column. Yield: 2.5 g, 4.5 mmol, 68%. [Boe Asp-
OpNP (0.800 g, 1.8 mmol, 32%) was recovered from the column.] Rt 0.23 
(CHCb/MeOH: 20/1). 1H-NMR DH (500 MHz, CDC!J): 7.25(m, SH), 6.95 (dd, 
2H, J = 7.8 Hz), 5.54 (d, lH, J = 8.5 Hz), 5.03 (s, 2H), 4.5 (dd, lH), 4.45 (m, 2H), 4.2 
(dd, lH), 2.79 (m, 3H), 1.6 (m, 3H), 1.36 (s, 9H), 1.1 (d, 3H), 0.84, (dd, 6H). 
Bz-Asp(OBn)-Leu-Thr-OMe 
Boc-Asp(OBn)-Leu-Thr-OMe (0.9037 g, 1.64 mmol) was dissolved in 8 
mL methylene chloride and 3 mL trifluoroacetic acid . The solution was 
stirred for 20 minutes then brought to dryness under a stream of nitrogen to 
yield a yellow oil. Twice, the oil was redissolved in a 10% toluene in 
methanol solution and brought to dryness. This step was repeated again with 
100% methanol. The oil was dissolved in 8 mL DMF and benzoic anhydride 
(0.5085 g, 2.2 mmol, 1.4 eq) and triethylamine (425 µL, 3.05 mmol, 2.3 eq) were 
added. The reaction was stirred for 24 hours. The solvent was removed by 
distillation and the reaction was purified on a 1/1 ethyl acetate/ hexane silica 
gel column. Yield: 0.8400 g, 1.5 mmol, 92%. Rt 0.51 (CHC!J/MeOH: 10/1). 
1H-NMR DH (500 MHz, CDCb): 7.7 (m, 3H), 7.5 (m, lOH), 5.0 (s, 2H), 4.5 (m, 
2H), 4.2 (m, lH), 3.6 (s, 3H), 2.95 (dd, lH), 2.8 (dd, lH), 1.6 (m, 2H), 1.5 (m, lH), 
1.1 (d, 3H), 0.8 (d, 3H), 0.7 (d, 3H). 
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Bz-Asp-Leu-Thr-OMe 
Bz-Asp(OBn)-Leu-Thr-OMe (380 mg, 0.82 mmol, 1 eq) was dissolved in 
4 mL methanol. The flask was evacuated and flushed with nitrogen three 
times. Palladium on activated carbon (10%, 61 mg) was added and the flask 
was evacuated and flushed with nitrogen again. Hydrogen was added to the 
reaction from a balloon. The reaction mixture was stirred for 30 minutes. 
The balloon was regenerated with hydrogen and the reaction was stirred for 
an additional 30 minutes. The mixture was filtered over celite and dried 
down to yield Bz-Asp-Leu-Thr-OMe (303 mg, 0.81 mmol, 99 %). Rf 0.17 
(CHCl3/MeOH: 5/1). 
Bz-Asp-Leu-Thr-NHMe 
Bz-Asp-Leu-Thr-OMe (260 mg, 0.70 mmol, 1 eq) was dissolved in a 
saturated solution of methylamine in anhydrous methanol (-15 mL) . The 
solution was stirred overnight and then dried down under a stream of 
nitrogen to quantitatively yield Bz-Asp-Leu-Thr-NHMe. Rf 0.11 
(CHCb/MeOH: 5/1). 
Examination of Bz-Asp(Cl)-Leu-Thr-OMe Reaction 
Bz-Asp-Leu-Thr-NHMe (0.0480 mg, 0.104 mmol, 1 eq) was dissolved in 
2 mL dry chloroform. Triethylamine (20.0 µL, 0.145 mmol, 1.4 eq, dried over 
calcium hydride) was added to the tripeptide solution. Oxalyl chloride (9.0 µL, 
0.104 mmol, 1 eq) was added and the solution was stirred for 30 minutes. A 
diazomethane solution was prepared from diazald as recommended by the 
manufacturer (Aldrich). This solution was added to the acid chloride 
solution until a pale yellow color persisted. After 30 minutes, the reaction 
was quenched with methanol and brought to dryness. The reaction mixture 
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was purified by preparative TLC in 10:1 chloroform:methanol. Three major 
products were isolated. NMR analysis revealed that the first product (Rf 0.95) 
was not peptidyl, the second product was identified as Bz-Asp(OMe)-Leu-Thr-
NHMe, and the third product was the succinimide cyclization of Bz-Asp(Cl)-
Leu-Thr-NHMe (13). Substantial cyclization (>35%) to the succinimide was 
observed along with other less predominant impurities (not identified). The 
diazomethyl ketone (7) was not detected. 
5.5.2 OT Affinity Labels - Epoxide Analogs 
Boc-L-Allyl Glycine (Boe-Ag-OH) 
Allyl glycine (0.3928 g, 3.4 mmol, 1 eq, Fluka) was dissolved in 6 mL 
dioxane and 5 mL water. Triethylamine (700 µL, 5.1 mmol, 1.5 eq) and 2-t-
butoxycarbonyl-oxyimino-2-phenylacetonitrile (BOC-ON, 0.9201g, 3.7 mmol, 
1.1 eq, Aldrich) were added to the allyl glycine solution and the reaction was 
stirred for 90 minutes. After starting material was no longer visible by TLC, 
the dioxane was removed and the solution was washed with 1/1 ethyl 
acetate/hexane. Aqueous layer was acidified with a 10% citric acid solution 
and the impure product was extracted into ethyl acetate. Product was purified 
on a silica column in chloroform. Yield: 0.7367 g, 3.4 mmol, 99%. Rf 0.55 
(CHCl3/MeOH: 10/1); 1H-NMR ◊H (500 MHz, CDCL3): 5.7 (m, lH), 5.1-5.2 (m, 
2H), 4.4 (m, lH), 2.5-2.6 (m, 2H), 1.5 (s, 9H). 
Boc-Ag-Leu-Thr-OMe 
Boe-Ag-OH (0.3953 g, 1.8 mmol) was dissolved in 9 mL DMF and the 
carboxylic acid was activated with HOBT (0.2618 g, 2.1 mmol, 1.15 eq) and 
HBTU (0.7193 g, 1.89 mmol, 1.05 eq). The TFA salt of Leu-Thr-OMe (0.7249 g, 
2.1 mmol, 1.15 eq) was added with triethylamine (370 µL, 2.7 mmol, 1.5 eq). 
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The solution was stirred at room temperature for 16 hours. The DMF was 
removed and the product was purified on a silica column in chloroform. 
Yield: 0.534 g, 1.3 mmol, 70%. Rf 0.60 (CHCb/MeOH: 10/1). 1H-NMR ◊H (500 
MHz, d4-MeOH): 5.78 (m, lH), 5.08 (dd, 2H), 4.84 (s, 2H), 4.49 (m, lH), 4.42 (d, 
lH), 4.27 (m, lH), 4.1 (m, lH), 3.7 (s, 3H), 2.3 - 2.5 (m, 2H), 1.42 (s, 9H), 1.15 (d, 
3H), 0.94 (dd, 6H). 
TFA-Ag-Leu-Thr-OMe 
Boc-Ag-Leu-Thr-OMe (0.2051 g, 0.48 mmol) was dissolved in 3 mL 
dichloromethane and 3 mL trifluoroacetic acid. The solution was stirred for 
30 minutes, blown dry three times from methylene chloride and lyophilized 
from water overnight to quantitatively yield the deprotected peptide. Rf 0.27 
(CHCl3/MeOH: 10/1). 1H-NMR ◊H (500 MHz, D2O): 5.76 (m, lH), 5.2 - 5.27 (m, 
2H), 4.53 (m, lH), 4.45 (d, lH), 3.98 (dd, lH), 3.72 (s, lH), 2.56 - 2.68 (m, 2H), 1.61 
- 1.65 (m, 3H), 1.15 (d, 3H), 0.95 (dd, 6H) . 
Bz-Ag-Leu-Thr-OMe 
TFA-Ag-Leu-Thr-OMe (0.2052 g, 0.44 mmol) was dissolved in 4.4 mL 
anhydrous THF and chilled to O 0 C. Anhydrous triethylamine (61 µL, 0.44 
mmol, 1 eq) and benzoyl chloride (52 µL, 0.44 mmol, 1 eq) were added. After 
one hour, the solution was filtered and concentrated. The product was 
purified on a silica column in 1/1 ethyl acetate/hexane. Yield: 0.1185 g, 0.27 
mmol, 60%. Rf 0.24 (CHCl3/MeOH: 10/1). 1H-NMR ◊H (500 MHz, CDCb) : 
7.88 - 8.02 (m, 4H), 7.46-7.49 (m, lH), 7.27-7.38 (m, 2H), 5.7 (m, lH), 5.07 (d, lH), 
4.98 (m, 2H), 4.63 (m, 2H), 3.76 (s, 3H), 2.54 (m, 2H), 1.59 (m, lH), 1.58 (m, lH), 
1.52 (m, lH), 1.15 (d, 3H), 0.72 (dd, 6H). 
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Bz-Ag-Leu-Thr-NHMe 
Bz-Ag-Leu-Thr-OMe (0.1296 g, 0.29 mmol) was dissolved in an 
anhydrous saturated solution of methylamine in methanol (~ 15 mL). The 
solution was stirred for 30 minutes and then blown dry twice from methanol 
to quantitatively yield the transamidated product C-terminal methyl amide. 
Rf 0.60 (CHCb/MeOH: 5/1). 1H-NMR 8tt (300 MHz, d4-MeOH): 7.83 (m, 2H), 
7.48 (m, 3H), 5.87 (m, lH), 5.20 (m, 2H), 4.59 (m, lH), 4.42 (m, lH), 4.21 (m, 2H), 
3.30 (m, 6H), 2.75 (m, SH), 1.70 (m, 3H), 1.13 (m, 3H), 0.92 (m, 6H). 
Bz-Epx-Leu-Thr-NHMe (14) - m-CPBA Oxidation 
Bz-Epx-Leu-Thr-NHMe (0.0864 g, 0.19 mmol) was dissolved in 290 µL 
chloroform and 40 µL methanol. A solution of m-chloroperbenzoic acid (m-
CPBA, 0.0539 g, 0.21 mmol, 1.1 eq in 460 µL chloroform) was prepared and 
added slowly to the peptide solution. Additional m-CPBA was added over 
the next 8 hours (0.1086 g, 0.63 mmol, 3.3 eq). Reaction was quenched with a 
10% solution of sodium nitrite and the organic layer was washed with 5% 
sodium bicarbonate and brine. The organic layer was dried down and the 
product was purified by preparative TLC in 20/1 chloroform/methanol. TLC 
analysis revealed that the desired product was formed in very poor yield. 
Acidic oxidation provided by these reaction conditions induced bond cleavage 
of the peptide backbone between the allyl glycine residue and leucine to afford 
the two major products. 
Bz-Epx-Leu-Thr-NHMe - Dimethyldioxirane (DMDO) Oxidation 
Dimethyldioxirane was generated in acetone from Oxone (Aldrich) as 
described by the manufacturer. Bz-Epx-Leu-Thr-NHMe (0.00046 g, 10 µmol) 
was dissolved in 250 µL acetone and the dioxirane solution was added in 
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excess until a persistant yellow color remained. The solution was stirred for 
45 minutes. Evaporation of the solvent yielded the product in quantitative 
yield . Rt 0.83 (CHCl3/MeOH: 4/1). FAB LRMS calcd for C23H34N4O6 (MH+) 
462, found 462. 1 H-NMR ◊H (500 MHz, d6-DMSO): 7.88 (m, 2H), 7.54 (m, 2H), 
7.47 (m, 2H), 4.84 (m, lH), 4.64 (m, lH), 4.34 (m, lH), 4.07 (m, lH), 3.98 (m, lH), 
3.00 (br s, lH), 2.67 (m, lH), 1.97 (m, 2H), 1.62 (m, lH), 1.49 (m, 2H), 0.97 (d, 3H, 
J = 6.4 Hz), 0.85 (br dd, 6H). 
Fmoc-Allyl Glycine (Fmoc-Ag-OH) 
A solution of 9-fluorenylmethoxycarbonyl succinimide ester (Fmoc-
OSu, 2.1098 g, 6.3 mmol, 1.2 eq) in 19.5 mL dioxane was added dropwise to a 
solution of allyl glycine (0.6038 g, 5.2 mmol) in 26 mL 10% sodium carbonate. 
A precipitate formed. After several hours, the mixture was washed four 
times with ether. The aqueous layer was chilled to O °C and brought to a pH 
of 2 with concentrated hydrochloric acid. The product precipitated out of 
solution and was extracted into ethyl acetate. Purification was performed on a 
silica column in 20 / 1 chloroform/ methanol and recrystallization in 
chloroform. Rt 0.30 (CHCl3/MeOH: 20/1). 
Fmoc-Ser-Phe-Ag-Leu-Thr-Val-Thr-NH2 
The peptide was synthesized by standard solid phase Fmoc protocols 
using PAL-PEG resin (0.2 meq/ g) and Enhanced Monitoring software on a 
Milligen 9050 automated synthesizer. The final deprotection cycle was 
omitted to yield the Fmoc protected amino acid. The peptide was cleaved 
from the resin by treatment with trifluoroacetic acid/thioanisole/ 
ethanedithiol/ anisole (90:5:3:2) for 2 hours to yield the carboxy terminus 
primary amide. The resin was filtered and washed with TF A. The combined 
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filtrates were concentrated to 2 mL and the peptide was precipitated with 2:1 
ether hexane. The peptide was washed with 2:1 ether /hexane several times 
and lyophilized overnight. To check the purity of the peptide, 1.5 mg were 
dissolved in 1 mL piperidine and stirred for 15 minutes. Soln was filtered 
and triturated three times with ether. Characterization was performed by 
analytical C-18 HPLC with a water/acetonitrile/0.1% TFA solvent system. A 
single major peak eluted at 26.3 minutes when the acetonitrile was increased 
from 0% to 60% over 30 minutes. 
Fmoc-Ser-Phe-Ag-Leu -Thr-Val -Thr-NH2 
The Fmoc protected heptapeptide (0.0420 g, 42.6 µrnol) was dissolved in 
400 µL acetic acid and m-CPBA (39.1 mg, 226 µmol, 5 eq) was added. The 
reaction was stirred and an additional 10 - 20 mg m-CPBA were added hourly 
for four hours. The reaction was diluted with 5 mL water and extracted with 
hexane (20 x 10 mL) and chloroform (10 x 25 mL). The chloroform layer was 
brought to dryness to yield slightly impure product (31.7 mg, 42 µl, 75% yield) . 
HPLC retention time (linear gradient 0 - 60% ACN, over 30 minutes) 22.5 
minutes. 
Ac-Ser-Phe-Epx-Leu-Thr-Val-Thr-NH2 (15) 
Frnoc-Ser-Phe-Ag-Leu-Thr-Val-Thr-Pal-Peg resin was deprotected via 
treatment with 20% (v /v) piperidine in DMF and the liberated N-terrninus 
was acylated with a solution of acetic anhydride and triethylamine in DMF. 
Cleavage and oxidation were performed as described above. F AB HRMS calcd 
for C3sH6oO12Ns (MH+) 821.4409, found 821.4388. 
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Enzyme Assays - Time Dependence of Inhibition 
Yeast oligosaccharyl transferase was solubilized as previously 
described.24 The solubilized yeast microsomes (225 µL) was combined with 
1575 µL assay buffer (50 mM Hepes, pH 7.5, 0.5 mg/mL PC, 1 % Triton-X, 10 
mM MnCl2, 0.1 mg/mL PMSF). Each epoxide inhibitor was dissolved in 
DMSO to yield a 100 mM solution. The inhibitor (45 µL or 22.5 µL) was 
combined with 855 µL of the enzyme solution to yield an inhibitor 
concentration of 5 mM or 2.5 mM. These solutions were preincubated at 
room temperature and aliquots of 150 µL were removed after 1, 15, 30, 60, and 
120 minutes. These aliquots were combined with 40 µL assay buffer, 10 µL 4 
mM Bz-Asn-Leu-Thr-NHMe (10) and 50,000 dpm Dol-P-P-GlcNAc-
[3H]GlcNAc (36.5 Ci/mmol).25 Assays were performed as described in 
Appendix A of this dissertation. Time dependence was determined relative 
to a control experiment. 
5.5.3 OT Affinity Labels - Mercury Compounds 
Peptide Synthesis 
Each peptide was synthesized on PAL-PEG resin (Millipore) with a 
support substitution of 0.140 meq/gram with standard Fmoc protocols and the 
enhanced monitoring system provided by Millipore. Couplings were 
performed with a three-fold excess of each amino acid. After attachment of 
the final residue, the Fmoc protecting group was removed from the N-
terminal amino acid, and while still attached to the resin, the N-terminus 
was capped in 4.5 mL DMF, with 105 µL triethylamine and approx. 170 mg 
benzoic anhydride. This reaction was stirred for two hours or until a negative 
Kaiser test was obtained. The resin was rinsed extensively with DMF, 
dichloromethane and MeOH, then dried overnight under reduced pressure 
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before cleavage. Cleavage from the resin was performed by shaking the resin 
with Reagan t R [ trifl uoroacetic acid/ thioanisole / ethanedi thiol / anisole 
(90:5:3:2)] for four hours. The resin was filtered and rinsed with TFA. The 
filtrate was concentrated under a stream of nitrogen and then triturated with 
2:1 ether:hexane six times to remove the excess cleavage agents. The peptide 
was lyophilized from water and purity was confirmed by analytical C-18 
HPLC. Bz-CLTVTK-NH2 and Bz-CLTTVK-NH2 did not require purification. 
Bz-NLCTVK-NH2 was purified by loading 20 mg onto a preactivated Sep-Pak 
and eluting the peptide with a slow gradient of acetonitrile (0.08% TFA) in 
water (0.1 % TFA). The peptide eluted at a concentration of 20% acetonitrile. 
Bz-CLTVTK-NH2: FAB HRMS calcd for C35H59O9N3S (MH+) 767.4125, found 
767.4111. 1H-NMR 8H (500 MHz, d6-DMSO): 8.51 (d, lH, J = 7.9 Hz), 8.20 (d, 
lH, J = 7.9 Hz), 7.87 (br d, 3H, J = 7.3 Hz), 7.82 (d, lH, J = 8.1 Hz), 7.66 - 7.46 (m, 
8H), 7.2 (s, lH), 7.0 (s, lH), 5.01 (br s, lH), 4.93 (br s, lH), 4.56 (m, lH), 4.37 (m, 
lH), 4.32 (m, lH), 4.26 (m, lH), 4.13 (m, 2H), 4.03 (m, lH), 3.97 (m, lH), 2.93 (m, 
lH), 2.84 (m, lH), 2.74 (m, 2H), 2.07 (m, lH), 1.62 (m, 2H), 1.49 (m, SH), 1.26 (m, 
4H), 1.03 (m, 6H), 0.87 - 0.81 (m, 14H). 
Bz-NLCTVK-NH2: FAB HRMS calcd for C35H53O9N9S (MH+) 780.4078, found 
780.4047. 1H-NMR 8H (500 MHz, d6-DMSO): 8.57 (d, lH, J = 7.5 Hz), 8.13 (d, 
lH, 7.8 Hz), 8.08 (d, lH, 7.8 Hz), 7.88 (d, lH, J = 7.9 Hz), 7.83 (m, 3H), 7.59 - 7.44 
(m, 8H), 7.19 (s, lH), 7.01 (s, lH), 6.96 (s, lH), 4.92 (d, lH, J = 5.1 Hz), 4.74 (q, lH), 
4.44 (m, lH), 4.29 (q, lH), 4.22 (m, lH), 4.15 (m, 2H), 4.02 (m, lH), 2.80 - 2.53 (m, 
5-6H, obscured by solvent), 1.99 (m, lH), 1.61 (m, 2H), 1.49 (m, SH), 1.28 (m, 
2H), 1.02 (d, 3H, J = 6.4 Hz), 0.84 (m, 14H). 
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Bz-Cys(SHg+ )-Leu-Thr-Val-Thr-Lys-NH2 (18) 
The mercury peptides were prepared according to the methods of 
Leavis and Lehrer.20 The peptide (0.0114 g, 14.9 µmoles, 1 eq) was dissolved in 
3 mL of an aqueous nitric acid solution (pH = 2.9). An Ellman's test was used 
to determine an accurate peptide concentration (3.4 mM). This peptide 
solution was added slowly to 7.5 mL 20 mM Hg(N03)2 in nitric acid (pH= 2.9) . 
The solution was stirred for 30 minutes, until an Ellman's test indicated that 
free thiols were no longer present. The solution was passed through an 
activated Sep-Pak with water to remove any remaining Hg(N03)2. The 
peptide was eluted slowly with a mixture of acetonitrile and water. Yield: 11.1 
mg, 11.5 µmoles, 74%. FAB HRMS calcd for C35H5909NsS (MH+) 969.3781, 
found 967.3700. 
Bz-Asn-Leu-Cys(SHg+ )-Thr-Val-Lys-NH2 (18) 
The peptide (0.0103 g, 13.2 µmoles, 1 eq) was dissolved in 1.3 mL of an 
aqueous nitric acid solution (pH = 2.9). The peptide concentration was found 
to be 4.9 mM by an Ellman's test. This solution was added slowly to 6.6 mL 20 
mM Hg(N03)2 in nitric acid (pH = 2.9). The solution was stirred for 30 
minutes, until an Ellman's test indicated that free thiols were no longer 
present. Solution was passed through an activated Sep-Pak with water to 
remove any remaining Hg(N03)2. The peptide was eluted slowly with a 
mixture of acetonitrile and water. Yield: 1.2 mg, 1.3 µmoles, 10%. 
Inhibition of OT by Bz-Cys(SHg+)-Leu-Thr-Val-Thr-Lys -NH2 
"High Sodium Chloride" Inhibition Studies 
Typically, a solution of the solubilized yeast protein (500 mM NaCl) 
was thawed and combined with the appropriate amount of a 1 M solution of 
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MnCb to afford a final concentration of 10 mM MnCl2. Solutions of the 
mercuric inhibitors were prepared in DMSO at concentrations of 5 mM, 0.5 
mM and 0.05 mM. An aliquot of each of these inhibitor solutions (24 µL) was 
added to an aliquot of the enzyme solution (95 µL) at time = 0 minutes, with 
shaking and vortexing to yield final incubation concentrations of 1 mM, 0.1 
mM and 0.01 mM. A parallel control was performed where DMSO was added 
in place of the mercuric peptide. After incubation times of 1, 15, 30 and 60 
minutes, 20 µL of each incubation mixture was diluted into a microcentrifuge 
tube which contained 50000 dpm Dol-P-P-GlcNAc-[3H]GlcNAc, 10 µL 2.5 mM 
Bz-Asn-Leu-Thr-NHMe and 170 µL assay buffer (50 mM Hepes, pH 7.5, 0.5 
mg/mL PC, 1 % Triton-X, 10 mM MnCl2). Aliquots of this mixture were 
removed at specific timepoints and quantitated as described in chapter two of 
this dissertation. Turnover rates were compared to the relevant control. The 
conditions described yield sodium chloride concentrations of 500 mM during 
the preincubation and 50 mM during the enzyme assay. 
Preparation of "Low Sodium Chloride" Oligosaccharyl Transferase 
Solubilized yeast oligosaccharyl transferase was purified on a 
concanavilin A column as previously described.24 The concanavalin A 
eluate was loaded onto a Mono-S column which had been equilibrated with 
buffer (140 mM sucrose, 25 mM NaCl, 50 mM succinate, 10 mM MgCb, 0.4% 
NP-40, 0.5 mg/mL PC). The protein was eluted with a NaCl gradient from 25 
mM to 400 mM over 140 minutes. Active fractions were pooled and dialysed 
against buffer to achieve the following composition: 140 mM sucrose, 25 mM 
sodium chloride, 10 mM MgCl2, 50 mM Tris-Cl, 0.4% NP-40, 0.5 mg/ mL PC. 
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Inhibition of Oligosaccharyl Transferase by 18 and 19 - "Low Sodium 
Chloride" Inhibition Studies 
Solutions of the two mercury peptides were prepared in DMSO at 
concentrations of 25 mM, 5 mM and 0.5 mM. The Mono-S purified 
oligosaccharyl transferase (54 µL) and 6 µL of each of the inhibitor solutions 
were combined to yield incubation concentrations of 2.5 mM, 0.5 mM and 0.05 
mM. A control was prepared which contained 6 µL DMSO instead of the 
mercury peptides. After two minutes, 40 µL of each incubation mixture was 
transferred to a microcentrifuge tube containing 150 µL assay buffer (50 mM 
Hepes, pH 7.5, 0.5 mg/mL PC, 1 % Triton-X, 10 mM MnCl2), 10 µL 2.5 mM Bz-
Asn-Leu-Thr-NHMe and 50,000 dpm Dol-P-P-GlcNAc-[3H]GlcNAc. Aliquots 
of this mixture were removed at specific timepoints and quantitated as 
described in chapter two of this dissertation. Turnover rates were compared 
to the relevant control. 
Substrate Protection - Bz-Asn-Leu-Thr-NHMe 
The incubation mixture was prepared in the same manner as described 
for the low salt assays except the enzyme solutions contained 1 mM Bz-Asn-
Leu-Thr-NHMe. The assay microcentrifuge tube contained 150 µL assay 
buffer (50 mM Hepes, pH 7.5, 0.5 mg/mL PC, 1% Triton-X, 10 mM MnCl2), 10 
µL DMSO and 50,000 dpm Dol-P-P-GlcNAc-[3H]GlcNAc. Experiments were 
compared to two controls, one which did not contain the mercuric peptide 
during the preincubation, and the second which did not contain the Bz-Asn-
Leu-Thr-NHMe (in this case, the substrate was added to the microcentrifuge 
tube prior to initiation of the assay) . Assays were quantitated as described in 
Appendix A of this dissertation. 
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Appendix A. Oligosaccharyl Transferase Assay 
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A.1 General Oligosaccharyl Transferase Assay 
A basic assay for oligosaccharyl transferase has been developed which can 
be modified to accommodate a wide variety of different kinetic experiments.1 
The fundamentals of this assay have been used throughout this dissertation; 
specific variations have been described in detail in the relevant experimental 
sections of each chapter. 
In vivo, OT catalyzes the transfer of a triantennary branched 
tetradecasaccharide from a lipid-linked donor to an asparagine residue in a 
nascent polypeptide chain. In vitro, a simpler substrate, Dol-P-P-GlcNAc-
GlcNAc, can be used as the oligosaccharide donor with similar efficiencies.2 This 
disaccharide donor can be prepared through a combination of synthetic and 
enzymatic steps,3 with the incorporation of a tritium radiolabel at the C-6 
position of the second GlcNAc. This radiolabel serves as a tag for facile 
quantification of OT activity. 
The OT assay used in this dissertation relies on the different solubility 
properties of the tripeptide glycopeptide product, Bz-Asn(GlcNAc-GlcNAc)-Leu-
Thr-NHMe, and the oligosaccharide donor, Dol-P-P-GlcNAc-GlcNAc. Briefly, 
the enzyme is combined with the two substrates under appropriately buffered 
conditions. At various time points, an aliquot is removed and quenched into a 
biphasic aqueous/ organic solvent system. The product and the unreacted 
oligosaccharide starting material are separated through a series of extractions. 
The lipid-linked donor remains in the organic phase, while aqueous washes 
remove the glycopeptide product. The tritium content of each phase is 
determined using a scintillation counter to calculate disintegrations per minute 
(dpm). A plot of dpm vs. time can be used to determine the glycosylation rate for 
each assay. This rate can be compared to other experiments performed under 
analogous conditions. 
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This assay is straightforward and can be manipulated to examine different 
aspects of the OT system. For example, the enzyme may be preincubated with 
exogenous compounds prior to the addition of one or both of the substrates; this 
type of experiment allows the specific binding sites of the two substrates to be 
examined separately (see chapter two). In addition, the concentrations of the two 
substrates can be altered for the determination of kinetic constants or for the 
examination of unnatural substrates (see chapter three). Also, the concentration 
of the enzyme can be adjusted to enable longer kinetic experiments (see chapter 
four). The assay conditions given below have been designed to yield an active 
and stable enzyme solution which demonstrates linear kinetics over a ten minute 
experiment. 
A.2 Experimental Method 
In a typical experiment, an aliquot of Dol-P-P-GlcNAc-[3H]-GlcNAc 
(50,000 dpm, specific activity 36.5 Ci/mmol)3 was blown dry under a stream of 
nitrogen in a small microcentrifuge tube. The radiolabelled carbohydrate 
substrate was redissolved in 10 µL of a DMSO solution of Bz-Asn-Leu-Thr-
NHMe (5 mM). An additional 10 µL DMSO were added with 160 µL assay buffer 
(50 mM Hepes, pH 7.5, 140 mM sucrose, 1.2% Triton X-100, 0.5 mg/mL PC, 10 
mM MnCb). The assay was initiated by adding 20 µL of the gently thawed S. 
cerevisiae OT enzyme to the substrate solution. During the course of the 
experiment, the enzyme mixture was gently agitated. Reaction aliquots (4 x 40 
µL) were removed at two minute intervals and quenched into 1.2 mL of 3:2:1 
chloroform/methanol/4 mM MgC}i. The tritiated glycopeptide was separated 
from the unreacted glycolipid through a series of extractions. The upper aqueous 
layer of the quenched reaction mixture was removed and the organic layer was 
extracted twice with 0.6 mL Theoretical Upper Phase with salt (TUP: 
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12/192/186/2.69 chloroform/methanol/water/0.25 M MgCl2). The combined 
aqueous layers were quantitated for tritium content in 5.5 mL Ecolite (ICN) as 
disintegrations per minute. The organic layers were dried and the remaining 
proteinaceous residue was redissolved in 200 µL Solvable (NEN), agitated for 30 
minutes and counted in 6 mL Formula 989 (New England Nuclear). The amount 
of radioactivity present in the aqueous extracts was normalized against the total 
radioactivity (aqueous and organic) for each sample. OT activity was 
determined by plotting the normalized value for tritium in the aqueous phase vs. 
time. 
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Appendix B. Synthesis and Evaluation of 
Bz-Amk-Leu-Thr-NHMe 
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B.1 Introduction 
The asparagine-linked glycosylation reaction is unusual in that the 
carboxarnide side chain of an asparagine residue appears to act as a 
nucleophile. Within the consensus sequence -Asn-Xaa-Thr /Ser-, this residue 
attacks the electrophilic oligosaccharide donor. Several mechanisms have 
been proposed which attempt to explain this surprising enhancement in 
nucleophilicity (see chapter one). The most recent of these sterns from the 
observation that the Asx-turn is the conformational motif most likely 
recognized by oligosaccharyl transferase. 1, 2 This conformation includes 
hydrogen bonds between the carbonyl of the asparagine side chain, the amide 
backbone and the required threonine or serine residue. The hydrogen 
bonding array of the Asx-turn and the catalytic machinery of OT may act in 
concert to promote tautornerization of the asparagine carboxarnide to an 
irnidol; this nucleophilic species may then complete the glycosylation event 
(Figure B-1).3 Tautornerization to the irnidol requires the presence of an 
active site base, and identification of this base has been the main driving 
forces behind several of the experiments presented in this dissertation. 
O;c~ H ',,._H NiR 
.. ,,H 
0 0 
N H ·,, N 
' --o '11 'f 
H ◊- 0 
Dol-P-P-Oligosaccharide 
Figure B-1. Proposed Tautornerization of the Peptide Substrate During 
Asparagine-Linked Gl ycosy la tion. 3 
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While investigating the presence of an active site base, a parallel study 
was designed to further characterize the tautomerization of the asparagine 
side chain. To accomplish this end, the compound Bz-Amk-Leu-Thr-NHMe 
(2) was designed. This peptide is an analog of the substrate Bz-Asn-Leu-Thr-
NHMe (1) in which the Asn carboxamide is replaced by a methyl ketone. 
1. R=NH2 
2. R = CH3 
The goal of this project was to incubate 2 with catalytic amounts of OT 
under deuterated or tritiated solvent conditions and to subsequently monitor 
2 for isotope incorporation into the methyl ketone (by NMR or scintillation 
counts). It was predicted that when 2 was bound to the OT active site, the 
same active site machinery that induces the amide to imidol tautomerization 
shown in Figure B-1 would induce the analogous ketone to enol 
tautomerization of the Amk side chain. This enolization, under deuterated 
or tritiated conditions, would greatly facilitate isotope incorporation by 
promoting proton exchange between the methyl group of the side chain and 
the exchangeable protons of the active site base and the threonine hydroxide 
(Figure B-2). With a catalytic amount of enzyme present, NMR experiments 
could be performed on the reaction mixture, without the need for isolation of 
2. Quantification of the amount of tritium incorporation, by means other 
than NMR, would require isolation of 2 and extensive washes to remove all 
the rapidly exchangeable protons prior to analysis. 
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Figure B-2. Proposed Method of Deuterium Incorporation into Bz-Amk-Leu-
Thr-NHMe (2). 
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B.2 Results and Discussion 
The synthesis of a methyl ketone analog of glutamine has recently been 
reported,4 and this method was used for the preparation of Cbz-Amk-OH. 
Briefly, Cbz-Asp-OH is condensed with formaldehyde to form the 
oxazolidinone prior to functional group manipulation on the amino acid side 
chain. The side chain carboxylate is then converted to the acid chloride and 
treated with diazomethane and hydroiodic acid .4 The a-amino acid is 
regenerated from the oxazolidinone by treatment with anhydrous sodium 
methoxide to produce the corresponding methyl ester; saponification affords 
the desired product (Cbz-Amk-OH, 3). 
3 
Unfortunately, incorporation of 3 into a tripeptide proved difficult and 
proceeded in poor yield. The Cbz- protected N-terminus had to be reprotected 
with a benzoyl group because enzyme assays of Cbz-Asn-Leu-Thr-NHMe 
revealed that the Cbz group substantially decreases the substrate affinity of 
this peptide for OT. Once the synthesis of 2 was completed, NMR analysis 
revealed the presence of diastereomeric products. The diastereomers proved 
to be difficult to separate, further decreasing the yields of the preparation. 
Additional analysis confirmed that significant racemization had occurred 
during ring opening of the oxazolidinone, prior to peptide synthesis. 
An enzyme assay of the diastereomeric mixture confirmed that 2 is a 
competitive inhibitor for OT; however, its binding affinity was very low and 
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inhibition was not observed until 2 was present at low millimolar 
concentrations (as compared to low micromolar concentrations of the 
competing substrate 1). The correct diastereomer of 2 is probably a slightly 
better inhibitor, since OT is unlikely to recognize the D-Amk containing 
tripeptide; however, neither isomer was isolated in pure form. Because of the 
poor affinity of OT for 2, this investigation was discontinued. 
B.3 Conclusions and Future Directions 
Because peptide 2 was never prepared in significant quantities nor to 
optical purity, it was never thoroughly examined as an inhibitor for OT and 
the NMR based isotope experiments described above were not undertaken. 
However, the fact that 2 is a competitive inhibitor of OT is remarkable and 
may deserve further scrutiny. Future efforts would require a separation 
method for the two enantiomers of the Amk amino acid prior to peptide 
incorporation. Probably the most straightforward approach would be to 
manipulate the protecting groups of the Amk amino acid so that an 
enzymatic resolution could be performed. Once accomplished, the overall 
synthesis of an Amk containing peptide could be streamlined by using solid 
phase synthesis methods. Such an approach would improve the yields of the 
peptide synthesis and, as an Fmoc protected amino acid, Amk could be 
incorporated into the cyclic structure described in chapter four to enhance 
binding to OT. 
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B.4 Experimental Methods 
B.4.1 Synthesis of Bz-Amk-Leu-Thr-NHME (2) 
(S)-3-Benzyloxycarbonyl-5-oxo-4-oxazolidinineacetic Acid 
N-Benzyloxycarbonyl-L-aspartic acid (10.3728 g, 38.8 mmol, leq), 
paraformaldehyde (2.3491 g, 78.3 mmol, 2 eq) and p-toluenesulfonic acid 
(0.4437 g, 2.33 mmol, 0.06 eq) were combined in 290 mL benzene. The reaction 
mixture was heated at reflux with a Dean-Stark Trap for 90 minutes. The 
solution was cooled and combined with 60 mL ethyl acetate. The organic 
solution was washed with 5% sodium bicarbonate (10 mL) and water (3 x 10 
mL). The organic layer was brought to dryness to yield a clear oil which 
slowly recrystallized at 4 °C. Yield: 9.53 g, 34.0 mmol, 88%. Rt 0.29 
(CHC!J/MeOH: 10/1). 1H-NMR 8tt (500 MHz, CDCl3): 7.30-7.41 (m, SH), 5.48 
(d, lH), 5.12-5.48 (m, 3H), 4.88 (s, lH), 4.40 (s, lH), 2.9-3.3 (m, 2H). 
( S )-3-Benzy loxycarbony l-4-(2-oxopropy l)-5-oxazol idi none 
(S)-3-Benzyloxycarbonyl-5-oxo-4-oxazolidinineacetic acid (1.655 g, 5.9 
mmol, 1 eq) was dissolved in 11 mL dry, ethanol free chloroform. Oxalyl 
chloride (616 µl, 7.1 mmol, 1.2 eq) was added with a catalytic amount of DMF 
(30 µL). After 1 hour, an additional 50 µL oxalyl chloride was added. The 
reaction was brought to dryness and the remaining residue was dissolved in 
10 mL dry THF, chilled in an ice bath and kept under nitrogen. A freshly 
prepared ether solution of diazomethane was added until the yellow color of 
excess diazomethane remained. The excess diazomethane was quenched 
with a small amount of acetic acid and the reaction was dried and stored at -20 
°C for 24 hours. The diazomethyl intermediate was redissolved in 50 mL 
anhydrous CHC!J and quenched by the slow addition of a solution of 6 mL HI 
(47% in CHCL3). After ten minutes, the brown solution was combined with 
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62 mL Chloroform and 31 mL water. The organic layer was further extracted 
with water to incompletely remove the iodine. The product was purified by 
silica gel chromatography first with 9 /1 ethyl acetate/hexane and then with 
CHC13. Yield: 1.10 g, 3.9 mmol, 66.8%. Rf 0.16 (CHCb). FAB HRMS calcd for 
C14H1sOsN (MH+) 278.103, found 278.103. 1H-NMR <>tt (500 MHz, CDCl3) : 
7.37-7.19 (br m, SH), 5.48 (br s, lH), 5.26 (s, lH), 5.19 (br s, lH), 5.13 (s, lH), 5.10 
(s, lH), 4.23 (s, lH), 3.52 (br d, lH, J = 6.2 Hz), 3.24 (br s, lH), 3.09 (br d, lH, J = 8.0 
Hz), 2.15 (br s, 3H). 
CBZ-Amk-OMe 
(S)-3-Benzyloxycarbonyl-4-(2-oxopropyl)-5-oxazolidinone (0.5993 g, 2.2 
mmol, 1 eq) was dissolved in 40 mL anhydrous methanol. An anhydrous 
sodium methoxide solution was prepared by dissolving sodium pellets 
(0.1212 g, 5.3 mmol, 2.4 eq) in 10 mL methanol. This solution was chilled in a 
salt/ice bath (-10 °C) and the ketone solution was added via cannula transfer. 
The reaction was stirred for 2 hours and slowly warmed to room temperature. 
HCl (lN, ~50 mL) was added and the MeOH was removed by evaporation. 
The aqueous layer was washed with hexanes and then the desired product 
was extracted into ethyl acetate. The organic solution was washed with a 5% 
sodium bicarbonate solution, dried with sodium sulfate and brought to 
dryness. No further purification was necessary. Yield: 0.440 g, 1.7 mmol, 
77.5%. Rf 0.55 (CHCl3/MeOH: 20/1) . FAB HRMS calcd for C14H17O5N (MH+) 
280.1185, found 280.1185. 1H-NMR <>tt (500 MHz, CDCl3): 7.35 (m, SH), 5.78 (br 
s, lH), 5.1 (s, 2H), 4.52 (m, lH), 3.72 (s, 3H), 3.22 (dd, lH), 2.99 (dd, lH), 2.18 (s, 
3H). 
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CBZ-Amk-OH (3) 
CBZ-Amk-OMe (0.415 g, 1.5 mmol, 1 eq) was dissolved in 3.9 mL 
dioxane and 3.9 mL water and the solution was chilled to -10 °C. A solution 
of lN NaOH (1.6 mL, 1.6 mmol, 1.1 eq) was added slowly and the reaction was 
stirred for 75 minutes. The reaction was quenched with 1.6 mL lN HCl and 
the dioxane was removed by evaporation. The aqueous solution was washed 
three times with chloroform and the organic layer was dried down to afford 
the pure product. Yield: 0.3811 g, 1.44 mmol, 97%. Rf 0.12 (CHCb/MeOH: 
10/1). FAB HRMS calcd for C13H1sOsN (MH-) 266.1041, found 266.1028. 1H-
NMR 8H (500 MHz, CDCb): 7.34 (m, SH), 5.81 (d, lH), 5.11 (s, 2H), 4.59 (m, lH), 
3.01 (dd, lH), 2.99 (dd, lH), 2.16 (s, lH). 
Cbz-Amk-Leu-Thr-NHMe (p-Nitrophenol Ester Coupling) 
CBZ-Amk-OH (0.0812 g, 0.29 mmol) was dissolved in 290 µl DMF. p-
nitrophenol (0.0425 g, 0.31 mmol, 1.05 eq) and dicyclohexylcarbodiimide 
(0.0625 g, 0.031 mmol, 1.05 eq) were added. After 3 hours, the precipitated 
dicyclohexylurea (DCU) was removed by filtration. The TFA salt of Leu-Thr-
OMe (0.130 g, 0.37 mmol, 1.3 eq), triethylamine (60 µl, 0.45 mmol, 1.5 eq) and 
1.2 mL DMF were added to the p-nitrophenyl ester of CBZ-Amk-OH. After 14 
hours, the DMF was removed and the product was purified by silica gel 
chromatography in CHCl3. Yield: 20 mg, 15% yield. Rf 0.46 (EtOAc/MeOH: 
9/1). 
Cbz-Amk-Leu-Thr-NHMe (Isobutylchloroformate Coupling) 
CBZ-Amk-OH and the TFA salt of Leu-Thr-NHMe were dried from 
toluene under vacuum. CBZ-Amk-OH (0.155 g, 0.585 mmol) was dissolved in 
5.85 mL dry THF with N-methylmorpholine (NMM, 64 µl, 0.585 mmol, 1 eq). 
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The solution was chilled to -23 °C and isobutylchloroformate (IBCF, 76 µl, 
0.585 mmol, 1 eq) was added. After five minutes, a chilled solution of the 
TFA-Leu-Thr-NHMe (0.235 g, 0.683 mmol, 1.17 eq) in 6.85 mL dry THF with 
NMM (64 µl, 0.585 mmol, 1 eq) was transferred via cannula into the CBZ-
Amk-OH solution. After one hour, the solution was brought to dryness, 
redissolved in chloroform and washed with 10% citric acid. The product was 
purified on silica gel in ethyl acetate. Yield: 181 mg, 0.37 mmol, 62%. Rf 0.1 in 
ethyl acetate. FAB HRMS calcd for C24H36O7N4 (MH+) 493.266, found 466.268. 
1H-NMR btt (500 MHz, CDCh): 7.35 (m, SH), 6.98 ( br s, lH), 6.63 (s, lH), 5.77 (d, 
lH), 5.11 (s, 2H), 4.55 (br s, lH), 4.42 (d, lH), 4.30 (m, 2H), 3.13 (dd, lH), 2.90 (dd, 
lH), 2.76 (d, 3H), 2.18 (s, 3H), 1.17 (m, 3H), 1.12 (d, 3H), 0.95 (d, 3H), 0.89 (d, 3H). 
Bz-Amk-Leu-Thr-NHMe 
Cbz-Amk-Leu-thr-NHMe (0.527 g, 0.107 mmoles, 1 eq) was dissolved in 
1 mL MeOH. The flask sealed, evacuated and flushed with nitrogen. 
Palladium on activated carbon (10%, 10 mgs) was added to the solution and 
hydrogen was released into the flask from a balloon. After 1 hour, the 
solution was filtered over celite and evaporated to dryness to yield 25.7 mg (72 
µmoles) of the deprotected tripeptide. This peptide was redissolved in 400 µL 
DMF and combined with the p-nitrophenyl ester of benzoic acid (0.0210 g, 86 
µmoles, 1.2 eq) and TEA (15 µL, 108 µmoles, 1.5 eq). After approximately 16 
hours, the DMF was removed. The peptide product was purified by reverse 
phase C-18 HPLC with an elution system of 30% acetonitrile/70% water /0.1 % 
TFA (isocrat). FAB HRMS calcd for (MH+) 463.2550, found 463.2557. lH-
NMR btt (500 MHz, d6-DMSO): 8.58 (lH, d, J = 7.2 Hz), 8.13 (d, lH, J = 8.1 Hz), 
7.82 (m, 2H), 7.54 (m, 3H), 7.46 (m, 3H), 4.79 (m, lH), 4.29 (m, lH), 4.07 (m, lH), 
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4.00 (m, lH), 2.95 (m, 2H), 2.59 (d, 4.6 Hz), 2.12 (s, 3H), 1.61-1.45 (m, 3H), 0.98 (d, 
3H, 6.3 Hz), 0.84 (d, 3H, J = 6.6 Hz), 0.80 (d, 3H, J = 6.5 Hz). 
Analysis of Racemization 
The optical rotations for two different preparations of CBZ-Amk-OH 
were examined. Prior to analysis, each sample was dissolved in enough 
CHCl3 to yield a 3 mg/mL solution. The rotation of each sample was 
measured five times in a 10 dm cell and the average value was used for all 
calculations. Preparation 1 (165.8 mg) was dissolved in 5.0 mL CHCb and a 
180.8 µL aliquot was diluted to 2.00 mL; the optical rotation was determined at 
25 cc. [a]Na = 100(0.0274)/0.3(1) = 9.13. Preparation 2 (453 mg) was dissolved in 
14.0 mL CHCb and a 185.4 µL aliquot was diluted to 2.00 mL; the optical 
rotation was determined at 25 cc. [a]Na25 = 100(0.0038)/0.3(1) = 1.27. 
B.4.2 Synthesis of Cbz-Asn-Leu-Thr-NHME 
CBZ-Asn-Leu-Thr-OMe 
CBZ-Asn-OpNP (0.3399g, 0.88 mmol, 1.1 eq) was dissolved in 3.9 mL 
DMF. The TFA salt of Leu-Thr-OMe (0.269 g, 0.78 mmol, 1 eq) and 
triethylamine (162 µl, l.32mmol, l.5eq) were added. The solution was stirred 
overnight. DMF was removed and the residue was washed with ethyl acetate. 
Product was collected by filtration. Yield: 0.2289 g, 0.46 mmol, 59.5%. Rf 0.43 
(CHCl3/MeOH: 5/1). 1H-NMR ◊H (500 MHz, CDCl3): 8.0 (d, lH), 7.9 (d, lH), 7.4 
(d, lH), 7.3 (m, 6H), 6.9 (s, lH), 5.0 (m, 3H), 4.4 (m, 2H), 4.2 (m, lH), 4.1 (m, lH), 
3.6 (s, 3H), 2.3 - 2.5 (m, 2H), 1.6 (m, lH), 1.45 (m, 2H), 1.1 (d, 3H), 0.8 (dd, 6H). 
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CBZ-Asn-Leu-Thr-NHMe 
CBZ-Asn-Leu-Thr-OMe (0.0327 g, 0.067 mmol, 1 eq) was dissolved in 15 
mL saturated methylamine in methanol with sonication. The solution was 
stirred for 15 hours. Product precipitated out of solution and was collected by 
centrifuge. The precipitate was washed three times with chloroform to yield 
the desired product. Yield: 13 mg, 0.023 mmol, 39%. Rt 0.30 (CHCb/MeOH: 
5/1). 1H-NMR <>H (500 MHz, d4-MeOH): 7.3 (m, SH), 5.08 (s, 2H), 4.5 (m, lH), 
4.32 (m, lH), 4.23 (m, 2H), 2.79 - 2.83 (dd, lH), 2.72 (s, 3H), 2.63 - 2.68 (dd, lH), 
1.64 - 1.71 (m, 3H), 1.16 (d, 3H), 0.86 - 0.94 (dd, 6H). 
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Appendix C. Design and Synthesis of Crosslinking 
Reagents for Oligosaccharyl Transferase 
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C.1 Design and Synthesis of Crosslinking Reagents 
Chapter two of this dissertation described the identification of a cysteine residue 
located at or near the oligosaccharide binding site of OT. This cysteine residue is highly 
reactive towards the alkyl alkanethiolsulfonate family of thioalkylating agents, 
including methyl methanethiolsulfonate (MMTS). Based on this observation, a novel 
biotinylated MMTS analog (BMTS) was prepared and used to characterize the Wbplp 
subunit of OT (see chapter two).1 The unusual reactivity of this cysteine makes it an 
ideal target for experiments designed to further characterize the enzyme. 
OT is a multisubunit, membrane bound protein; Wbplp is just one of as many as 
six different subunits and the organization of these subunits, relative to each other, is 
currently unknown (see chapter one).2 Chemical crosslinking agents are commonly 
used to demonstrate that two subunits are in proximity with each other in an intact 
protein. With the observation that the Wbplp polypeptide encompasses all or part of 
the oligosaccharide binding site (and possibly the active site), it is of interest to identify 
which other subunits directly interact with Wbplp; adjacent polypeptides could be 
involved in completing the enzyme active site machinery. With this goal in mind, 
several novel crosslinking reagents were designed which connect the reactive portion of 
MMTS to a benzophenone or p-azidobenzoic acid photoaffinity label (Figure C-1, 1- 3). 
Each of these compounds contains a aminoethanethiolsulfonate group which has been 
condensed either immediately with the carboxylic acid of the photoactive moiety (1) or 
extended by a hexanoic linker prior to addition of the photoreactive group (2 - 3). The 
preparation of these compounds was straightforward and they are ready for analysis 
with OT. 
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1 
3 
Figure C-1. Chemical Structures of New Crosslinking Agents. 
C.2 Experimental Methods 
p-Benzoyl benzoyl-OpNP 
p-Benzoyl benzoic acid (0.2049 g, 0.91 mmoles, 1 eq) was dissolved in 2.5 mL THF 
with p-nitrophenol (0.195 mg, 0.95 mmoles, 1.05 eq). Dicyclohexylcarbodiimide (DCC, 
0.1501 g, 0.11 mmoles, 1.2 eq) was added. After three hours, an addition 0.010 g p-
nitrophenol and 0.010 g DCC were added. The reaction was stirred for an additional 
hour. The dicyclohexylurea (DCU) was removed via filtration and the reaction product 
was used without further preparation. 
p-BzBz-aminoethanethiolsulfonate (1) 
Methyl aminoethanethiolsulfonate hydrobromide (44 mg, 0.19 mmol)3 and p-
benzoyl benzoyl-OpNP (0.0400 g, 0.173 mmoles, 1 eq) were dissolved in 750 µL 
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anhydrous DMF with sonication. The solution was chilled in an ice bath and TEA (35 
µL, 253 µmoles, 1.5 eq) was added slowly. After one hour, an additional 0.0320 g p-
benzoyl benzoyl-OpNP (92 µmoles, 0.47 eq) were added. The reaction was left 
overnight. The DMF was removed by distillation and the reaction product was purified 
by silica gel chromatography in 1/1 ethyl acetate/hexanes. Yield: 53.7 mg, 148 µmoles, 
85%. Rf 0.11 (ethyl acetate/ hexanes: 1/1). 1H-NMR OH (300 MHz, CDCl3): 7.96 - 7.76 
(m, 6H), 7.63 (t, lH), 7.51 (t, 2H), 7.09 (br s, lH), 3.88 (q, 2H), 3.46 (t, 2H), 3.39 (s, 3H). 
Boc-6-aminohexanoy 1-aminoethanethiolsulf onate 
Boc-6-aminohexanoic acid (0.1978 g, 0.855 mmoles) was dissolved in 1.0 mL DMF 
with DCC (0.1951 g, 0.947 mmoles) and p-nitrophenol (0.1313 g, 0.942 mmoles). The 
solution was stirred for three hours and 0.25 eq DCC (0.0444 g, 0.216 mmoles) was 
added. After an additional hour, the DCU precipitate was removed by filtration. 
Methyl aminoethanethiolsulfonate hydrobromide (86.7 mg, 0.375 mmol, 1 eq)3 was 
dissolved in 500 µL DMF and combined with 500 µL of the activated ester solution of 
Boc-6-aminohexanoic acid. The solution was chilled in an ice bath and TEA (77 µL, 
0.557 mmoles, 1.5 eq) was added slowly. Two additional 100 µL aliquots of the 
activated Boc-6-aminohexanoic acid ester were added over three hours. The reaction 
was stirred for approximately 16 hours and the DMF was removed under reduced 
pressure. The reaction product was purified by silica gel chromatography: Mixture was 
loaded in 1/1 ethyl acetate/hexanes and the product was eluted with pure ethyl acetate. 
Rf 0.4 (ethyl acetate). Yield: 98.5 mg, 266 µmoles, 71 %. 1H-NMR OH (500 MHz, CDCl3): 
6.2 (br s, lH), 3.60 (dd, 2H, J = 9.3, 6.1 Hz), 3.36 (s, 3H), 3.31 (t, 2H, J = 6.4 Hz), 3.09 (t, 
2H, J = 6.9 Hz), 2.19 (t, 2H, J = 7.5 Hz), 1.64 (m, 2H), 1.46 (m, 2H), 1.43 (s, 9H), 1.34 (m, 
2H). 
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TF A-6-aminohexanoyl-aminoethanethiolsulfonate 
Boc-6-aminohexanoyl-aminoethanethiolsulfonate (98.5 mg, 0.266 mmoles, 1 eq) 
was dissolved in methylene chloride (~5 mL) and TFA (~2 mL) was added. The 
reaction was stirred until TLC analysis indicated that the starting material was no 
longer visible. Solution was dried down under a stream of nitrogen, redissolved in 
methylene chloride and brought to dryness again. The product was dissolved in water 
( ~5 mL) and shell frozen. Lyophilization yielded the desired product in quantitative 
yield. Rf 0.08 (ethyl acetate). 
p-azidoBz-6-aminohexanoyl-aminoethanethiolsulfonate (2) 
TFA-6-aminohexanoyl-aminoethanethiolsulfonate (240 µmoles) was dissolved in 
1.2 mL anhydrous DMF. An aliquot of this solution (300 µL, 60 µmoles) was chilled in 
an ice bath and combined with the succinic acid ester of p-azidobenzoic acid (0.0182 g) 
and TEA (12 µL, 86.7 µmoles, 1.4 eq). The reaction was slowly warmed to room 
temperature. After three hours, an additional 0.5 equivalents of the succinic acid ester 
of p-azidobenzoic acid (0.0087 g) and TEA (4 µL) were added. After two more hours, 
the DMF was removed under reduced pressure. The product was purified by silica gel 
chromatography in ethyl acetate. Yield: 34.4 mg. 1 H-NMR ◊H (500 MHz, d4-MeOH): 
7.63 (d, 2H), 7.12 (d, 2H), 3.5 (t, 2H), 3.35 (m, 2H), 2.41 (t, 2H), 1.64 (m, 4H), 1.40 (m, 2H). 
p-BzBz-6-aminohexanoyl-aminoethanethiolsulfonate (3) 
TFA-6-aminohexanoyl-aminoethanethiolsulfonate (240 µmoles) was dissolved in 
1.2 mL anhydrous DMF. An aliquot of this solution (300 µL, 60 µmoles) was chilled in 
an ice bath and combined with p-Benzoyl benzoyl-OpNP (0.0254 g, 73.2 µmoles, 1.2 eq) 
and TEA (12 µL, 86.7 µmoles, 1.4 eq). The reaction was slowly warmed to room 
temperature. After three hours, an additional 0.5 equivalentsp-Benzoyl benzoyl-OpNP 
(0.0102 g, 29.4 µmoles) were added. After three more hours, the DMF was removed 
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under reduced pressure. The product was purified by silica gel chromatography in 
20/1 chloroform/methanol. Yield: 33.7 mg, 71 µmoles,> 100 %, contains traces of p-
nitrophenol. Rf 0.34 (CHCl3/MeOH: 20/1). 1H-NMR ◊H (300 MHz, CDCb): 8.02 - 7.78 
(m, 7H), 7.63 (t, lH), 7.51 (t, 2H), 6.80 (br t, lH), 6.41 (br t, lH), 3.61 (dd, 2H, J = 12.0, 6.0 
Hz), 3.52 (dd, 2H, J = 12.9, 6.6 Hz), 3,36 (s, 3H), 3.33(t, 2H), 2.26 (t, 2H, J = 7.2 Hz), 1.70 
(m, 4H), 1.44 (m, 2H). 
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Appendix D. Selected NMR Spectra 
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